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I Summary 
Cervical cancer (CxCa) is the second most common cancer among women world-wide. DNA of 14 
high-risk human papillomavirus (hrHPV) types is found in almost all cervical cancers (>96.3%), 
with HPV16 being the most prevalent type. Cervical cells can be screened for abnormalities using 
the cytological Papanicolaou (Pap) test and for the presence of HPV DNA and HPV E6/E7 full-
length mRNA. However, all of the available tests show considerable drawbacks exhibiting either 
poor clinical sensitivity or specificity. Reduced clinical specificity leads to over-treatment, 
additional costs and enormous anxiety for women concerned. A highly specific identification of 
high-grade lesions is desirable since those require surgical therapy contrary to early lesions that are 
likely to regress spontaneously. Recently described HPV16 RNA patterns comprising the 
upregulated transcripts E6*II and/or E1C, and the downregulated transcripts E1^E4 and/or L1 in 
HPV16-transformed cervical cells showed potential to substantially improve HPV-based cervical 
precancer screening: in a small cytology-based pilot study these patterns identified severe HPV16-
induced cervical lesions with a clinical sensitivity of 74% and a specificity of 84%. However, 
singleplex nucleic acid sequence-based amplification (NASBA) assays used in the previous work 
was labour, time and cost intensive.  
In this PhD thesis, novel quantitative multiplex high-throughput reverse transcription PCR were 
developed for the detection of the HPV16 RNA patterns with detection limits below 102 transcript 
copies per PCR. Cross-reactivity with unspliced HPV16 sequences and cellular background 
DNA/RNA was excluded. The comparison of the newly developed assay and the established 
singleplex NASBA assays using RNA from 32 HPV16-positive fresh-frozen oropharyngeal 
squamous cell carcinomas indicated a good quantitative correlation. The concordance of HPV16 
RNA patterns between both methods was 100%. In order to validate HPV16 RNA patterns as 
diagnostic marker for cervical cancer and its severe precursor lesions 165 single HPV16 DNA-
positive cervical cell samples were analysed. The sensitivity for CIN3 and CxCa was 88% and the 
specificity 84%, even in archived specimens with low RNA quality. Several HPV16 RNA patterns 
“false-positive” CIN1 lesions in follow-up had progressed to CIN2 or CIN3 lesions, raising the 
possibility that HPV RNA patterns could be an earlier marker for developing severe lesions than 
histology. Poor quality of RNA extracted from formalin-fixed paraffin embedded tissues strongly 
limits HPV16 RNA patterns analysis. To extend the HPV RNA patterns to the further seven most 
frequent hrHPV types 18, 31, 33, 35, 45, 52 and 58, unknown splice junctions were identified. For 
HPV18 singleplex assays were developed. The detection limit ranged between 101 E6*I and E1C 
and 102 E1^E4 copies per PCR and will be improved in future experiments.  
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II Zusammenfassung 
Das Zervixkarzinom (CxCa) ist weltweit die zweithäufigste Krebserkrankung bei Frauen. An dessen 
Entstehung sind humane Hochrisiko-Papillomviren, insbesondere HPV16 beteiligt. Zervixabstriche 
können sowohl zytologisch mit Hilfe des Papanicolaou (Pap) Tests, als auch durch den Nachweis 
von HPV DNA und HPV E6/E7 volle-Länge mRNA auf Abnormitäten untersucht werden. Alle 
bisher in der Zervixvorsorgeuntersuchung verfügbaren Methoden weisen einen Mangel an klinischer 
Sensitivität oder Spezifität auf. Beispielsweise kann eine geringe/moderate klinische Spezifität zur 
unnötigen Behandlung von Patientinnen, zu zusätzlichen Kosten und zur immensen Sorge der 
Betroffenen führen. Um dem vorzubeugen ist eine hochspezifische Identifizierung von hochgradigen 
Läsionen erstrebenswert, da nur diese Frauen chirurgischer Therapie bedürfen. Frühe Läsionen 
regredieren im Gegensatz dazu voraussichtlich spontan. Kürzlich wurden diagnostische HPV16 
RNA Muster identifiziert, die die Hochregulierung der E6*II und/oder E1C Transkripte und die 
Herunterregulierung der E1^E4 und/oder L1 Transkripte in HPV16-transformierten zervikalen 
Zellen beinhalten. Diese Muster weisen das Potential auf, bisherige HPV-basierte Tests deutlich zu 
verbessern: In einer kleinen, Zytologie basierten Pilotstudie konnten mittels der Muster mit einer 
klinischen Sensitivität von 74% und Spezifität von 84% zwischen leichten und schweren Läsionen 
unterschieden werden, jedoch mit dem Nachteil, dass die verwendeten singleplex 
Nukleinsäuresequenz-basierten Amplifikations-Reaktionen (NASBA) arbeits-, zeit- und 
kostenaufwendig sind.  
In der vorliegenden Arbeit wurde eine neue quantitative Hochdurchsatz-PCR für die Detektion der 
HPV16 RNA Muster entwickelt. Die analytische Sensitivität erstreckte sich zwischen 101 und 102 
Trankriptkopien pro PCR. Kreuzreaktionen mit ungespleißten HPV16 Sequenzen und mit zellulärer 
Hintergrund-DNA/RNA wurden ausgeschlossen. Der Vergleich der neuen Methode und der 
etablierten NASBA, anhand von RNA aus 32 HPV16-positiven frisch-gefrorenen Karzinomen des 
Oropharynx, deutet sowohl eine gute quantitative Korrelation als auch eine 100%ige qualitative 
Konkordanz an. Um die HPV16 RNA Muster als diagnostische Marker zur Erkennung von CxCa 
und den hochgradigen Vorstufen zu validieren, wurden 165 –ausschließlich HPV16 DNA-positive– 
in PreservCyt gelagerte Zervixabstriche analysiert und eine klinische Spezifität von 84% und eine 
Sensitivität von 88% berechnet, selbst unter der Verwendung archivierten Materials mit geringer 
RNA Qualität. Mehrere durch HPV16 RNA Muster „falsch-positive“ CIN1 Läsionen schreiten in 
Verlaufsbeobachtungen zu CIN2 oder CIN3 fort, was ein Hinweis darauf sein könnte, dass die 
HPV16 RNA Muster ein früherer Marker für die Entwicklung schwerer Läsionen sind als 
histologische Untersuchungen. Schlechte Qualität extrahierter RNA aus Formalin-fixiertem, 
Paraffin-eingebetteten Gewebe limitiert die HPV16 RNA Muster Analyse stark. Um die HPV RNA 
Muster auf die häufigsten sieben Hochrisiko-HPV Typen zu übertragen, wurden alle bisher 
unbekannten Spleiß-Junctions identifiziert und bereits für die Entwicklung von singleplex PCR für 
HPV18 RNA Muster genutzt, deren analytische Sensitivität sich zwischen 101 und 102 
Trankriptkopien pro PCR erstreckt und in zukünftigen Experimenten noch verbessert wird. 
Introduction 
 
3 
1 Introduction 
1.1 Papillomaviruses 
Papillomaviruses (PV) form their own family, Papillomaviridae, and are small, non-
enveloped viruses. Their icosahedral ~55 nm diameter capsid is composed of 72 pentameric 
capsomers (Figure 1.1). 
PV infect the skin and mucosal epithelium of mammals but also birds. Some PV types cause 
benign tumours, e.g. condylomata acuminata, and other types can transform cells leading to 
malignant tumours. Several mucosal human papillomaviruses (HPV) are associated with the 
development of cancer, including cervical, vaginal, vulvar, penile, anal and oropharyngeal 
cancer.  
 
Figure 1.1. Structure of HPV. Electron microscopic pictures of HPV1. 
 
1.2 Human papillomaviruses 
1.2.1 HPV genome organisation 
All PV contain closed-circular double-stranded circular DNA which replicates as an 
extrachromosomal plasmid in the nucleus of infected keratinocytes. Although the viral 
genome can vary slightly in size between different HPV types, it typically contains around 
8,000 basepairs (bp), and encodes up to nine open reading frames (ORF) from the same 
DNA strand. Three functional areas have been identified: the long control region (LCR), 
also called upstream regulatory region (URR), the “early” and the “late” transcription 
regions (Figure 1.2). The URR of about 800 bp contains no ORF but numerous regulatory 
sequence elements, such as transcription factor binding sites, viral transcription factor E2 
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binding sites, and the origin of viral DNA replication with binding sites for the viral 
replication protein E1. Furthermore, it contains silencer as well as enhancer sequences and 
harbours the p97 core promoter upstream of the E6 ORF. The “early” region consists of the 
E1, E2, E4-E7 ORF that are necessary for the replication of viral DNA. The “late” region 
encodes the L1 and L2 protein that are necessary for the assembly of newly produced virus 
particles2-4. 
 
Figure 1.2. HPV genome showing the arrangement of early (E) and late genes (L) and the upstream 
regulatory region (URR)5. In yellow and orange: late structural proteins; in blue, green, red and purple: early 
proteins; in red and purple: viral oncogenes. 
 
1.2.2 HPV transcription 
HPV generates mRNAs that can express than one functional protein through independent, 
tandemly arranged ORF. Since HPV16 has a focal role within this work, the transcription 
mechanisms are exemplarily presented for this type (Figure 1.3).  
The expression of HPV16 is a complex process using at least two promoters, multiple splice 
donor and acceptor sites and two polyadenylation signals. The process also includes post-
transcription mechanisms. All transcripts are poly-cistronic. 
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The promoter (p97) for the early genes is located in the URR and the late promoter (p670) 
for the late genes in the E7 region. The activity of p670 is suppressed in undifferentiated 
cells and activated in terminally differentiating keratinocytes6.  
Depending on splicing events, up to three different reading frames are utilised for 
translation. Maturation of viral RNA involves complex splicing. The HPV16 transcriptome 
exhibits several splice donor (nt 226, 880, 1302 and 3632) and acceptor (nt 409, 526, 742, 
2582, 2709, 3358 and 5639) sites creating at least 11 different splice junctions4,7-12. The 
functions of the various spliced transcripts are still under investigation. Spliced transcripts 
may allow more effective translation of a downstream ORF13-15. One mechanism to achieve 
this is leaky scanning in which upstream start codons when lying in an unfavourable context 
are ignored16,17. Moreover, the translation of spliced transcripts can generate truncated 
proteins with functions important for the regulation of the viral life cycle18,19. HPV 
transcript patterns and splice junctions have been investigated in HPV16-infected cervical 
lesions20, cell lines11,21-24 and keratinocytes immortalised by HPV1610,20.  
 
 
Figure 1.3. Transcription map of HPV16. ORF are shown as colored rectangles in their proper reading 
frames (top of the figure). The first number at the upper left end of the rectangles matches to the nucleotide 
(nt) position of the ORF start, id est (i.e.) the first nt following a stop codon. The second number is the nt 
position of the first ATG, also indicated by a dotted line within the rectangles. The position of the last nt in the 
stop codon of each ORF is written at the lower right corner of the rectangles. Located below the genome scale 
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are diagrams of spliced mRNA species with their coding potential at the right. Untranslated exons are 
illustrated by black rectangles, while intervening introns are indicated by black lines. Colored rectangles 
indicate in-frame sequences that can potentially code for proteins. Numbers printed below the lines indicate 
the 5' and 3' splice junctions. The promoter for the last three transcripts i.e. species N-P has not been mapped. 
Transcripts encoding full length (fl) E1 and L2 protein are not shown. Potential truncated gene products of E6 
and E1 are indicated by asterisks (*). The fusion product of the E1 and E4 protein is indicated as E1^E425. 
Source 26. 
 
1.2.3 Major HPV16 proteins and their transcripts 
The fl E1 protein is encoded by the unspliced E1 ORF-containing transcript. It is required 
for viral DNA replication, has a helicase activity and binds to cellular proteins including 
replication protein A (RPA) and DNA polymerase α primase27-30. E1 with a truncated N-
terminus (E1C) is translated from 880^2582 spliced mRNA (Figure 1.6, species I-K) and 
acts as trans-activator of the URR18,31.  
The E2 protein is mainly encoded by spliced 226^2709 (E6*IV) mRNA (species H) but also 
to a lower extent by the 880^2709 mRNA (species E-G) and 880^2582 mRNA (species I-K) 
initiating mostly from the p97 promoter17. Viral DNA replication and viral segregation 
require E232. E2 is a DNA-binding protein recognizing a palindromic motif in the non-
coding region of the viral genome (four such motifs in HPV16). Via protein-protein 
interaction, E2 recruits E133. E2 can also be active as a transcription factor that regulates the 
viral early promoter p97 causing auto-regulation of E2 expression and regulation of the 
expression of viral oncogenes (E6 and E7). At low level, E2 is a transcriptional activator, 
whereas at high level, E2 represses oncogene expression34. A shorter form of E2 (E2C), 
translated from the spliced 1302^3358 mRNA (species N), is presumably a replication and 
transcription repressor that inhibits the function of fl E235. The presumed E2M protein with 
unknown function could be expressed from double-spliced transcripts (species O). 
The E4 ORF, located in the early region, overlaps with the E2 ORF in a different reading 
frame. Its gene product, E1^E4 translated from 880^3358 spliced mRNA (species A-C, L) is 
only expressed in differentiated, upper epithelial layers and plays a role by binding to 
proteins of the keratin cytoskeleton during virus assembly and virus release36. 
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The E5 protein is translated from an unspliced E2/E5 transcript (species E-G, M), but not 
from the E1^E4/E5 transcript (species A-C, L)37. It is a transmembrane protein that remains 
predominantly in the endoplasmatic reticulum (ER), by associating with the vacoular 
proton, it can delay the process of endosomal acidification38-40. This leads by affecting the 
recycling of growth factor receptor on the cell surface to an increase in epidermal growth 
factor-mediated (EGF) receptor signalling and the maintenance of a replication competent 
environment in the upper epithelial layer41. The E5 expression is observed to be lost during 
the integration of HPV DNA into the cellular genome, seen during progression to cervical 
cancer42. E5 is therefore not obligatory in late events of HPV-mediated carcinogenesis. 
The E6 protein is solely encoded by mRNA containing the fl E6 ORF (including species A, 
G, K), promoting proliferation of infected cells and thus leading to their resistance to 
apoptosis. The high-risk (hr) E6 protein forms a tripartite complex with p53 and the cellular 
ubiquitin ligase E6-associated protein (E6AP), which leads to proteosome-mediated 
degradation of p5343. On the other hand, E6 proteins from low-risk HPV (lrHPV) types do 
not bind p53 at detectable levels and have no effect on p53 stability in vitro44. The hrHPV 
E6 proteins have a C-terminal PDZ ligand domain that activates the degradation of several 
cellular targets, thought to be involved in the regulation of cell growth and attachment45. 
Another important characteristic of E6 is its ability to stimulate the catalytic subunit of 
telomerase, which adds hexamer repeats to the telomeric ends of chromosome46. Such an 
activity may predispose to long-term infection. However, in case of E7 absence, p16INK4A 
would inhibit these E6 functions47. Additionally to the fl E6, spliced RNA species can 
generate four either truncated (E6*I and *II) or fused E6 forms (E6*III or *IV). However, 
the functions of the proteins generated from the different transcripts are unclear. Alloul et al. 
reported that E6*I trans-activated and E6*IV trans-represses the viral URR18, other 
researchers argued that these protein fragments are not themselves important, and that the 
splicing event is responsible for a shift in favour of E7 translation13. Recently, an E6^E7 
fusion transcript, spliced from 226^742 and of unknown function has been described48.  
E7 is translated from alternatively spliced E6*I mRNA (species B, E, I) that all use the same 
splice donor (nt 226) and acceptor (nt 409) sites13-15, or as others suggest, from the full-
length (fl) E6/E7 mRNA11,16,49. The E7 protein is mainly responsible for maintaining 
differentiating cells in S-phase50. It binds to the retinoblastoma tumour suppressor protein 
(pRb) and disrupts the association between pRb and the E2F family of external growth 
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factors. E2F then trans-activates cellular proteins, including p16INK4A and enables rapid 
entry of the cell into S-phase. In addition, E7 targets a wide range of proteins involved in 
cell proliferation, as histone deacetylases, components of the transcription complex AP1 and 
the cyclin-dependent kinase inhibitors p21 and p27. It also stimulates the S-phase genes 
cyclin A and E. These interactions induce multiple cellular responses including inhibition of 
p16INK4A and stabilisation of the p53 protein that normally counteract the stimulated cell 
replication by induction of apoptosis. However, as stated above, only hrHPV E6 increases 
degradation of p53 and thereby blocks the cellular response. Conversely, E7 acts 
synergistically with E6 by rescuing it from p16INK4A inhibition (reviewed in51).  
L1 is encoded in transcripts initiated at p670, either unspliced or spliced between splice 
donor nt 1302 and splice acceptor nt 5639 (species P) (described in W12 cells10) or nt 3632 
(species O). Studies addressing cell binding with non-infectious virus-like particles (VLP) 
that self-assembled from overexpressed L1 or both L1 and L2 showed similar binding 
characteristics, implying that L1 contains the major determinants for initial attachment2,52,53. 
L2 protein is expressed only from unspliced late transcripts. During late stages of the 
productive infection the minor capsid protein, L2, and the major capsid protein, L1, are 
expressed in differentiated cells close to the surface of the epithelium. They form the viral 
capsids in the granular cell layer and virions are believed to be released in a non-cytolytic 
manner3. L1 protein has been found only in the upper layers of the epithelium. However, L1 
and L2 RNA can also be detected in lower epithelial layers54,55 indicating that their 
expression is also regulated post-transcriptionally4,31. 
 
1.2.4 HPV life cycle 
HPV replicates solely in keratinocytes of the stratified epithelium of skin and mucosa. 
Mucosal HPV are mainly sexually transmitted and thus people with multiple sexual partners 
are at increased risk for acquiring an infection. The productive life cycles of all HPV are 
organised in a similar way (Figure 1.4) and are tightly linked to the differentiation program 
of the host keratinocytes.  
The cycle is initiated by infectious particles reaching the basal layer of the epithelium, 
where they bind and enter into cells through small breaks5. Receptors involved in viral entry 
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are thought to be heparin sulphate proteoglycans playing a role in initial binding and/or 
virus uptake56. The presence of secondary receptors seems to be required for an efficient 
HPV infection, such as α6 integrin57. For HPV16, papillomavirus pseudovirions are taken 
into the cell by clathrin-coated endocytosis58.  
Following virus binding, entry and transport to the nucleus, the viral genome establishes 
itself as stable low copy-number episome in the basal cells (approximately 20-100 copies 
per cell)32,59,60. A stable pool of infected cells is maintained in the basal epithelial layer, 
while infected daughter cells detach and migrate into the suprabasal layer. Normally, 
suprabasal cells exit the cell cycle and begin to differentiate. During this process, nuclei are 
mostly degraded. However, in HPV-infected keratinocytes, the restraint on cell-cycle 
progression is lost by stimulating the G1-to-S phase through the expression of E6 and E7. 
As the cells move up through the epithelium, the activation of the late, differentiation-
dependent viral promoter (p670 for HPV16) and as consequence an increase of viral 
transcription lead to a productive replication of the viral genome to thousands of copies per 
cell. 
The up-regulation of the differentiation-dependent promoter is critical for the onset of late 
events and directs two set of transcripts; one set terminates at the early poly-A site while the 
second set terminates at the late poly-A site downstream of L1. The first group of late 
transcripts encodes E1^E4, E5, E1 and E2 and the second encodes the capsid proteins L1 
and L2. The first protein expressed in the late phase of the viral life cycle is E1^E4. It is 
detected in the spinous and granular cell layers and has several functions4,31,61. Virus capsid 
proteins L1 and L2, are expressed only in cells of the granular layer with viral particle 
assembly taking place in the cornified layer. Infected cells are scaled off from the epithelial 
surface and may be transmitted directly to other individuals31. 
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Figure 1.4. HPV life cycle organisation and viral protein expression. Modified from 59. Cell layers of the 
epithelium are described and plotted on the left. Red nuclei indicate expression of E6 and E7 and green cells 
the expression of E1-E5. The expression of L1 and L2 (yellow) occurs in viral DNA containing cells in the 
upper epithelial layers. 
 
1.3 Cervical cancer 
Cervical cancer (CxCa) is the second most common cancer among women world-wide, with 
530,000 estimated new cases and nearly 250,000 deaths every year62,63. About 86% of the 
cases occur in developing countries64. Worldwide, mortality rates of cervical cancer are 
substantially lower than incidence rates with a relative ratio of 52%65. In Germany, the 
annual number of new invasive CxCa cases in 2008 was 4,440 and the annual number of 
deaths due to CxCa was 2,018.  
Approximately 80-85% of CxCa are squamous cell carcinomas (SCC) which are generated 
from dividing keratinocytes in the squamous epithelium of the ectocervix. Further 10-15% 
are adenocarcinomas (ADC) which arise from glandular cells located in the endocervix and 
adenosquamous cell carcinomas (ADSCC)66. Other CxCa histologies such as 
neuroendocrine tumours are rare4. 
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1.4 HPV and its association with cervical cancer 
Thus far, more than 150 HPV types have been identified of which 51 types infect the genital 
mucosa. The genital HPV types are divided into three groups based on their epidemiological 
association with CxCa: 14 hrHPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 
and 68), 6 putative hrHPV (26, 53, 67, 70, 73 and 82) and 31 lrHPV (e.g. 6, 11, 40, 42, 43, 
44, 71)67,68. DNA of one of the 14 hrHPV types is found in almost all CxCa (>96.3%), with 
HPV16 being the most prevalent type when squamous cell carcinoma is diagnosed69,70 
(Figure 1.5). A milestone for public health which was awarded with the Nobel Prize in 2008 
(Harald zur Hausen) was the discovery that CxCa is a consequence of an infection with 
some mucosal hrHPV types and has been designated as the first ever identified necessary 
infectious cause for a human cancer. 
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Figure 1.5. Prevalence of HPV DNA in cervical cancer cases. Modified from 71.  
Most women are infected with HPV soon after beginning their first sexual relationship72, 
with the highest prevalence in women aged 25 to 30 years. Thereafter, prevalence decrease 
rapidly. A second peak has been seen in older women73,74. The progression from an initial 
infection to carcinoma is a slow process over years to decades and is characterised by pre-
malignant phases that can be diagnosed by cytological examination of exfoliated cervical 
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cells and confirmed by histological examination of cervical biopsies (Figure 1.6). Cytology 
distinguishes between the “no intraepithelial lesion or malignancy” (NIL/M), “atypical 
squamous cells of undetermined significance” (ASC-US), “low-grade squamous 
intraepithelial lesions” (LSIL) and “high-grade squamous intraepithelial lesions” (HSIL). 
Precursor lesions are defined histologically as cervical intraepithelial neoplasia (graded 
CIN1 to CIN3).  
While 60-80% of women worldwide will be infected at least once per life time with genital 
HPV only 1-4% develop CxCa75. It has been assessed that the majority of CIN1 lesions (up 
to 57%) regresses spontaneously in healthy individuals, probably mediated by cellular 
immunity75. However, CIN1 lesions may remain (32%) or progress (11% to 20%) to 
CIN259,75. CIN2 lesions still display a high regression rate (43% to 55%), while 22% 
progress to CIN3 and the rest persists76-78. Finally, CIN3 lesions may regress (32%), persist 
(56%) or progress (>12%) to CxCa59,75,79.  
Persisting infection with a hrHPV type increases the probability of developing CIN2, CIN3 
and CxCa (≥CIN2)31,80. The transforming potential of hrHPV is induced by the deregulation 
of the viral oncogenes E6 and E7, together with additional alterations of viral and cellular 
genes and pathways81,82. This results ultimately in chromosomal instability and the 
accumulation of mutations. The underlying mechanisms for deregulation are diversely and 
integration, methylation as well as the involvement of HPV16 E1C protein are discussed: 
Integration of the HPV genome is a characteristic step in cervical cancer development and 
correlates with progression and for HPV16 DNA occurs in ~55% of cervical cancer cases 
during carcinogenesis83. This event often leads to a loss of E2 expression and, thus, to an 
elevated expression of the viral oncogenes E6 and E7. In CxCa HPV DNA integration has 
occurred into various regions of the human genome, with certain preferences. Recently, 
indications of a non-random integration and an accumulation in hotspot regions like the 
cytogenetic bands 3q28, 8q24.21 and 13q22.1 have been published84. However, the 
integration breakpoints of the viral and cellular genomes are different in all CxCa85. 
Integration though an indicator of progressed lesions, is not a necessity for 
transformation31,83,84,86. Thus, in CxCa containing episomal HPV genome methylation of the 
viral URR may affect regulatory features, such as the repressive function of E2, that control 
transcription and replication of the viral genome82. Fundamental changes in the methylation 
profile of transcription factor binding sites in the HPV16 URR may trigger neoplastic 
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transformation82. Furthermore, it has been described that the overexpression of HPV16 E1C 
protein may contribute to the transformation of cervical cells87. While the exact role of E1C 
remains to be elucidated, Alloul et al.17 described this protein as possible trans-activator of 
the viral URR that could upregulate expression of E6 and E7. 
Other risk factors increasing the risk of cancer development in addition to hrHPV infection 
are: deficiency of cellular immunity such as mediated by adjunctive HIV infection, 
pharmacological immunosuppression as well as long-term use of oral contraceptives and 
smoking88-94, age at first intercourse, number of life-time partners, co-infection with 
chlamydia trachomatis, parity, age at first birth, and genetic predisposition4,95-99. 
During the progression to CxCa, the distribution of HPV16 proteins E4, L1 and E7 
changes59. LSIL or CIN1 caused by HPV are similar to productive infection in the patterns 
of viral gene expression, and viral coat proteins can usually be detected in cells at the 
epithelial surface59 (see chapter 1.2.4). HSIL or CIN2 or CIN3 lesions have a more 
extensive proliferative phase, with a retarded expression of viral coat proteins (Figure 1.6)31. 
In CxCa, the expression of viral coat proteins is entirely lost. 
 
Figure 1.6. HPV-mediated progression to cervical cancer. Adapted from 59. Red nuclei indicate expression 
of E7, green cells the expression of E4 and yellow nuclei the expression of L1. 
 
1.5 Cervical cancer precursor screening 
Most transient infections and mild lesions (CIN1 or LSIL) regress spontaneously, while low 
number of severe lesions (CIN2, CIN3 or HSIL) regress and high number progress to CxCa 
(Figure 1.7)59,75,77-79. Effective screening needs to distinguish between infections or mild 
lesions versus severe lesions and, thus, enable treatment of HSIL, CIN2 and CIN3 to reduce 
the risk of CxCa development. Several effective strategies for secondary cervical cancer 
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prevention by precursor screening have been identified, including either conventional or 
liquid-based cytology (LBC) detecting abnormal cells in the endocervical canal, hrHPV 
DNA tests looking for the presence of an infection, hrHPV DNA high viral load tests and 
hrHPV RNA testing (Figure 1.7) identifying presence of any lesion. These mentioned 
screening tests are described in detail in the following chapters. 
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Figure 1.7. Overview of spectrum of progression stages towards CxCa and their detection by HPV-based 
screening methods. Modified from 100. The sizes of blue-framed boxes indicate the fraction of women in the 
various groups. The size and direction of arrows indicate the relative frequencies of spontaneous regressions as 
well as progressions, respectively. The HPV-based screening tests are shown with the grey boxes indicating 
the range of CxCa progression stages reacting positive in the various assays. HPV DNA cannot discriminate 
between infection and high-grade lesion, HPV DNA high viral load as well as HPV E6/E7 mRNA does not 
discriminate any grade of CIN. HPV RNA patterns potentially discriminate between ≤CIN1 and ≥CIN2.  
 
1.5.1 Screening using cytology and histology 
Although it has never been tested in a controlled, randomised trial, the effectiveness of 
Papanicolaou (Pap) smear screening in reducing cervical cancer mortality is nearly 
universally accepted. Most developed countries saw dramatic reductions in the incidence 
and death rates from cervical cancer after the implementation of organised screening 
programs. The Pap test is a microscopical search for abnormal cells among exfoliated cells 
collected from the opening of the cervix during a pelvic examination and smeared and 
finally stained on a glass slide. However, the Pap test for cervical screening has severe 
limitations. One is the dependence on subjective judgement of the degree of mitotic activity 
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and nuclear atypia making lesion categorisation only moderately reproducible101,102. 
Another one is the poor sensitivity which implies a high failure rate in detecting cervical 
abnormalities in approximately 50% (10 to 70%) of women compared to colposcopy103. The 
moderate specificity of Pap smear cytology results in a high number of patients that are 
unnecessarily treated for a non-existing disease31. A newer method called LBC, in which the 
swab is suspended in preservative fluid, the cell layer applied by machines to the glass slide 
is more homogenous, allows computer-assisted reading and has logistical and operational 
advantages (interpretation at higher speed, lower rate of unsatisfactory smears and 
possibility of ancillary molecular testing using remnant cell suspension), but is more 
expensive and neither more sensitive nor more specific than conventional cytology104-106. 
Colposcopy-directed biopsies followed by histology are the clinical reference standard for 
diagnosing and grading of precancerous lesions. Advancing grades of CIN (grades 1–3) are 
distinguished mainly according to the extent of the vertical extension of abnormal cells in 
the cervical epithelium. Abnormal cells confined to the basal third are designated CIN1, 
abnormal cells restricted to the basal two-thirds are designated CIN2, and full-thickness 
extension of abnormal cells are designated CIN3. This division is arbitrary. A significant 
lack of reproducibility in CIN classifications has been described which can lead to 
inadequate treatment decisions107-109. 
 
1.5.2 Screening using HPV DNA tests 
The combination of cytological results and HPV testing reaches a better sensitivity, with 
only slight reduction of specificity110-112. Cohort studies over five to ten years have shown 
that the combination of normal cytological result and negative HPV provide better long-
term protection against CIN3 than cytological testing alone113-117. Women hrHPV DNA-
positive in a single specimen and those with two or more positive specimens over time, 
were 16 and 216 times more likely to develop CIN than women who were HPV DNA-
negative31,118-120. 
Despite the high sensitivity of HPV DNA testing, HPV infection is widespread and as many 
as 90% of women positive for HPV DNA subsequently test negative within 6-24 months121-
123. Consequently, HPV DNA tests recognise also clinically not relevant infections or 
regressing lesions. Therefore, the positive predictive value (PPV) of a single hrHPV DNA-
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positive result for the presence of or risk of developing an advanced cervical lesion is low: 
The resulting high proportion of test-positive but disease-negative diagnoses cause 
considerable anxiety for women concerned, over-treatment and unnecessary costs124,125. 
According to the guidelines of the “Deutsche Gesellschaft für Gynäkologie und 
Geburtshilfe” (DGGG) in 2010, HPV DNA testing is still not a part of cervical cancer 
precursor screening in Germany112. However, in the Netherlands the Health Council 
recommends that hrHPV testing should replace cytology as the primary screening method in 
women above 30 years in five to ten years intervals. To prevent unnecessary colposcopy 
referrals, hrHPV-positive women should not be offered colposcopy immediately but should 
be further stratified by means of triage testing. It is appropriate to use cytology for this 
purpose126. 
There are several tests in routine use for HPV DNA detection. The first-generation HPV 
DNA test, FDA proven in 1995, was the hybrid capture tube (HCT) (Qiagen, Hilden) and 
the second generation hybrid capture 2 (HC2) (Qiagen, Hilden), FDA proven in 1999. Both 
methods use direct signal amplification for the detection of eight hrHPV types (16, 18, 31, 
33, 35, 45, 51, 56) without distinguishing which type(s) are present. HC2 includes 
additionally types 39, 52, 58, 59 and 68. The sensitivity range of HC2 has been recorded at 
about 80 to 90% and the specificity between 57 and 89%127. Both, the sensitivity (65% to 
80-90%, Table 1.1) as well as the specificity (60% to 57-87%, Table 1.1) was increased 
compared to HCT through decreasing the detection limit (50,000 to 5,000 viruses/sample) 
and the cutoff, respectively128. Apart from HPV testing for carcinogenic types collectively, 
specific genotyping has recently been raised as one of the options to improve triage and 
screening129. One commercially available genotyping assay, the Linear Array HPV 
Genotyping (LA) (Roche Molecular Systems, Basel) is a qualitative PCR technique 
detecting 37 most prevalent (low, intermediate, and carcinogenic) HPV types: 6, 11, 16, 18, 
26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 
71, 72, 73, 81, 82, 83, 84, IS39, and CP6108. However, LA tests exhibited greater 
sensitivity (91-97%), but lower specificity (47-51%), than HC2 for detecting ≥CIN2 (Table 
1.1)130,131. 
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Table 1.1. Sensitivity and specificity of HPV-based tests127,130,131,128,139,140,132.  
Diagnostic test Detecting
Sensitivity in 
detecting ≥CIN2
Specificity in 
detecting ≥CIN2
Hybrid Capture Tube (HCT) HPV DNA ~65% ~60%
Hybrid Capture 2 (HC2) HPV DNA 80-90% 56-89%
Linear Array HPV Genotyping (LA) HPV DNA 91-97% 47-51%
PreTectTM HPV-Proofer HPV RNA 72% 79%
APTIMA HPV assay HPV RNA 99% 47%  
Besides the commercial tests, several in-house HPV DNA tests had been developed. Since 
the BSGP5+/6+-PCR/MPG assay was used in this thesis, it is described briefly: The assay 
comprises the homogeneous amplification of all known genital HPV types and a Multiplex 
HPV genotyping (MPG) assay with bead-based xMAP Luminex suspension array 
technology133. The Luminex analyser measures a hybridisation product of bead-coupled 
probes and streptavidin-R-phycoerythrin stained PCR-amplicons. The beads contain two 
spectrally distinct fluorochromes. A precise ratio of these fluorochromes creates 100 
different beads with different spectra enabling a simultaneous detection (multiplexing) of up 
to 100 beads per reaction134. BSGP5+/6+-PCR/MPG determines viral load as this is a more 
clinically useful marker with a relatively simple technical feasibility of measurements and 
interpretation. An excellent clinical sensitivity and specificity for CIN3 and CxCa (≥CIN3) 
over 95% has been described134. However, it cannot discriminate between different grades 
of lesion, but between lesion and no lesion (Figure 1.7) and consequently, reduces the 
number of false-positive women with no lesion134. 
 
1.5.3 Screening using HPV RNA tests 
Unlike HPV DNA testing, RNA detection allows the identification and analysis of 
transcriptionally active viruses. The introduction of preservation media for cervical smears 
that, apart from DNA and cell morphology, also conserve RNA, enhanced the application of 
HPV RNA detection methods. Using quantitative assays, high expression of E6/E7 fl and 
E6*I was found to correlate with cytologically diagnosed severe cervical dysplasia135,136. 
Thus, detection and quantitation of mRNA from E6 and E7 genes of hr types could be a 
more specific marker of the presence of high-grade disease and cancer similar to HPV DNA 
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tests measuring viral load (Figure 1.7). Commercial tests targeting HPV E6 and E7 mRNA 
are the PreTectTM HPV-Proofer developed by NorChip/BioMérieux, Inc. (Klokkarstua, 
Hurum, Norway) and the APTIMA® HPV assay by Gen-Probe (San Diego, CA, USA). The 
PreTectTM HPV-Proofer detects early fl mRNA by NASBA targeting E6 and E7 sequences 
(E6/E7) from hrHPV types 16, 18, 31, 33 and 45. Since a simultaneous DNA detection by 
this test has been described137, a false-positive test result for a substantial number of HPV 
DNA-positive women with normal cytology is not surprising138-140. Overall, the sensitivity 
of the HPV-proofer for the detection of ≥CIN2 is 72.8% and the specificity 78.8% (Table 
1.1)140,141. The APTIMA® HPV assay is an isothermal E6/E7 mRNA amplification method 
for 14 HPV types detecting ≥CIN2 with a sensitivity of 98.5% and a specificity of 46.9% 
(Table 1.1)132. In summary, like DNA-tests, E6/E7 transcript-based RNA tests will lead to 
considerable anxiety for women concerned, over-treatment and additional unnecessary 
costs. 
 
1.6 p16INK4a as diagnostic marker for development of CIN 
As discussed, alterations in the viral gene expression pattern mark the progression of a 
productive to a transforming infection. p16INK4a is a cellular correlate of the increased 
expression of oncogenic E6/E7 mRNA: p16INK4a overexpression has been shown in the vast 
majority of cervical precancers and cancers, whereas in normal tissue, p16INK4a expression is 
found only rarely142,143. Consequently, an overexpression of p16INK4a is a promising 
immunohistochemical biomarker for HPV-related cancers144. Immunochemical staining for 
p16INK4a offers a diagnostic adjunct in the evaluation of cervical histology specimens as well 
as cytological samples. However, in cytological diagnosis a dual staining with proliferation 
marker Ki-67 can provide a high sensitivity level for detecting underlying CIN2 and CIN3, 
whereas the specificity using this morphology independent dual biomarker approach may be 
further improved compared to specificity rates observed when single immunoreactivity for 
p16INK4a is applied145.  
Several studies describe an overexpression of p16INK4a in CIN1 (54-72.3%), CIN2 (86-
91%), CIN3 (96-98.3%) and CxCa (98.5%) using p16INK4a histology and in LSIL (37%), 
HSIL (93%) and CxCa (99%) using p16INK4a cytology142. For these approaches, a 
commercial assay, the CINtec® p16INK4a (Roche mtm laboratories), has been introduced. 
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Because a single protein target would detect CIN associated with any carcinogenic HPV 
type, the cost of a p16INK4a assay is likely to be lower than direct HPV tests which require 
multiplexed reagents to reach equivalent sensitivity100.  
 
1.7 HPV16 RNA patterns 
Recently, diagnostic HPV16 RNA patterns were identified with the potential to improve the 
clinical specificity of HPV-based tests substantially31,87,146.  
The expression levels of ten spliced HPV16 RNA sequences, 226^409 (encoding the E6*I 
protein), 226^526 (E6*II), 226^3358 (E6*III), 226^2709 (E6*IV), 880^2582 (E1C), 
880^2709 (E2, E5), 880^3358 (E1^E4), 1302^3358 (E2C, E2M), 1302^5639, 3632^5639 
(L1), five fl sequences, E6 fl, E7 fl, E1 fl, E5 fl, L1 fl and the cellular p16INK4A had been 
determined in NIL/M, LSIL, HSIL and CxCa by singleplex nucleic acid sequence-based 
amplification (NASBA)146 31. NASBA is a one-step isothermal process for amplifying RNA 
and consists of avian myeloblastosis virus reverse transcriptase (AMV-RT), reverse 
transcriptase (RT), T7 RNA polymerase and RNAse H with two oligonucleotide primers. 
NASBA quantified the viral transcripts using external standard curves. 
Of all analysed HPV16 RNA sequences, five spliced transcripts E6*I, E6*II, E1^E4, E1C 
and L1 were identified to be highly diagnostic for discriminating mild from severe lesions. 
The prevalence of E6*I, E6*II and E1C gradually increased from NIL/M to CxCa while the 
prevalence of spliced E1^E4 and L1 encoding transcripts decreased from LSIL to CxCa. 
Whereas the qualitative presence of the spliced transcript E1C was already a highly specific 
marker for severe lesions, the prevalence of E6*I, E6*II, E1^E4 and L1 alone could not 
discriminate the lesion grade.  
Based on the upregulation of HPV16 transcripts E6*II and/or E1C and the downregulation 
of E1^E4 and/or L1 transcripts in HPV16- transformed cells146, two HPV16 RNA patterns 
were defined, each comprising a ratio of two quantified spliced HPV16 transcripts: The 
amount of E6*II normalised to the amount of E1^E4 (pattern 1) and the amount of E1C 
normalised to the amount of L1 (pattern 2). Although both E6*II and E6*I could be used for 
discriminating between mild and severe lesions, E6*II was upregulated more strongly in 
CxCa than E6*I and included in pattern 1.  
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The computation of ratios of two viral transcripts allowed normalising for variable 
quantities of HPV-infected cells in cervical smears, since it has to be kept in mind that by 
far not every cell in a cervical smear is HPV-infected. On average, a LBC slide contains 
23,000 cells (range 1,000 to 100,000). Among NIL/M specimens, on average 0.2 HPV-
positive cells per slide (1 case with a total of 6 HPV-positive cells), in LSIL approximately 
127 (range 0-1,000; 0.56%) and in HSIL 450 (range 0-6,250; 1.95%) has been described147. 
Although the computation of ratios can compensate the variable number of HPV-infected 
cells in cervical smears, a high analytical sensitivity but also the presence of HPV-infected 
cells in the cervical smear is necessary in order to reduce the number of false-negative 
diagnosis.  
In a pilot study comprising 77 cytologically diagnosed HPV16 DNA-positive samples, the 
two ratios of the four marker transcripts were determined. In total, 100% of CxCa (7 out of 
7) and 67% of HSIL (16 out of 24) samples were correctly classified as severe and 74% of 
LSIL (17 out of 23) and 92% of NIL/M (21 out of 23) samples as mild lesions87 (Figure 
1.8). The specificity of the HPV16 RNA patterns for discriminating severe and mild 
cytological lesions was 83%, the specificity was 74%. 
However, the pilot study was limited by small sample numbers defined by cytology only 
and the labour, time and cost intensity of singleplex NASBA assays not suitable for routine 
diagnostic test. In addition, the quantification of transcripts worked only in ten-fold steps 
over four to five magnitudes and was at best semi-quantitative. The slope of the transcript 
standard curves differed, being almost linear for E1^E4, E6*I and L1 but polynomal for 
E1C complicating the accurate quantification (Figure A8.1). Reproducibility of quantifying 
viral RNA in HPV16 DNA-positive cell lines was only moderate showing the highest 
variation for quantification of E1C148. 
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Figure 1.8. Distribution of HPV16 RNA patterns in exfoliated cervical cells of women with HPV16 DNA-
positive mild (NIL/M and LSIL, open triangles) and severe lesions (HSIL and CxCa, filled triangles). 
Pattern 1 (x-axis) and pattern 2 (y-axis) (data of ref 87, kindly provided by Dr. Markus Schmitt (DKFZ)). 
Cutoff (1.5 for E6*II/E1^E4 ratio and 0.003 for the E1C/L1 ratio) is shown as dotted line. If E1C and L1 were 
positive in NASBA, an E1C/L1 ratio was calculated; if one transcript was negative, its value was set to 0.001 
to calculate the E1C/L1 ratio; if both transcripts were negative, the E1C/L1 ratio was set below 0.0001. If 
E6*II and E1^E4 were positive in NASBA, an E6*II/E1^E4 ratio was calculated; if one transcript was 
negative, its value was set to 0.001 to calculate the E6*II/E1^E4 ratio; if both transcripts were negative, the 
E6*II/E1^E4 ratio was set to 0.0001. 
 
1.8 Aim of the thesis 
The association of hrHPV infection and cervical cancer development has been 
unequivocally shown. This is particularly true for HPV16 causing about 55% of CxCa 
cases. While HPV DNA tests exhibit excellent sensitivity and a very high negative 
predictive value (NPV), they show deficiencies in specificity and PPV for advanced lesions. 
As a consequence, they lead to overtreatment of patients, and may not be suited for stand-
alone solutions in screening programs. The impetus for new screening technologies in the 
developed world is predominantly driven by the need to increase the PPV and reduce 
overmanagement of low-grade and often transient abnormalities. Detection of HPV16 RNA 
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patterns has been identified as a novel biomarker with potential to sensitively and 
specifically differentiate mild from severe cervical precancerous lesions. However, RNA 
patterns detection has been based on laborious, cost-intensive singleplex NASBA reactions 
and had been validated with a small number and only cytologically defined specimens. 
The aim of this thesis was the design, development and validation of multiplex reverse 
transcriptase quantitative PCR (RT-qPCR) for the detection of the spliced HPV16 
transcripts (E6*II, E1^E4, E1C, L1) and the cellular housekeeping gene ubiquitin C (ubC). 
This project was part of a collaborative research agreement with Roche Molecular Systems, 
Inc.. With the novel RT-qPCR an important step towards high-throughput analyses of large 
studies and diagnostic applications would be done. Furthermore, the clinical sensitivity and 
specificity of HPV16 RNA patterns should be determined more accurately using a large 
number of histologically defined cervical samples.  
Another aim was provide the basis to diagnostic HPV RNA patterns analysis to lesions 
caused by the other prevalent hrHPV types 18, 31, 33, 35, 45, 52 and 58.  
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2 Materials 
2.1 Reagents 
2-(N-Morpholino) ethanesulfonic acid (MES)   Sigma-Aldrich, Steinheim 
20% Sarcosyl (N-Lauroylsarcosine)   Sigma-Aldrich, Steinheim 
RNase-free 
5-Bromo-4-chloro-3-indoyl-β-D-   Carl Roth, Karlsruhe  
glactopyranoside (X-gal) 
Agarose     GIBCO Life Technologies, Paisley 
(Scotland)  
Ampicillin    Roche, Mannheim  
Bacto-Agar    Becton Dickinson, Sparks (MD, USA) 
DMEM   Sigma, Deisenhofen 
EDTA-Disodium, RNase-free    AppliChem, Darmstadt 
Ethanol (EtOH) (abs.)    Riedel-de Haёn, Seelze 
Ethidium bromide (EtBr)    Sigma-Aldrich, Steinheim 
Fetal Bovine Serum (FCS)   Invitrogen, Carlsbad (CA, USA) 
Glycerol 100%, waterfree   Carl Roth, Karlsruhe 
Isopropanol    J.T Baker, Deventer (The Netherlands) 
N-(3-dimethylaminopropyl)- N-   Pierce, Thermo, Rockford (IL, USA) 
ethylcarbodiimide (EDC) 
Natriumhypochloride (NaClO)   Carl Roth, Karlsruhe 
Phenol/Chloroform   Carl Roth, Karlsruhe 
PreserveCytTM solution    Cytyc Corp., Boxborough (MA, USA) 
RNA ladder „low range“   NEB, Frankfurt am Main  
RNA, MS2   Roche, Applied Science, Mannheim 
RNase away spray     Molecular Bioproducts, San Diego (CA, 
USA) 
Smart ladder    NEB, Frankfurt am Main  
Sodium acetate (NaAc)   J.T. Baker, Deventer (The Netherlands) 
Sodium dodecyl sulfate (SDS)    Serva Electrophoresis, Heidelberg 
Streptavidin-R-Phycoerythrin (Strep-PE)   Molecular Probes, Eugene (OR, USA) 
TE buffer, RNase-free, 1x   Acros Organics, Geel (Belgium) 
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
Tetramethylammonium chloride (TMAC)   Sigma-Aldrich, Steinheim 
Tris-HCl, pH 8.0, RNase-free, 1 M    Jena Bioscience, Jena 
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Trypsin-EDTA (0.25%)   Life-Technologies, Karlsruhe  
Tween20®, RNase-free    Serva Electrophoresis, Heidelberg 
Water, DNase/RNase-free    Invitrogen, Carlsbad (CA, USA) 
xMAPTM Sheath Fluid    Luminex Corp., Austin (TX, USA) 
Xylene cyanol    Merck, Darmstadt  
 
2.2 General buffers and solutions 
10 x NTP stock solution   mixture of 2 mM of each NTP  
ATP, TTP, CTP, GTP in H2O   storage at -20°C 
50 x Electrophoresis-buffer (TAE)    2 M Tris, pH 7.8 
   0.25 M NaAc (water free) 
   0.05 M EDTA 
   H2O ad 8 L 
   storage at RT 
50% Glycerol   25 mL glycerol (100%) 
   25 mL H2O 
   autoclave 
DNA-loading buffer    0.02% xylene cyanol, 
   40% (w/v) sucrose in H2O 
   storage at -20°C  
Ethidium bromide stock solution    10 mg/mL in H2O 
   storage at 4°C in the dark 
LB-Agar   LB medium 
   1.5% (w/v) Bacto-Agar 
   autoclave , storage at 4°C 
LB medium    10 g (1% (w/v)) Bacto-Trypton 
   5 g (0.5% (w/v)) Bacto-yeast extract 
   10 g (1% (w/v)) NaCl 
   H2O bidest ad 1 L 
   adjust to pH 7.5 with NaOH (5 M) 
   autoclaved, storage at 4°C 
PBS (Phosphate buffered saline),    124 mM NaCl 
1 x, pH 7.4    22 mM Na2HPO4 
storage at RT   10 mM KH2PO4  
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2.3 Luminex buffers 
Detection solution Luminex DNA/RNA 2 M TMAC 
75 mM Tris-HCl, pH 8.0  
6 mM EDTA, pH 8.0  
1.5% (w/v) Sarcosyl 
DNA hybridisation solution 0.15 M TMAC  
75 mM Tris-HCl, pH 8.0  
6 mM EDTA, pH 8.0  
1.5% (w/v) Sarcosyl  
Hybridisation wash buffer Luminex 0.02% Tween 
1 x PBS, pH 7.4 
0.1 M MES coupling buffer 4.88 g MES 
 H2O ad 250 mL  
 adjust to pH 4.5 with NaOH (5 M) 
Wash buffer I (coupling) 50 µL Tween 
 H2O ad 250 mL  
Wash buffer II (coupling) 2.5 mL of SDS (10%) 
 H2O ad 250 mL  
 
2.4 Enzymes and inhibitors 
Proteinase K   Sigma-Aldrich, Steinheim 
Restriction enzyme: EcoRV  Fermentas, St. Leon-Rot  
RiboLock RNase Inhibitor   Fermentas, St. Leon-Rot 
T7 RNA Polymerase   Fermentas, St. Leon-Rot 
 
2.5 Commercial kits and reagents 
DH5α competent cells   Invitrogen, Carlsbad (CA, USA) 
Gelextraction QIAquick Kit  QIAGEN, Hilden 
High Pure PCR Template Preparation Kit  Roche Applied Science, Mannheim 
Light Cycler 480 RNA     Roche Applied Science, Mannheim 
Master Hydrolysis Probe Kit 
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MagNA Pure 96 Cellular RNA Large Volume Kit Roche Applied Science, Mannheim 
MagNA Pure 96 DNA and    Roche Applied Science, Mannheim 
viral NA Large Volume Kit 
Mini-preparation QIAprep®Spin Miniprep Kit  QIAGEN, Hilden 
Pure-Link FFPE Total RNA Isolation Kit  Invitrogen, Carlsbad (CA, USA) 
Qiagen Multiplex PCR Kit   QIAGEN, Hilden 
QIAsymphony DSP Virus/Pathogen Kit  QIAGEN, Hilden 
RNAeasy MinElute Cleanup Kit  QIAGEN, Hilden 
StrataClone Blunt PCR Cloning Kit   Agilent Technologies, Santa Clara  
   (CA, USA) 
 
2.6 Commercial plasmid vector 
Bluescript M13-KS vector   Agilent Technologies, Santa Clara (CA, 
USA) 
pSC-B-amp/kan vector  Agilent Technologies, Santa Clara (CA, 
USA) 
 
2.7 Consumables 
Tubes, graduated, flat-base, 5ml   QIAGEN, Hilden 
96 PCR plate  Sorenson, Bioscience Inc., Utah, USA 
Cell culture flask (75, 150 cm)   Greiner, Frickenhausen 
Conductive Filtered Tips (50 µL), QIAgility  QIAGEN, Hilden 
Disposable protective coats-Foliodress   Steinbrenner Laborsysteme, Wiesenbach 
Falcon-tubes (15 mL)   TPP®, Trasadingen (Switzerland) 
Filter sterile (0.2 µm)  Renner, Dannstadt 
Filter tips 0.5-10 µL  nerbe plus GmbH, Winsen  
Rainin filter tips LTS, 1,000 µL  Steinbrenner Laborsysteme, Wiesenbach 
Filter tips:   star lab GmbH, Ahrensburg 
Extended 0.1 to 10 µL (S1120-3810)  
2 to 20 µL (S1120-1810) 
20 to 200 µL (S1120-8810) 
200 to 1000 µL (S1126-7810) 
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Filter tips, 5,000 µL   Eppendorf, Hamburg 
LightCycler®480 Multiwell Plate 96, white  Roche Applied Science, Mannheim 
LightCycler®480 Sealing Foil  Roche Applied Science, Mannheim 
Litter plastic bags  Greiner Bio-one, Frickenhausen 
Low-retention LR tubes   G. Kisker GbR, Steinfurt 
Multiscreen 96-well wash plates   Millipore, Bedford (MA, USA) 
Petri dishes (Ø 8,5 cm)   Greiner bio-one, Frickenhausen 
Pipette tips for motor pipette   Biozym, Hessisch Oldendorf 
Polypropylen protective sheet   HJ-Bioanalytik GmbH, Mönchenglattbach 
Reagent Reservoir 4870 (50 mL)    Corning Incorporated, Corning (NY, USA) 
SeroMapTM beads   Luminex Corp., Austin (TX, USA) 
Syringe (50 mL)   Terumo, Leuven, Belgium  
 
2.8 Laboratory devices 
8-channel pipette 0.5–10 µL  Brand, Roskilde (Denmark) 
8-channel pipette 20-200 µL   Brand, Roskilde (Denmark) 
8-channel-motor pipette Precision®             Biozym Diagnostik, Hessisch Oldendorf 
Agarose gel electrophoresis chamber  Renner, Dannstadt 
including gel tray and combs 
Agilent 2100 bioanalyzer    Agilent, Santa Clara (CA, USA) 
Bunsen burner   Buddeberg, Mannheim 
Centrifuge (Minifuge GL)  Heraeus-Christ, Osterode 
Cobas z480      Roche, Applied Science, Mannheim 
Drigalski spatula   Buddeberg, Mannheim 
Eppendorf Research pipette 5,000µL            Eppendorf, Hamburg 
Freezer -20°C             Liebherr, Bulle (Schweiz) und Bosch 
Freezer -80°C   Forma Scientific (OH, USA) 
Fridge 4°C  Liebherr, Bulle (Schweiz) und Bosch 
Gilson pipettes   Gilson-Abimed, Düsseldorf 
(2 µL, 20 µL, 200 µL, 1,000 µL)  
Heating block Thermomixer compact   Eppendorf, Hamburg 
Ice machine (automatic ice maschines AF30)  Scotsman, Mailand (Italy) 
Image Master ® VDS  Pharmacia Biotech, Freiburg 
Laboratory Oven (120°C)   Bachofer, Reutlingen 
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Light Microscope     Leica Microsystems, Wetzlar 
Luminex 100 Analyser   Luminex Corp., Austin (TX, USA) 
MagNA Pure 96 System            Roche Applied Science, Mannheim 
Mastercycler Eppendorf   Eppendorf, Hamburg 
Mega Centrifuge 40R     Heraeus-Christ, Osterode 
Micro wave   Mikromat AEG, Nürnberg 
Mini-centrifuge   Labnet, Woodbridge (NJ, USA) 
Mini-centrifuge   Qualitron Inc., Karachi (Pakistan) 
NanoDrop 1000             Thermo Scientific, Wilmington  
            (DE,USA) 
Neubauer Zählkammer     Carl Roth, Karlsruhe 
Pasteur Pipettes  Sigma-Aldrich, Steinheim 
pH-Meter   inoLab®, WTW, Weilheim 
Pipetboy   Integra Biosciences, Fernwald 
QIAgility            QIAGEN, Hilden 
QIAsymphony SP instrument            QIAGEN, Hilden 
Rainin Multichannel pipette 10-1,200 µL LTS  Steinbrenner Laborsysteme, Wiesenbach 
Shaker at 37°C   INFORS AG, Bottmingen (Switzerland) 
Shaker at 37°C SM25  Edmund Bühler, Tübingen 
Shaker at RT UNIMAX 1010   Heidolph, Schwabach 
Table Centrifuge 5415 D   Eppendorf, Hamburg 
Table Centrifuge Sigma 2K15   Sigma, Osterode/Harz 
Vacuum-wash station   Millipore, Bedford (MA, USA) 
Vortex Genie    Bender & Hobein, Zürich (Switzerland) 
Vortex R LABIN   Kurt Migge, Heidelberg 
Vortex Reax top   Heidolph, Schwabach 
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2.9 Oligonucleotides 
All primers and probes, designed for the HPV16 RNA patterns assay were synthesised by 
Roche Molecular Diagnostics, Pleasanton, CA and primers and probes, and by Sigma-
Aldrich, St.Louis (USA) in HPLC purification quality. Detailed sequence information of 
primers and TaqMan probes are not presented for reason of intellectual property (IP) 
protection, but can be made available upon request with appropriate IP protection 
agreement. 
 
2.10 Cloned plasmids containing spliced HPV16 transcripts 
All plasmids containing spliced HPV16 transcripts were kindly provided by Dr. Schmitt 
(DKFZ) (Table 2.1).  
Table 2.1. Overview of plasmids. 
Name
Accession 
number
Cloned region from 
reference genome
Cloning vector
E6*I HPV16Ra 83-795 Bluescript M13-KS vector
E6*II HPV16R 83-795 Bluescript M13-KS vector
E1C HPV16R 83-4210 Bluescript M13-KS vector
E1^E4 HPV16R 804-4210 Bluescript M13-KS vector
L1 HPV16R 3368-5882 Bluescript M13-KS vector
HPV16 fl HPV16R 1-7904 Bluescript M13-KS vector  
a HPV16 sequence and base positions are numbered according to the 1996 sequence database (Los Alamos 
National Laboratory). http://hpv-web.lanl.gov/COMPENDIUM_PDF/95PDF/1/A1-9.pdf 
 
2.11 Clinical specimens 
A convenience sampling strategy was used to include patients in the study. Any patient who 
visited the routine colposcopy clinic in Bad Münder in the period between October 2010 
and March 2012 was eligible to participate. A patient was referred to the routine colposcopy 
clinic in Bad Münder after suspicious cytological finding by the women´s gynaecologists. A 
total of 691 exfoliated cervical cell samples were collected and stored in PreservCyt at 4°C 
for up to 2 years (Table 2.2). The patients’ age ranged from 20 to 65 years, with a medium 
Materials 
 
30 
of 31 years of age. Furthermore, one colposcopy-directed biopsy was taken from each 
patient. Hematoxylin and eosin (HE) and p16 stained sections from formalin-fixed paraffin-
embedded (FFPE) biopsy tissues were read independently by two histologists, one of them, 
following standard clinical practice, was aware of the patient’s HPV DNA status determined 
in the cytology sample by LA HPV genotyping test (Roche Molecular Diagnostics). In a 
period of 24 months 114 patients were followed-up at least once after abnormal cytology. 
The study was enriched by HPV16 DNA-positive PreservCyt cervical cytology samples 
(stored at 4°C for 7 years before RNA extraction) from CxCa patients (n=27)12 and NIL/M 
cases (n=71)149 from HPV prevalence studies conducted in Ulaanbaatar, Mongolia in 2005 
(Table 2.2). From all CxCa patients also FFPE biopsies were available. Fixation and 
processing of FFPE blocks followed the same protocol. The FFPE biopsies were previously 
characterised by histology, HPV DNA and ultra-short E6*I mRNA RT-PCR assays (see 
methods 3.5)12. HPV16 E6*I mRNA positive patients (n=27) were included in this study.  
Furthermore, 24 FFPE samples from the Barcelona study collected from the worldwide 
Catalan Institute of oncology (ICO) in nine different countries (Portugal, Peru, Colombia, 
Lebanon, Paraguay, Venezuela, Philippines, Greece and France) between year 1929 and 
2006 were included in this thesis to examine the applicability of HPV16 RNA patterns to 
these materials (Table 2.2)4,150. The FFPE samples had been determined as singly HPV16 
RNA-positive by ultra-short E6*I mRNA RT-PCR assays and singly HPV16 DNA-positive 
by BSGP5+/6+-PCR/MPG (see methods 3.2)4 (Halec et al., submitted to JNCI151). 
Additionally, 32 RNA specimens isolated from sections of fresh-frozen oropharyngeal 
squamous cell carcinomas (OPSCC)152 obtained from the Ear, Nose and Throat Department 
of the University Hospital Heidelberg, Germany, collected between 1990 and 2008, were 
used for a comparison of the established NASBA assays with the newly developed RT-
qPCR assays (Table 2.2). All OPSCC had been determined to be HPV16 DNA-positive by 
the BSGP5+/6+-PCR/MPG. NASBA data of the OPSCC have recently been described152. 
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Table 2.2. Overview of different studies included in this PhD thesis. 
Study Material Number
Storage time 
(in months)
Bad Münder PreservCyt samples 691 9-24
Mongolia PreservCyt samples 98 84
Mongolia FFPE material 27 60
Barcelona FFPE material 24 48-92
Heidelberg Fresh-frozen OPSCC samples 32 0  
 
2.12 Ethical clearance 
The Mongolian population-based HPV prevalence study was approved by ethical review 
boards of the Mongolian Health Ministry. All patients gave written informed consent and 
completed standard WHO questionnaires149. The OPSCC study as well as the Bad Münder 
were approved by the Ethics Committee of the Medical Faculty of the University of 
Heidelberg, study codes 176/2002152 and S-004/2010, respectively. 
 
2.13 Computer programs 
Luminex 100 IS 2.3 SP1 Software  Luminex Corp., Austin (TX, USA)  
Microsoft Office   Microsoft Corp., Unterschleißheim  
Microsoft Windows XP   Microsoft Corp., Unterschleißheim  
GraphPad Prism® 5   GraphPad Software, Inc. La Jolla, (CA, USA) 
SAS 9.3  SAS Institute Inc., Cary (NC, USA) 
LightCycler Probe Design software 2.0 Roche Molecular Diagnostics (CA, USA) 
 
2.14 Online software  
Blast NCBI  http://www.ncbi.nlm.nih.gov/BLAST/ 
EMBL-EBI ClustalW2  http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
FastPCR     http://www.biocenter.helsinki.fi/bi/Programs/fastpcr.htmL 
Nucleotide NCBI  http://www.ncbi.nlm.nih.gov/nuccore/ 
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2.15 Services  
Multiplexion GmbH http://www.multiplexion.de/ 
GATC Biotech http://www.gatc-biotech.com/de/index.html 
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3 Methods 
3.1 DNA and RNA isolation and quality determination 
3.1.1 DNA extraction from exfoliated cells 
DNA was released from 800 µL exfoliated cervical cell samples from Bad Münder using the 
QIAsymphony DSP Virus/Pathogen Midi Kit on the platform of the QIAsymphony SP 
instrument in combination with the Complex800_V5_DSP protocol. DNA was eluted in 60 
µL elution buffer (Qiagen, Hilden, Germany) according to the manufacturer´s instructions. 
DNA from Mongolian samples was extracted as described previously149. DNA from the 32 
fresh frozen OPSCC samples had been isolated using Qiagen's QIAamp DNA Mini Kit as 
described152. 
 
3.1.2 RNA extraction 
For RNA extraction, 106 cells per cell line, including CaSki153, MRI-H196154 and MRI-
H186154, SiHa22 and exfoliated cervical cell samples from Bad Münder and Mongolia were 
subjected to an automated extraction on the MagNA Pure 96 in combination with the RNA 
LV 2.0 protocol. According to the manufacturer´s recommendations, the MagNA Pure 96 
Cellular RNA Large Volume Kit was applied with some modifications. Briefly, 4,000 µL 
and 1,000 µL cervical sample volume, respectively, were centrifuged for 10 min at 4,700 x 
g. The pellet was resuspended in 200 µL of PreservCyt medium, applied to the MagNA pure 
96 and RNA eluted in 50 µL elution volumes and stored at -80°C until use. Similarly, 106 
cultured cells were resuspended in 200 µL PBS and applied to the instrument. Cell 
equivalents were computed based on the assumption that each cell contains about 17 pg of 
total RNA148. Additionally, RNA from exfoliated cervical cell samples was extracted with 
another kit (MagNA Pure 96 DNA and viral NA Large Volume Kit) under same conditions 
as described before. 
Total RNA from the 27 FFPE was prepared using the Pure-Link FFPE Total RNA isolation 
kit as described12 and stored at -20°C until use. Same extraction procedure was performed 
with the 24 FFPE samples from the Barcelona study. RNA from the 32 fresh frozen OPSCC 
samples had been isolated using Qiagen RNeasy Mini kit as described152. 
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3.1.3 RNA quality determination 
The concentration of all RNA extracts was measured with the NanoDrop 2000. RNA 
samples were also run on an Agilent 2100 bioanalyzer, which automatically calculates the 
RNA Integrity Number (RIN). Integrity is no longer determined by the ratio of the 
ribosomal bands, but the entire electrophoretic profile of the RNA sample. An RNA profile 
is separated according to the molecular weight and subsequent detection via laser-induced 
fluorescence in channels of microfabricated chips. The algorithm that underlies the RIN 
calculation divides the entire RNA profile into nine different regions (pre-, marker-, 5S-, 
fast-, 18S-, inter-, 28S-, precursor- and post-region) and applies a statistic to these giving a 
continuous value from 10 down to 1 defining the extend of RNA degradation (10=intact, 
1=totally degraded)155. 
 
3.2 HPV DNA analysis of clinical specimens 
The BSGP5+/6+-PCR/MPG assay comprises the BSGP5+/6+-PCR, which homogenously 
amplifies all known genital HPV types generating biotinylated amplimers of ~150 bp from 
the L1 region156 and the MPG assay with bead-based xMAP Luminex suspension array 
technology, which is able to simultaneously detect 51 HPV types and the ß-globin (bg) 
gene31,133,157. Briefly, amplification was performed using the Multiplex PCR Kit (Qiagen, 
Hilden, Germany) using 0.2–0.5 µM of each BSGP5+ and 5´-biotinylated BSGP6+ primers 
and 0.15 µM of each ß-globin primer MS3 and 5´-biotinylated MS10. Following PCR 
amplification, 10 µL of each reaction mixture is hybridised to bead coupled probes as 
described before156. Results were measured with the Luminex 100 analyser. The median 
reporter fluorescence intensity (MFI) of at least 100 beads was computed for each bead set 
in the sample. As described earlier158, the cutoff value (5 net MFI) to define HPV positivity 
was applied. 
 
3.3 HPV viral load analysis 
Quantification of HPV signals was implemented with the MFI values obtained by the 
BSGP5+/6+-PCR/MPG assay. In detail, for each positive reaction, the relative HPV MFI 
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signal (%) was computed by dividing the measured HPV MFI value with the maximum 
value detected of this HPV type using PCR product where DNA, available in form of 
colonies, was directly applied. Finally, the relative MFI (%) was divided by the measured ß-
globin MFI value to form a non-descriptive viral load value (%HPV MFI/ß-globin MFI). 
High viral load was assessed for all HPV types by a HPV type-independent high viral load 
cutoff (0.0007 units) correlating to 0.46 HPV copies per cell, as recently described133,134.  
 
3.4 NASBA assays 
Singleplex NASBA assays detecting E6*II, E1^E4, E1C and L1 HPV16 transcripts in 
OPSCC samples were carried out as described31,87,152. Briefly, purified mRNA was 
quantified using the principle of competitive NASBA, which is based on the simultaneous 
co-amplification of calibrator RNA (primer binding sites and amplicon size identical to 
target RNA, but unique probe binding site), combined with subsequent hybridisation to 
oligonucleotide probes coupled to Luminex beads. 
 
3.5 Ultra-short E6*I mRNA RT-PCR assays 
The ultra-short E6*I mRNA RT-PCR assays designed for the analysis of FFPE samples 
comprised duplex PCR amplifying the E6*I mRNA of one type plus ubC mRNA, followed 
by Luminex hybridisation as described previously12. In total, the presence of 12 high-risk 
HPV types and 8 possibly high-risk HPV types can be determined in 20 duplex PCR. 
 
3.6 Identification of splice junctions for seven hrHPV types 
So far, splice junctions for E6*I of the seven hrHPV types 18, 31, 33, 35, 45, 52 and 58 
were described before159,160. Also the E1^E4 splice junction of HPV18 (929^3434), HPV31 
(887^3295)161, HPV33 (894^3351), the E1C splice junction of HPV31 (877^2646)162 and 
the L1 splice junction of HPV31 (3832^555)161 have been identified. For the identification 
of the remaining unkown HPV16 equivalent splice junctions E1C, E1^E4 and L1, 72 
exfoliated cervical cell samples harboring DNA of hrHPV types 18, 31, 33, 35, 45, 52 and 
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58 were selected from participants of a Mongolian population-based HPV prevalence study. 
The criterion for sample selection was presence of hrHPV types of interest as single or 
multiple infections. Of 72 exfoliated samples, 5 harbored HPV18, 9 HPV31, 6 HPV33, 13 
HPV35, 13 HPV45, 13 HPV52 and 14 HPV58. One samples harbored combination of the 
two types of interest. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). DNase treatment (RNase-Free DNase Set, Qiagen, Hilden, Germany) was 
performed to remove potentially co-extracted DNA. Using Fast PCR programme, type 
specific primers (Sigma-Aldrich, Hamburg, Germany) were designed for amplification of 
E1C, E1^E4 and L1 spliced transcripts. For the E1^E4 amplification of HPV58, 52, 35 and 
45 primers were re-designed two times as well as for the L1 amplification of HPV35, 33 and 
18 primers. Presence of spliced transcripts was verified by 2% agarose gel electrophoresis. 
Amplimers with expected size (271-400 bp for spliced transcripts) were excised and 
extracted using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Cloning 
followed the protocol of the StrataClone Blunt PCR Cloning Kit (Stratagene, Agilent 
Technologies, California, USA). Cloned fragments were sequenced at GATC (Konstanz, 
Germany). HPV types were identified by BLAST search. 
 
3.7 Agarose gel electrophoresis 
DNA/RNA fragments can be separated by size in an agarose gel using gel electrophoresis 
and become visible under UV light (260 nm) after ethidium bromide staining. Depending on 
the DNA/RNA size to be examined, agarose concentrations differed between 1% for 
separation of 1-10 kb fragments and 2% for analysis of small PCR products and in vitro 
transcribed RNA.  
For a 2% gel, 3 g of agarose and 150 mL of 1 x TAE electrophoresis buffer were briefly 
boiled in a microwave oven, supplemented with 15 µL of 10 mg/mL ethidium bromide 
stock solution and poured into a gel chamber to solidify at room temperature. PCR products 
and digested plasmids were supplemented with 1/5 volume of 6 x DNA loading buffer and 
separated electrophoretically at 90 to 120 V in 1 x TAE buffer. The Smart-Ladder DNA 
marker was used to determine size and concentration of DNA fragments in agarose gels. For 
RNA analyses, RNA was supplemented with equal quantities of 2 x RNA-loading buffer. 
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The RNA ladder “low range” marker was used for size determination. Digital photographs 
were taken using Image Master VDS. 
 
3.8 Design of RT-qPCR primers and probes 
The aim was to design specific primers and probes binding all isolates from HPV16. 
Sequences available at public nucleotide database of the NCBI homepage were aligned 
using ClustalW2. Primers were selected flanking the HPV16 splice junctions 226^409 
(coding potential E6*I), E6*II, E1C, E1^E4 and L1 and, as an internal RNA quality control, 
the spliced ubiquitin C (ubC) transcript (5455^6267) analogously to recently described 
NASBA primers31,87. To be splice-site specific, TaqMan probes were positioned covering 
the splice junctions (Figure 3.1). Splice junctions of HPV16 have already been 
published7,14,163. Probes were labelled with different fluorochromes to enable multiplex 
detection of PCR products. To ensure the specificity of primers and splice-site specificity of 
probes, prior to practice, an in silico analysis was done. For this purpose, BLAST at the 
NCBI homepage was performed for the comparison of the amplicons with homologous 
sequences. In order to exclude unspecific amplification of other HPV types, at most nine 
consecutive nucleotides within the primer and probe region was tolerated. All primers and 
probes were assessed for their annealing temperature by FastPCR. Primers and probes 
match the following criteria: Melting temperature of primers should be around 50°C–60°C 
and the probe should be approximately 10°C higher, amplicon length should be ideally 
maximal 150 bp and as few degenerate nucleotides as possible should be present. All 
primers and probes were tested in single- and multiplex quantitative reverse transcriptase 
PCR (RT-qPCR).  
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Figure 3.1. Position of primers and TaqMan probes. While primers for the detection of spliced transcripts 
bound in close proximity to a splice junction (black arrows), exemplarily shown for the 880^3358 transcript, 
TaqMan probes directly covered the splice junction (green lines). 
 
3.9 Preparation of RT-qPCR controls  
3.9.1 Production of in vitro transcripts 
HPV16 in vitro transcripts were generated from Bluescript M13-KS vector (Stratagene) 
containing spliced E6*I, E6*II, E1^E4, E1C, L1 and ubC cDNA, respectively, in 2007 by 
Dr. Markus Schmitt as described earlier31,87. HPV18 in vitro transcripts were generated from 
pSC-B-amp/kan vector (Stratagene) containing spliced E6*I, E1^E4, E1C or L1. Absence of 
residual DNA was confirmed by DNA-directed PCR (see chapter 3.2). The viral copy 
number per unit mass was calculated by assuming that 1 bp weighs about 340 Da. Assuming 
an in vitro transcript size of 2,000 bp, this corresponds to a mass of 9.8 x 10–10 ng per 
transcript molecule. Knowledge of the concentration of the purified RNA preparations 
allowed computing the number of in vitro transcripts per µL. 
 
3.9.2 Cervical cancer cell lines 
Cell lines CaSki, MRI-H196, MRI-H186 and SiHa were cultured as monolayers in cell 
culture flasks. In order to quantify cell numbers prior to RNA isolation, DMEM medium 
was aspirated. Cells were washed with PBS. PBS was removed and cells were treated with 2 
mL of trypsin/EDTA for 2 to 5 min. After cells detached from the flask, 8 mL of medium 
containing 10% FCS was added to inactivate trypsin. Subsequently, a coverslip wetted with 
E6  E7  E4 E5ORF 
qRT target 
880 3358
880^3358 
Primerpair P1 
TaqMan probe 
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exhaled breath was slid over the Neubauer counting chamber back and forth using slight 
pressure until Newton’s refraction rings appeared. Under sterile conditions one drop was 
added to one side of the chamber viewed under a light microscope using x 20 
magnification31. The number of visible living cells was counted in all four main squares 
(each comprising 16 small squares). The cell number in the suspension was calculated as 
follows: 
 Total number of counted cells of all four main chambers divided by two 
 multiplied by 10,000 (correction factor) and by 10.0 (volume of cell suspension). 
Each cell line was authenticated using Multiplex Cell Authentication by Multiplexion 
(Heidelberg, Germany)164. The SNP profiles matched known profiles. The purity of cell 
lines was validated using the Multiplex cell Contamination Test by Multiplexion 
(Heidelberg, Germany)165. No Mycoplasma, SMRV or interspecies contamination was 
detected.  
 
3.9.3 Negative controls 
As PCR negative controls, DNA extracted from human placenta and genomic HPV16 
DNA69 were included. Human placenta DNA had been extracted as recently described31 and 
was provided by Dr. Markus Schmitt (DKFZ).  
 
3.10 Quantitative reverse transcriptase PCR (RT-qPCR) 
3.10.1 Principle of quantitative PCR 
In the quantitative PCR, signals were expressed as crossing point (Cp) values that indicate 
the cycle at which the increase of fluorescence is highest. The TaqMan system used in the 
newly developed RT-qPCR contains probes labelled with a fluorescence reporter and a 
fluorescence quencher, in close proximity to each other (Figure 3.2). When the probe is 
intact, the quencher dye is close enough to the reporter dye to suppress the reporter 
fluorescent signal. During PCR, the 5´nuclease activity of the polymerase cleaves the 
hydrolysis probe, separating the reporter and quencher. In the cleaved probe, the reporter is 
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no longer quenched and can emit a fluorescence signal when excited. There is a correlation 
between Cp and concentration: the higher the concentration of target RNA in starting 
material, the sooner a significant increase in fluorescent signal will be observed, yielding in 
a lower Cp (Figure 3.2). This correlation between amount of template and value of Cp 
facilitates quantitative analysis.  
Forward primer Probe
QuencherFlourophore
Backward primer
5
3
Amplification assay
5
3
Probe displacement
and cleavage
Polymerisation
5
3
Flourescence
Amplification curve
Cp:19.5 23 39.633.526.3 29.6 35.5
 
Figure 3.2. Schematic principle of quantitative PCR using TaqMan probes and the sigmoidal profile of 
fluorescence accumulation across cycles during amplification. 
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3.10.2 Singleplex RT-qPCR 
Mastermix of the Light Cycler 480 RNA Master Hydrolysis Probes Kit was prepared in a 
laminar flow hood equipped with UV light. In order to reduce contamination, all pipettes, 
reagents and machines were tidied up before. The singleplex RT-qPCR were performed in a 
final volume of 20 µL comprising 1x Light Cycler®480 RNA Master Hydrolysis Probes 
(Roche Applied Science, Germany), 1x Enhancer, 3.25 mM Mn(OAc)2 and the novel 
primers and TaqMan probes. The primer and probe concentration was chosen as depicted in 
table 3.1 ranging between 0.25 and 0.5 µM. In the singleplex RT-qPCR, one to two in case 
of E1C primer pairs and one TaqMan probe were applied per mastermix. The mastermix 
and 1 µL of purified RNA or in vitro transcripts were pipetted by QIAgility (Qiagen). In all 
runs, tubes that contained all PCR components but without template RNA were used to 
ensure that the reagents were free of contamination. Every RNA sample was tested in 
duplicates. 
Because PCR is so sensitive, strong laboratory discipline and specialised conditions to 
prevent contamination of samples by PCR products or sample-to sample carry-over were 
required. Physically separated hoods and machines for serial dilution preparation, PCR 
preparation, and PCR analysis were used. During the whole procedure sterile disposable 
plates and tubes, pipette filter tips and gloves had to be used. 
The PCR plate were transferred to Cobas z480 (Roche Molecular Diagnostics, Pleasanton), 
which was located in a separated laboratory. A 3 min reverse transcription step at 63°C was 
followed by a 30 s denaturation step at 95°C. The amplification was performed in 50 cycles 
including a denaturation step at 95°C for 10 s, an annealing step at 60°C for 30 s and an 
extension step at 72°C for 1 s. Cooling was performed at 40°C for 10 s. 
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Table 3.1. Primer and probe concentrations. 
Transcript HPV type Primer and probe name
Primer 
concentration in 
SPa [µM]
Probe 
concentration in 
SP [µM]
E6*I 16 526S, bw1_409, p1_409 0.5 0.25
fw_526, bw2_409, p1_490 0.5 0.25
E6*II 16 fw_526, bw1_526, p_526m 0.5 0.25
526S, 526A, p_526m 0.5 0.25
E1C 16 2582A, 2582S, 2582F, 2582R2, p2_2582b 0.5 0.35
2582A, 2582S, p1_2582 0.5 0.35
2582R, 2582S, p2_2582 0.45 0.35
fw2_2582,bw1_2582,p2_2582 0.5 0.35
E1C_sjc 16 S8_2582,2582R2,p3_2582 0.5 0.25
S6_2582,2582R2,p3_2582 0.5 0.35
E1^E4 16 2582S, bw1_3358, p1_3358 0.5 0.25
2582S, bw2_3358, p1_3358 0.5 0.25
fw3_3358, 3358R, p1_3358 0.5 0.25
L1 16 fw3_5639, bw3_5639, p_5639 0.5 0.35
fw2_5639, bw3_5639, p3_5639 0.5 0.35
fw2_5639, bw4_5639, p3_5639 0.5 0.35
ubC fw2_ubC, bw2_ubC, p2_LubC 0.5 0.25
fw2_ubC, bw1_ubC, p2_LubC 0.5 0.25
fw5_ubC, ubCR, p5_LubC 0.5 0.25
E6*I 18 fw1_e6I, bw2_e6I, HPV18_short 0.25 0.35
f_e6I, bw2_e6I, HPV18_short 0.125 0.35
E1C 18 S_e1c, A_e1c, p_e1c 0.5 0.35
S_e1c, R_e1c, p_e1c 0.5 0.35
E1^E4 18 fw1_e1 e^4, E1E4R, p_e1e4 0.25 0.35
f_e1 e^4, E1E4A, p_e1e4 0.125 0.35
L1 18 S_18, A_18, p_L1_18 0.5 0.35
S_18, R_18, p_L1_18 0.5 0.35  
a singleplex (SP), b four primers amplifying E1C (seminested), c forward primer covers splice junction 
 
3.10.3 Changed parameters for E1C singleplex RT-qPCRE1C  
The HPV16 singleplex E1C RT-qPCR (RT-qPCRE1C) using 0.5µM of the primers 2582A, 
2582S, 2582F and 2582R2 and 0.35µM of p2_2582 probe applied to Light Cycler 480 RNA 
Master Hydrolysis Probes Kit was performed as singleplex RT-qPCR assays with some 
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modifications: 2 µL purified RNA were used and 3.0 mM Mn(OAc)2; the reverse 
transcription time was increased to 5 min and the annealing time to 40 s.  
 
3.10.4 Fiveplex RT-qPCR  
The procedure was performed as for the singleplex RT-qPCR. The single difference was 
that only one mastermix of the Light Cycler 480 RNA Master Hydrolysis Probes Kit was 
prepared, including all primers and probes. The fiveplex RT-qPCR was optimised with 
varying concentrations of the following reagents: primers and probes, Mn(OAc)2 and an 
enhancer. Primers and probes were tested in concentration ranging from 0.125 µM to 0.5 
µM (Table 3.2), Mn(OAc)2 was titrated ranging from 3.0 mM to 3.5 mM and enhancer was 
included and excluded, respectively.  
Table 3.2. Concentration of primers and probes in fiveplex RT-qPCR. 
Primer Probe Primer Probe Primer Probe
E6*I 526S, bw2_409, p1_409 0.25 0.35 0.25 0.35 0.125 0.35
E1C 2582R, 2582S, p2_2582 0.5 0.35 0.313 0.35 0.313 0.35
E1^E4 2582S, bw1_3358, p1_3358 0.25 0.35 0.25 0.35 0.19 0.35
L1 fw3_5639, bw3_5639, p_5639 0.25 0.35 0.5 0.35 0.5 0.35
ubC fw2_ubC, bw2_ubC, p2_LubC 0.25 0.25 0.25 0.25 0.125 0.25
Concentration combination 1 [µM]Transcript Primer and probe name Concentration combination 2 [µM] Concentration combination 3 [µM]
 
Furthermore, the fiveplex RT-qPCR was also performed with mastermix of HawkZ Kit in a 
final volume of 20 µL comprising 1x HawkZ05 Fast Master Mix (Roche Applied Science, 
Germany) and 1.5 mM Mn(OAc)2 and the novel primers and TaqMan probes concentration 
combination 2 (Table 3.2). PCR run protocol with the Cobas z480 (Roche Molecular 
Diagnostics, Pleasanton) were adapted to the HawkZ Kit: A 5 min reverse transcription step 
at 63°C was followed by a 5 s denaturation step at 92°C. The amplification was performed 
in 50 cycles including a denaturation step at 95°C for 5 s, an annealing step at 60°C for 40 s 
and an extension step at 72°C for 1 s.  
 
3.10.5 Colour compensation 
To compensate for spectral overlap of the probes, a colour compensation template was 
generated according to the LightCycler 480 Instrument Operator’s Manual: three replicates 
of spliced transcripts were applied to the singleplex RT-qPCR as well as one blank RT-
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qPCR without primers, probes and template. The temperature profile used mimics the 
typical PCR as described in 3.10.2.  
 
3.10.6 Triplex RT-qPCR 
The triplex RT-qPCR (RT-qPCRTP) was performed according to singleplex RT-qPCR and 
quantified the high-abundance viral transcripts E6*I, E1^E4 and ubC. The RT-qPCRTP was 
performed in a final reaction volume of 20 µL comprising 1x Light Cycler®480 RNA 
Master Hydrolysis Probes (Roche Applied Science, Germany), 1x Enhancer, 3.0 mM 
Mn(OAc)2, 1 µL of purified RNA or in vitro transcript, and optimised with different primer 
and probe concentrations ranging from 0.05 to 0.125 µM of each primer and 0.25 to 0.35 
µM of each probe (Table 3.3). 
Table 3.3. Different primer and probe concentration in RT-qPCRTP. 
Primer Probe Primer Probe Primer Probe
E6*I 526S, bw2_409, p1_409 0.125 0.35 0.2 0.35 0.125 0.35
E1^E4 2582S, bw1_3358, p1_3358 0.125 0.35 0.125 0.35 0.125 0.35
ubC fw2_ubC, bw2_ubC, p2_LubC 0.1 0.25 0.05 0.25 0.05 0.25
Transcript Concentration combination 1 [µM] Concentration combination 2 [µM] Concentration combination 3 [µM]Primer and probe name
 
 
3.10.7 Duplex RT-qPCR 
The duplex RT-qPCR (RT-qPCRDP) quantified the low-abundance E1C and L1 transcripts. 
The RT-qPCRDP was performed using Light Cycler 480 RNA Master Hydrolysis Probes Kit 
(Roche Applied Science, Germany). The procedure of mastermix preparation and PCR 
program was performed as for the RT-qPCRTP with the single difference of used primers 
and probes (Table 3.4).  
Table 3.4. Different primer and probe concentration in RT-qPCRDP. 
Primer Probe
L1 fw3_5639, bw3_5639, p_5639 0.25 0.35
E1C 2582A, 2582S, p1_2582 0.5 0.35
Transcript Concentration [µM]Primer and probe name
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3.11 Standard curves and quantification of transcripts 
Standard curves for all transcripts were obtained by amplification of a dilution series of 106 
to 101 copies of in vitro transcripts in the background of 20 ng/µL MS2 RNA (Roche 
Applied Science, Germany). Copy numbers were plotted against the measured Cp values. 
Absolute quantification of copy numbers was achieved by linear regression analysis 
comparing the Cp value of the unknown sample against the standard. 
 
3.12 Definition and statistics 
PCR efficiency (E), a quantitative expression of the quality of the PCR process, was 
calculated from the slope of the standard curves according to the equation E=10^[-
1/slope]166. The highest quality PCR run with an efficiency of 2, meaning that the number of 
target molecules doubles with every PCR cycle. The correlation between Cp and the log of 
transcript copy number per PCR was described by the coefficient of determination, denoted 
R2 (1.00 indicated perfect correlation). The reproducibility was described by the coefficient 
of variation (CV). Statistical analyses were performed with the SAS software, version 9.3 
(SAS Institute). Pearson correlation analysis was run on comparison of transcript 
quantification by NASBA and RT-qPCRTP and RT-qPCRE1C and on comparison of 
transcripts in repeated RNA extraction. Pairwise comparison of ubC, E6*I, E1^E4 and E1C 
copy numbers were done by Wilcoxon-signed-rank test. Comparisons of the HPV16 RNA 
patterns in all histological or cytological grades were performed by the non-parametric 
Mann-Whitney test. The agreement of histological or cytological examinations and HPV16 
RNA patterns was monitored by kappa statistic (κ), where a value of 1 represents complete 
agreement, 0 represents no agreement. All tests were two-sided, and a p value <0.05 was 
considered significant. Where appropriate, 95% confidence intervals (CI) were computed. 
To calculate the difference of RNA quality in fresh-frozen MRI-H196 and in archived 
exfoliated cervical cell samples, the median ubC RNA copies per cell detected in the 
archived and in the fresh-frozen samples were divided. 
A clinical RNA sample was classified as valid if >80 ubC or >200 E6*I copies per PCR 
were detected. UbC as the longest amplicon with 238 bp is most susceptible to RNA 
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degradation and thus used for monitoring validity. The classification included additionally 
the E6*I copies in order to increase number of valid samples.  
RNA samples were applied in duplicates to the RT-qPCRTP and RT-qPCRE1C and scored as 
positive if both duplicates showed a cutoff Cp value below 42. E6*I/E1^E4 ratios were 
calculated as: mean E6*I copies per PCR over mean E1^E4 copies per PCR. If E6*I or 
E1^E4 was negative, value was set to 1 copy per PCR and E6*I/E1^E4 ratio calculated. 
With the positive controls run on every PCR plate, a correction factor for the E6*I/E1^E4 
ratio was calculated and used in order to reduce plate differences. The cutoffE6*I/E1^E4 was 
determined to be 0.095 units for cervical RNA samples (see chapter 4.1.7.7) and 45 units for 
OPSCC RNA samples. An OPSCC sample with the E6*I/E1^E4 ratio and E1C below cutoff 
was defined as CxCa-like RNA patterns-negative OPSCC (CxCaRNA-). Tumours with 
either the E6*I/E1^E4 ratio or E1C above cutoff were defined as CxCa-like RNA patterns-
positive OPSCC (CxCaRNA+)152.  
Histological diagnosis were summarised in severe (≥CIN3) and mild (NIL/M, suspicious 
cytology but normal histology (CIN0), CIN1: ≤CIN1) lesions, respectively. CIN2 was 
categorised as intermediate and not classified within the severe lesions.  
An exfoliated cervical cell sample was classified as mild lesion if the E6*I/E1^E4 ratio and 
E1C were below cutoff and classified as severe lesion if at least one of the E6*I/E1^E4 ratio 
or E1C was above cutoff. Clinical samples negative for the 3 viral transcripts but positive 
for ubC were automatically scored as mild lesion.  
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4 Results  
HPV16 RNA patterns (see 1.7) so far detected by singleplex NASBA assays may have the 
potential to replace current cervical cancer screening tests such as cytological examinations 
and HPV DNA-based tests (see 1.5). Large studies to confirm HPV16 RNA patterns as 
possibly clinically useful biomarker are still needed, but singleplex NASBA assays quantify 
only 10-fold differences, are laborious and cost-intensive and not applicable as routine 
screening test with high sample numbers.  
The aim of this thesis was to transfer the singleplex NASBA assays to multiplex RT-qPCR 
and to validate the HPV16 RNA patterns with a large number of exfoliated cervical cell 
samples in comparison to cytology and/or histology (Figure 4.1). 
For the development of RT-qPCR assays, primers and probes were designed to detect 
sensitively and specifically the viral transcripts E6*II, E1^E4, E1C and L1, as well as the 
housekeeping transcript ubC. In addition, a RT-qPCR for HPV16 E6*I was co-developed. 
This was necessary since other hrHPV types do not express E6*II but only E6*I encoding 
transcripts. With regard to extending the HPV16 RNA patterns to other hrHPV types, it 
could be beneficial to use uniform target sequences. Furthermore, essential PCR parameters 
were optimised comprising combinations and concentrations of primers and TaqMan 
probes, PCR annealing and reverse transcription times, and the amount of purified RNA 
applied per reaction. Moreover, the maximal multiplexing degree of single RT-qPCR was 
explored. In addition, the most efficient RNA isolation method as well as the reproducibility 
of RNA isolation and RT-qPCR were determined.  
In a further step, the newly developed RT-qPCR assays were compared to the previously 
developed singleplex NASBA assays. Additionally, the HPV16 RNA patterns were 
validated using 360 HPV16 DNA-positive exfoliated cervical cell samples and compared to 
cytology and histology as well as to viral load for predicting the presence of cervical 
lesions.  
Finally, the applicability of RT-qPCR in FFPE biopsies was explored. As a first step 
towards extending the HPV16 RNA patterns analyses to other prevalent hrHPV types -id est 
(i.e.) HPV 18, 31, 33, 35, 45, 52 and 58- HPV16-like splice junctions were identified for 
these seven additional hrHPV types. 
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Figure 4.1. Structure of result sections. 
 
4.1 HPV16 RNA patterns 
4.1.1 Design of primers and TaqMan probes 
RT-qPCR uses different enzymatic conditions than NASBA and consequently requires 
different primers and probes including different length and melting temperatures. All 
primers and probes with the potential to sensitively and specifically detect the spliced 
HPV16 transcripts E6*I, E6*II, E1C, E1^E4 and L1 as well as the housekeeping transcript 
ubC had to be systematically re-designed.  
For each target sequence several forward (fw) and backward (bw) primers were designed 
(Table 4.1). Primers were between 18 and 26 nucleotides long with theoretical annealing 
temperatures of 51.8°C - 60.5°C as calculated by the FastPCR program. Final amplicon 
sizes varied between 108 and 238 bp.  
Primers were designed to flank the splice junctions of the six transcripts and TaqMan probes 
to cover the splice junctions with one exception: For the E1C transcript the same splice 
donor is used as for the E1^E4 and thus the two transcripts compete for the same forward 
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primer. Therefore an alternative strategy was explored with the E1C forward primers -rather 
than the probes- spanning the splice junction.  
Primers and probes were located within sequence regions conserved among all HPV16 
isolates available in public Nucleotide data bases at the NCBI homepage. To exclude 
HPV16 primers and probes binding to sequences of other HPV types only a maximum of 
eight consecutive nucleotide matches with non-HPV16 sequences was allowed. 
Table 4.1. Overview of primers and probes tested for the quantification of HPV16 and ubC. 
226^409 E6*I FJ610152.1 3 2 6 2 2 JA270 610-645
226^526 E6*II FJ429103.1 3 5 15 12 3 JA270 610-645
880 2^582 E1C HM057182.1 5 4 20 8 3 FAM 495-521 
880 2^582 E1C_sje HM057182.1 8 1 8 8 2 FAM 495-521 
880 3^358 E1^E4 K02718.1 2 4 8 10 3 HEX 540-580 
3632^5639 L1 FJ610152.1 4 4 16 7 3 Coumarin 435-470
5455^6267 ubC NG_027722.1 7 7 49 27 10 Cy 5.5 680-700
N of combinations 
testedc
TaqMan 
probesd
Excitation and 
emission filters
Fluorochrome
Transcript 
splice site
Coding 
potential
Accession 
number
fwa 
primers
bwb 
primers
N of theoretical 
combinations
 
a number (N) of forward (fw) primers designed, b number of backward (bw) primers designed, c tested in 
singleplex RT-qPCR, d number of TaqMan probes designed, e primers covering splice junction (sj) 
TaqMan probes were between 26 and 33 nucleotides long with theoretical melting 
temperatures of 56.1°C-63.9°C. For later multiplexing, they contained a transcript-specific 
fluorescent reporter dye attached to the 5´-end and a BHQ-2 quencher at the 3´-end (Table 
4.1).  
As this thesis was performed in a collaborative research agreement with Roche Molecular 
Systems, Inc., detailed sequence information of primers and TaqMan probes are not 
presented for reason of intellectual property (IP) protection, but can be made available upon 
request with appropriate IP protection agreement. 
In total, 32 fw primer, 27 bw primer and 26 TaqMan probe sequences were selected and 
synthesised. In the next chapter the functional characteristics of primers and probes 
established in singleplex RT-qPCR are described.  
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4.1.2 Singleplex RT-qPCR 
Primers and TaqMan probes were tested in singleplex PCR. In vitro transcripts, generated 
from Bluescript M13-KS vector containing spliced E6*I, E6*II, E1^E4, E1C, L1 and ubC 
cDNA, respectively, were added to the RT-qPCR mix. At first, detection limits (DL) of 
different primer and TaqMan probe combinations were determined using ten-fold and/or 
three-fold dilution series of the in vitro transcripts. The specificity of primers and TaqMan 
probes was assessed with all in vitro transcripts as well as full-length HPV16 DNA and 
human placenta DNA as templates. Water was used as negative control template.  
 
4.1.2.1 Transcript detection limits in singleplex RT-qPCR 
Serial dilutions of the in vitro transcripts E6*I, E6*II, E1C, E1^E4, L1 and ubC with copies 
ranging from 2 to 106 copies per µL were applied in duplicates to singleplex RT-qPCR 
using different combinations of primers and TaqMan probes. For each transcript up to three 
combinations are exemplarily shown in table 4.2.  
For the E6*I, both primer and TaqMan probe combinations detected 10 copies per PCR with 
a median Cp value of 36 (Table 4.2). The coefficient of determination (R²) obtained by both 
E6*I combinations indicated a perfect linear correlation between crossing point (Cp) and the 
log of transcript copy number per PCR. The PCR efficiency was slightly better for 
combination 2. One million E6*I copies were detected at cycle 21 using combination 1 and 
at cycle 20 using combination 2. The same analyses are depicted also for the other HPV16 
transcripts and for ubC in table 4.2. The E1C singleplex RT-qPCR combination 1 also 
included two primer pairs in order to increase the detection limit (refer to 5.3.2 for 
discussion). 
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Table 4.2. Singleplex detection limit for spliced transcripts. 
Transcript Primer and probe name
Combi-
nation
DLa (copies 
per PCR)
Median 
Cp at DL R
2 b Ec
Median Cp 
at 106 copies 
per PCR
Used in 
further 
experiments d
E6*I 526S, bw1_409, p1_409 1 10 36 0.99 2.20 21 no
526S, bw2_409, p1_490 2 10 36 1.00 2.09 20 yes
E6*II fw_526, bw1_526, p_526m 1 1,000 33 0.95 1.98 23 no
526S, 526A, p_526m 2 100 38 1.00 1.77 22 no
E1C 2582A, 2582S, 2582F, 2582R2, p2_2582 1 2 40 0.98 2.02 20 yes
2582A, 2582S, p1_2582 2 10 38 0.99 2.14 23 no
2582R, 2582S, p2_2582 3 10 41 0.99 2.18 35 no
fw2_2582,bw1_2582,p2_2582 4 10,000 41 0.99 2.18 35 no
E1C_sje S8_2582,2582R2,p3_2582 1 6 37 0.99 2.07 20 yes
S6_2582,2582R2,p3_2582 2 10 38 0.98 1.95 21 no
E1^E4 2582S, bw1_3358, p1_3358 1 10 40 1.00 2.08 24 yes
2582S, bw2_3358, p1_3358 2 1,000 35 0.97 2.70 27 no
fw3_3358, 3358R, p1_3358 3 10,000 36 0.96 4.60 34 no
L1 fw3_5639, bw3_5639, p_5639 1 10 40 1.00 2.07 21 yes
fw2_5639, bw3_5639, p3_5639 2 100 43 1.00 1.78 27 no
fw2_5639, bw4_5639, p3_5639 3 1,000 39 0.95 1.69 26 no
ubC fw2_ubC, bw2_ubC, p2_LubC 1 10 38 1.00 2.07 21 yes
fw2_ubC, bw1_ubC, p2_LubC 2 100 32 1.00 1.78 27 no
fw5_ubC, ubCR, p5_LubC 3 100 40 0.95 1.69 26 no  
a detection limit (DL) defined as lowest copy number tested with signals above background in duplicates, 
b coefficient of determination (R2) describes the correlation between crossing point (Cp) and the log of 
transcript copy number per PCR, c PCR efficiency (E); under optimal conditions PCR run with an efficiency of 
2, meaning that the number of target molecules doubles with every PCR cycle, d the combination with lowest 
DL but at most 10 copies per PCR was selected for further experiments; in case both had same DL, the one 
with E closer to 2 was chosen, e primers covering splice junction (sj) 
E6*II singleplex RT-qPCR lacked good detection limits in all 12 tested combinations and 
was replaced by E6*I RT-qPCR in the subsequent developments.  
After testing multiple primer and TaqMan probe combinations, a sensitive quantification of 
all spliced transcripts was achieved with DL ranging from 2 to 10 copies per PCR.  
 
4.1.2.2 Specificity of singleplex RT-qPCR 
Specificity of singleplex RT-qPCR is mediated by (A) HPV16 type-specific primers and (B) 
by splice-site and type-specific TaqMan probes. In addition, specific detection of splice-
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sites further provides an advantage because it cannot be affected by co-amplified 
contaminating DNA.  
HPV16 transcript specificity of the RT-qPCR was evaluated using the in vitro transcripts 
E6*I, E1^E4, E1C, L1 and ubC. Genomic HPV16 DNA with copy numbers ranging from 
104 to 106 copies per µL and human placenta DNA with concentrations ranging from 0.1 to 
100 ng/µL were used to demonstrate RNA specificity of the RT-qPCR and to exclude cross-
hybridisation with unspliced HPV16 sequences and cellular background DNA, respectively. 
Templates were applied in duplicates to singleplex RT-qPCR using finally selected primer 
and TaqMan probe combinations determined to be most sensitive (see 4.1.2.1, primer and 
probe combination 2 for E6*I and combination 1 for the other transcripts).  
With one exception, no unspecific PCR products were detected for the transcripts as well as 
for 106 HPV16 genome copies and 100 ng/µL human placenta DNA (corresponding to 
about 1.5 x 104 cellular genome equivalents). The exception was the E1C_sj RT-qPCR 
which detected 105 genomic HPV16 DNA copies with a Cp of 36 (Figure 4.2, d). Even by 
shortening the splice junction covering forward E1C_sj primer by six nucleotides the 
unspecific amplification of genomic DNA remained (data not shown). Consequently, the 
E1C_sj primer and TaqMan probe combination was not used in future experiments.  
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Figure 4.2. Specificity of singleplex RT-qPCR with finally selected primer and probe combinations. 
Dilution series of in vitro transcripts, HPV16 DNA and human placenta DNA were used as templates in E6*I 
(a), E1^E4 (b), E1C (c), E1C_sj (d), L1 (e) and ubC (f) RT-qPCR using the finally selected primer and probe 
combinations. All templates were applied in duplicates, error bars show standard deviation. Most duplicates 
were nearly identical and error bars too small to be visible. Negative results, i.e. no detectable RT-qPCR signal 
within 42 cycles, are indicated as Cp 45 below the dotted Cp 42 line. E values are indicated. 
None of the other RT-qPCR gave rise to unspecific signals proving specificity of the assays.  
 
4.1.3 Fiveplex RT-qPCR 
Multiplexing with simultaneous presence of all primers and probes in one reaction can 
potentially result in higher detection limits for the transcripts, for example through dimer 
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formations of primers and probes. Furthermore, the presence of all transcripts in one 
reaction can lead to interference in template amplification and product detection through 
competition for PCR reagents. At least theoretically multiplexing could also result in 
reduced specificity due to new amplification products from combinations of primers 
designed for different targets. 
To achieve simultaneous sensitive and specific detection of the four HPV16 transcripts and 
the ubC transcript in a fiveplex RT-qPCR, variations of primer and probe concentrations, 
PCR reagents including various concentrations of Mn(OAc)2 and the presence/absence of an 
enhancer were tested with in vitro transcripts and with RNA from HPV16-transformed 
cervical cancer cell lines. The salt concentrations (Mn(OAc)2) can affect the annealing 
temperature and the enhancer, supplied in the Light Cycler 480 RNA Master Hydrolysis 
Probe Kit (LC480) (Roche, Mannheim), can improve the amplification of difficult, e.g. GC-
rich targets and increase the fluorescence intensity when using low RNA concentrations.  
The fiveplex reaction contained five probes each labelled with a different fluorochrome 
(Table 4.1). As the wavelengths of light emitted by the different fluorescent dyes can 
overlap and thus can cause one detector channel to pick up signals from more than one 
fluorochrome, a colour compensation template was generated according to the Light Cycler 
480 Instrument Operator’s Manual. 
 
4.1.3.1 Variation of primer and probe concentration for fiveplex RT-qPCR 
Three different concentrations of chosen primer and probe combinations, determined as 
most sensitive in singleplex RT-qPCR (Table 3.2), were titrated. The final primer 
concentration was titrated between 0.125 and 0.5 µM, the probe concentrations between 
0.35 and 0.25 µM and the concentration of Mn(OAc)2 between 3.25 and 3.5 mM. The 
enhancer was either in- or excluded. Under all these various conditions, DL was determined 
applying in vitro transcripts E6*I, E1C, E1^E4, L1 and ubC ranging from 101 to 106 copies 
per PCR as single template. 
The DL for each of the five in vitro transcripts ranged between 101 and 103 (Figure 4.3). 
Most sensitive transcript detection ranging from 101 to 102 was achieved with primer and 
probe concentration 2: The R2 varied between 0.99 and 1 indicating a perfect linear 
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correlation of the data points with the standard curves. PCR efficiency ranged from 1.93 
(E6*I) to 2.32 (E1C). 
 
Figure 4.3. Effect of primer and probe concentrations on Cp values in fiveplex RT-qPCR. Standard 
titration curves of E6*I (a), E1^E4 (b), ubC (c), E1C (d) and L1 (e) in vitro transcripts with three different 
primer/probe concentrations (light, middle and dark blue triangles), Mn(OAc)2 concentration of 3.0 mM and 
the inclusion of enhancer. Data of singleplex RT-qPCR from figure 4.2 are given for comparison (red 
triangles). All templates were applied in duplicates, error bars show standard error of the mean. Most 
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duplicates were nearly identical and error bars too small to be visible. Negative results, i.e. no detectable RT-
qPCR signal within 42 cycles, are indicated as Cp 45 below the dotted Cp 42 line. 
Attempts to improve the DL of the RT-qPCR with primer and probe concentration 2, by the 
exclusion of the enhancer or by changing the Mn(OAc)2 concentration to 3.25 or 3.5 mM 
were unsuccessful and resulted in DL for the five in vitro transcripts between 102 and 103, 
102 and 103 or 102 and 104, respectively (data not shown). 
 
4.1.3.2 Co-amplification of transcripts in HPV16-positive cell lines  
The next step was to test the co-amplification of all transcripts present in HPV16-
transformed cervical cancer cell lines in the five singleplex and the fiveplex RT-qPCR using 
the identified sensitive conditions, namely primer and probe concentration 2, a Mn(OAc)2 
concentration of 3.0 mM and enhancer included. Total RNA (33 ng, corresponding to 
approximately 2,200 cells) extracted from cell lines MRI-H186 and CaSki was used. Both 
cell lines had also been analysed previously by NASBA methods148 and are compared to 
RT-qPCR results in chapter 4.1.6.1. 
The abundant transcripts E6*I, E1^E4 and ubC were efficiently quantified in both cell lines 
with the fiveplex RT-qPCR setting (Figure 4.4). Statistical analyses to determine differences 
between fiveplex and singleplex RT-qPCR were not performed due to small number of data 
points. Compared to singleplex RT-qPCR, similar mean copy numbers per PCR of E6*I, 
E1^E4 and ubC were identified in both cell lines also by the fiveplex RT-qPCR.  
 
Figure 4.4. Effect of co-amplification of transcripts in fiveplex RT-qPCR. Copies per PCR of E6*I, E1^E4, 
ubC, E1C and L1 in 33 ng RNA from HPV16-tranformed cervical cancer cell lines MRI-H186 (a) and CaSki 
(b) quantified in fiveplex (blue bars) and singleplex (red bars) RT-qPCR. All templates were analysed in 
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duplicates and represented as means with standard deviation. If duplicates are nearly identical, error bars 
cannot be recognised. Negatives were set to 1.2 copies per PCR. 
However, sensitivity for the low-abundance transcript E1C (negative in fiveplex versus 500 
copies in MRI-H186 and 1,500 in CaSki in singleplex) and L1 (600-fold reduced copies in 
MRI-H186 fiveplex) was strongly reduced (Figure 4.4). In the fiveplex RT-qPCR the 
simultaneous amplification of high-abundance transcripts appeared to inhibit concurrent 
amplification of low-abundance transcripts much more severely than that of other high-
abundance transcripts. 
Despite the high sensitivity optimised on the basis of in vitro transcript dilution series, an 
accurate detection of all transcripts known to be present in cell lines could not be achieved 
by the fiveplex RT-qPCR, requiring further protocol development. 
 
4.1.3.3 Variation of fiveplex RT-qPCR protocols 
For a better detection of the low-abundance viral transcripts E1C and L1 in the fiveplex RT-
qPCR, the HawkZ Kit was explored and compared to the standard Light Cycler 480 RNA 
Master Hydrolysis Probes Kit (LC480 RNA) used before. 
In duplicates, 33 ng RNA extracted from MRI-H186 and CaSki were applied to two 
fiveplex RT-qPCR containing the HawkZ and the LC480 RNA reagents, respectively. 
In MRI-H186, the mean copy number of detected E6*I, E1^E4 and ubC was up to 35-fold 
higher using the LC480 RNA (Table 4.3). Statistical analyses were not performed due to 
small number of data points. Likewise, the mean copy number of the quantified E6*I and 
ubC in CaSki was up to 10-fold higher using the LC480 RNA but nearly identical for E1^E4. 
The detection of L1 and E1C was not improved in the tested cell lines by using the HawkZ 
Kit with both transcripts remaining negative (Table 4.3).  
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Table 4.3. Influence of two different one-step RT kits on the quantification of transcripts in HPV16-
transformed cervical cancer cell lines. 
LC480 RNAa 
(copies/PCR)
HawkZb 
(copies/PCR)
LC480 RNA 
(copies/PCR)
HawkZ 
(copies/PCR)
E6*I 1 223,152 10,100 288,214 31,861
2 202,143 2,015 217,959 17,923
Mean 212,648 6,058 253,086 24,892
E1^E4 1 11,142 5,072 250,094 305,914
2 10,522 2,482 147,037 115,163
Mean 10,832 3,777 198,566 210,538
ubC 1 443,296 19,206 67,794 5,294
2 100,559 16,743 8,670 2,716
Mean 271,928 17,975 38,232 4,005
E1C 1 0c 0 0 0
2 0 0 0 0
Mean 0 0 0 0
L1 1 5 0 0 0
2 1 0 0 0
Mean 3 0 0 0
CaSki
Transcript
Dupli-
cate
MRI-H186
 
a Light Cycler 480 RNA Master Hydrolysis Probes Kit (LC480 RNA), b HawkZ Kit, c negative results, i.e. no 
detectable RT-qPCR signal within 42 cycles  
As no L1 and E1C amplification was achieved with neither the HawkZ nor the LC480 RNA 
using the fiveplex RT-qPCR, a triplex RT-qPCR (RT-qPCRTP) for the high-abundance 
transcripts E6*I, E1^E4, and ubC and a duplex RT-qPCR (RT-qPCRDP) for the low-
abundance viral transcripts E1C and L1 were explored using the LC480 RNA.  
 
4.1.3.4 Performance of triplex RT-qPCR (RT-qPCRTP) for high-abundance transcripts 
Three concentrations of primers and TaqMan probes (Table 3.3) were applied to the RT-
qPCRTP. DL was determined using serial dilutions of in vitro transcripts E6*I, E1^E4 and 
ubC ranging from 101 to 106 copies per PCR each as single templates and in parallel 33 ng 
RNA extracted from MRI-H186 and CaSki were applied to quantify all three transcripts in 
one reaction. 
The DL for the three in vitro transcripts in all three primer and TaqMan probe 
concentrations ranged between 101 and 103 (data not shown). Most sensitive transcript 
detection with a DL of <10 copies per PCR was achieved for all three targets with primer 
and probe concentration 3 (Figure 4.5, a). The R2 varied between 0.98 and 1 indicating a 
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perfect linear correlation of data points with the standard curves. The PCR efficiency value 
E ranged from 1.92 (ubC) to 2.03 (E6*I) indicating optimal PCR conditions.  
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Figure 4.5. Standard curves and quantification of transcripts in the RT-qPCRTP with the finally selected 
primer and probe concentration 3. Standard titration curves of the in vitro transcript E6*I (grey), E1^E4 
(green) and ubC (blue) (a). E6*I (grey), E1^E4 (green) and ubC copies (blue) quantified in 33 ng of RNA from 
MRI-H186 and CaSki (b). All templates were applied in duplicates as indicated by the error bars (standard 
deviation). If duplicates are nearly identical, error bars cannot be recognised.  
With the finally selected primer and probe combination the quantity of three highly 
abundance-transcripts ranged between 25,399 and 291,678 copies in MRI-H186 and CaSki 
(Figure 4.5, b).  
Overall, RT-qPCRTP appeared to be highly sensitive for the simultaneous detection and 
quantification of the two viral transcripts and of ubC and was used further in the validation 
of HPV16 RNA patterns in clinical samples (see chapter 4.1.7). 
 
4.1.3.5 Performance of duplex RT-qPCR (RT-qPCRDP) for low-abundance transcripts 
The performance of duplex RT-qPCRDP (Table 3.4) was analysed using serially diluted in 
vitro transcripts and RNA from cell lines MRI-H186 and MRI-H196. Additionally, in order 
to examine a potential competition during PCR when E1C and L1 are present at the same 
time, serial dilutions of each transcript ranging from 101 to 106 copies per PCR in a 
background of 104 copies per PCR of the other transcript were applied. In these analyses 
CaSki was replaced by MRI-196 cells because it is known to contain both E1C and L1148. 
The DL for the in vitro transcripts E1C and L1 was 10 copies per PCR in the background of 
MS2RNA as well as when the other viral transcript was present with 104 copies per PCR 
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(Figure 4.6, a). The Cp values at the dilution steps between 103 and 106 copies per PCR 
were almost identical in the absence but also presence of co-amplification of the other viral 
RNA. In contrast, for 102 to 101 copies per PCR Cp values increased with simultaneous co-
amplification of the other viral transcript. At a 100-fold excess of the other viral transcript, 
101 E1C and L1 copies were only borderline positive (Figure 4.6, a). 
In 33 ng of MRI-H186 and MRI-H196 RNA, singleplex RT-qPCR detected in mean 15 and 
643 E1C and 961 and 11 L1 copies, respectively. In MRI-H186, RT-qPCRDP detected no 
E1C, but 914 copies of the L1 (Figure 4.6, b). In MRI-H196, RT-qPCRDP detected 670 EIC 
transcript copies but no L1. Consequently, if L1 were more frequent than E1C in one 
sample, E1C detection was reduced and vice versa, though it should be kept in mind that 
E1C (in MRI-H186) and L1 (in MRI-H196) were only borderline positive in the singleplex 
RT-qPCR.  
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Figure 4.6. Titration and quantification of transcripts in duplex RT-qPCRDP. (a) Standard titration curves 
of the in vitro transcript E1C and L1 standard curves without (coloured) and with (black) 104 copies of the L1 
or E1C as background RNA, respectively. Cutoff (Cp=42) is indicated by the dotted line. (b) E1C (green) and 
L1 (blue) quantified in 33 ng of RNA from MRI-H186 and MRI-H196 in RT-qPCRDP and in singleplex RT-
qPCR using same primer and TaqMan probe combination and concentrations. Negative results, i.e. no 
detectable RT-qPCR signal within 42 cycles, are indicated as 1.2 copies per PCR. All templates were applied 
in duplicates as indicated by the bars (standard deviation). If duplicates are nearly identical, error bars cannot 
be recognised.  
A reduced detection of E1C and L1 was observed once both transcripts were co-amplified 
simultaneously and suppressed by the presence of high-abundance transcripts in one sample. 
As a consequence, reliable detection of these transcripts appeared to be possible in 
singleplex reactions only.  
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4.1.3.6 Comparison of RT-qPCRDP and singleplex RT-qPCRE1C in clinical specimens 
As mentioned before, E1C is an important component of the HPV16 RNA patterns for the 
identification of severe lesions. Since it is known to be a low-abundance transcript, 
detection should be as sensitive as possible. To decide whether E1C detection is more 
sensitive in singleplex RT-qPCRE1C than in duplex RT-qPCRDP, a comparison was 
performed using clinical specimens. 
RNA extracted from HPV16 DNA single-positive exfoliated cervical cell samples defined 
as NIL/M (n=10), normal histology (CIN0, n=6), CIN1 (n=3), CIN2 (n=24), CIN3 (n=17) 
and CxCa (n=18) (Chapter 2.11) were analysed by singleplex RT-qPCRE1C (Chapter 3.10.3) 
and by RT-qPCRDP (Chapter 3.10.7).  
Despite its high analytical sensitivity with in vitro transcripts (chapter 4.1.3.5), the duplex 
RT-qPCRDP never simultaneously identified L1 and E1C in any of the cervical cell samples 
(Figure 4.7). E1C were found only in one CxCa and one NIL/M sample with 174 and 51 
copies, respectively. E1C was negative in all CIN0, CIN1, CIN2 but detected in one CIN3 
with 28 copies. L1 were not detected in any of the CxCa and of the NIL/M samples. L1 
copies ranging from 267 to 1,982 (mean 862) were detected in one CIN1, six CIN2 and two 
CIN3.  
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Figure 4.7. Influence of L1 co-quantification on E1C detection in different cytological or histological 
stages. The x-axis compares duplex detection of E1C and L1 (filled triangles) with singleplex E1C detection 
only (open rhombi). The y-axis shows copies per PCR. All templates were applied in duplicates and the mean 
Cp value was used for calculation of copies per PCR. Samples were set below 1 copy per PCR if transcripts 
showed negative RT-qPCR results, i.e. no detectable RT-qPCR signal within 42 cycles.  
In singleplex RT-qPCRE1C, one CIN2 and two CIN3 being positive with 488 to 1,983 L1 
copies in the duplex only, turned E1C-positive which demonstrated the higher sensitivity of 
the singleplex reaction. Likewise, a significant proportion of CxCa (n=3) and CIN3 (n=6) 
samples was additionally E1C-positive only by RT-qPCRE1C (Figure 4.7), while at the same 
time, no additional NIL/M, CIN0 or CIN1 samples tested positive by RT-qPCRE1C. 
Overall, a low number of E1C copies per PCR was observed leading to <1 copy per cell. 
However, it should be kept in mind that not every cell in a cervical smear is HPV-
infected147. The low number of E1C copies in clinical specimens had been already noted in 
the pilot NSABA study87. Nonetheless, to exclude potential errors in the quantification, the 
in vitro transcription of E1C as well as the titration curve of the transcript dilutions was 
repeated and quantification of the RT-qPCRE1C was confirmed to be correct and 
reproducible. 
In conclusion, an adequate and highly sensitive detection of E1C was possible in singleplex 
RT-qPCRE1C reactions only. 
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4.1.3.7 Critical examination of L1 contribution to HPV16 RNA patterns classification 
As already introduced in chapter 1.7, the qualitative and quantitative detection of viral 
transcripts E6*I, E1^E4 and L1 alone cannot discriminate the grade of a cervical lesion: A 
low number of cancerous cells in a cervical smear, exemplarily, would result in a low 
number of E6*I copies and consequently in a false-negative classification. The computation 
of ratios of two viral transcripts allowed normalising for variable quantities of HPV-infected 
cells in cervical smears assuming that the transcript ratio is similar in the majority of HPV-
positive cells in a given sample. Thereby, false classification can be substantially reduced. 
In contrast to the mentioned transcripts above, the qualitative presence of the spliced 
transcript E1C is already a highly specific marker for severe lesions as already shown in the 
pilot study87. Assuming that three RT-qPCR for the detection of four viral transcripts are not 
viable for a routine diagnostic test, the aim of this chapter -based on data from the NASBA 
pilot study- was to explore whether L1 detection could be omitted from the HPV16 RNA 
patterns classification. 
In the NASBA pilot study, RNA extracted from HPV16-infected DNA-positive exfoliated 
cervical cell samples defined as NIL/M (n=25), LSIL (n=23), HSIL (n=24) and CxCa (n=7) 
were analysed by the E1C and L1 singleplex NASBA. If E1C and L1 were positive in 
NASBA, an E1C/L1 ratio was calculated; if one transcript was negative, its value was set to 
0.001 to calculate the E1C/L1 ratio; if both transcripts were negative, the E1C/L1 ratio was 
set to 0.00001. A cervical sample above the E1C/L1 cutoff of 0.003 was classified as severe 
lesion87. 
Overall, 1 of 25 NIL/M, 6 of 23 LSIL, 10 of 24 HSIL and 4 of 7 CxCa were defined as 
severe lesion either due to the detection of E1C alone or due to a high E1C/L1 ratio which 
resulted from high E1C and low L1 signals (Figure 4.8, blue and red triangles). For these 
cervical samples, the normalisation of E1C with L1 showed no benefit over E1C detection 
alone. Moreover, none of the E1C-positive NIL/M or LSIL were negative using the E1C/L1 
ratio indicating that a normalisation with L1 did not increase the test specificity. However, 
three HSIL (12.4%) and one CxCa (14.3%) were above E1C/L1 ratio cutoff and thus 
classified as severe lesion by the presence of very low L1 copies alone (E1C-negative) that 
would be missed by the exclusion of L1. However, identifying a high-grade lesion or cancer 
just by the presence of few L1 copies is questionable.  
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Figure 4.8. Influence of L1 on HPV16 RNA patterns classification in different cytological stages (x-axis, 
categories). The y-axis shows ratio of E1C wildtype (wt)/calibrator (q) divided by L1 wildtype (wt)/calibrator 
(q) signal. Cervical sample with detection of E1C (blue) and L1 (green) only and with simultaneous detection 
of E1C and L1 (red) are colour-coded. A sample was set to a ratio of 0.00001 if both transcripts showed 
negative NASBA results (black). Cutoff is indicated by dotted line. 
In summary, in the NASBA pilot study the normalisation of E1C signals with L1 did not 
increase the test specificity and contributed little to the test sensitivity, justified to exclude 
L1 from further analyses.  
 
4.1.4 RNA extraction 
Automated RNA isolation enables high-throughput and highly reproducible extraction of 
purified RNA. Despite automation, the choice of RNA extraction kits and extraction 
volumes can influence the RNA yield. This will be described in the following two chapters. 
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4.1.4.1 Influence of RNA extraction kits on RNA yield  
Two MagNA Pure96 kits were tested to determine which one was best suited for the RNA 
extraction from clinical specimens.  
For RNA extraction, 1,000 µL PreservCyt volume of HPV16 DNA-positive patients from 
Mongolia cytologically defined as NIL/M (n=3), LSIL (n=4), HSIL (n=4) and CxCa (n=4) 
were processed with the MagNA Pure96 DNA and Viral NA Large Volume Kit (Viral NA) 
extracting total nucleic acids and with the MagNA Pure96 Cellular RNA Large Volume Kit 
(Cell RNA) that includes a DNaseI treatment extracting total RNA. One µL of RNA was 
applied to the E6*I and ubC singleplex RT-qPCR. 
The mean nucleic acid concentrations among all cervical samples were 34.4 ng/µL (range 
4.6-80.2) using Viral NA (extraction of DNA and RNA) and 14.2 ng/µL (range 2.9-37.7) 
using Cell RNA (extraction of RNA only) (Table 4.4). 
E6*I copies could not be detected in the Viral NA extracts. In contrast, the mean E6*I copy 
number per PCR quantified in the Cell RNA extracts was 223 (range 97 to 448). The Cell 
RNA was also superior in extracting amplifiable ubC as depicted by a mean copy number 
per PCR of 740 (Viral NA) versus 2,128 (Cell RNA). The reduced number of RNA in the 
Viral NA extracts might be an explanation for the insufficient E6*I detection. Furthermore, a 
strong variation of ubC was observed in the Viral NA extracts ranging between 4 and 4,854 
copies. Differences of ubC quantification in comparison to cell RNA were highest in the 
CxCa samples (up to 2,000-times reduced) but also present in HSIL, LSIL and NIL/M 
samples (median of 2-times, range 1-24). A PCR inhibition by the co-existence of DNA 
might be an explanation. 
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Table 4.4. E6*I and ubC copies per PCR detected in RNA samples extracted by two MagNA Pure96 kits. 
Mean 
Cpa
copies
/PCR
Mean 
Cp
copies
/PCR
Mean 
Cp
copies/
PCR
Mean 
Cp
copies/
PCR
Viral NA b Cell RNA c
CxCa 15.6 4.7 >42 0 33.7 245 36.5 11 29.4 1,528
CxCa 9.2 3.1 >42 0 33.6 284 35.4 24 29.9 1,058
CxCa 15.2 2.9 >42 0 33.8 226 37.0 7 29.3 1,609
CxCa 4.6 6.8 >42 0 33.0 448 37.9 4 27.4 6,681
HSIL 26.4 6.9 >42 0 34.3 157 31.2 504 28.8 2,333
HSIL 14.7 26.9 >42 0 34.2 164 31.6 365 30.3 809
HSIL 11.6 4.0 >42 0 33.9 215 33.7 83 29.1 1,970
HSIL 70.3 28.5 >42 0 33.6 265 28.1 4,854 27.1 8,270
LSIL 37.9 21.7 >42 0 34.0 195 31.3 471 30.0 1,005
LSIL 19.6 8.3 >42 0 34.3 156 31.3 482 29.1 1,948
LSIL 77.2 17.3 >42 0 >42 0 30.2 1,016 29.9 1,039
LSIL 80.2 15.9 >42 0 >42 0 29.5 1,764 29.0 2,105
NIL/M 42.5 37.7 >42 0 34.8 97 32.1 251 31.5 327
NIL/M 65.4 18.2 >42 0 >42 0 30.0 1,228 30.1 893
NIL/M 25.6 9.5 >42 0 >42 0 34.7 38 31.4 347
Mean: 34.4 14.2 >42 0 33.9d 223e 31.6 740 29.4 2,128
Cell RNA
Cytology
Viral NA Cell RNA
E6*I ubC
Nucleic acid 
concentration [ng/µL]
Viral NA
 
a all templates were applied in duplicates and mean Cp values were used for the calculation of copies per PCR, 
b MagNA Pure96 DNA and Viral NA Large Volume Kit (Viral NA), c MagNA Pure96 Cellular RNA Large 
Volume Kit (Cell RNA), d >42 were excluded for calculating the mean, e 0 copies per PCR were excluded from 
the calculation of mean 
Although the total nucleic acid concentration was higher in the Viral NA extracts (in part at 
least due to co-extracted DNA), quantification of ubC copies per PCR was at least 1.7-times 
higher and quantification of E6*I only possible using the Cell RNA. Consequently, the latter 
will be used in future analyses.  
 
4.1.4.2 Influence of extraction volume on HPV16 RNA quantification 
The amount of PreservCyt volume used for RNA extraction can influence the RNA yield 
and consequently the quantification of HPV16 RNA.  
For RNA extraction, 1,000 µL and 4,000 µL PreservCyt volume of HPV16 DNA-positive 
cervical samples from Mongolian women cytologically defined as NIL/M (n=44) and CxCa 
(n=27) were processed with the MagNA Pure96 Cellular RNA Large Volume Kit. Elution 
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volume was constantly 50 µL. RNA was applied to RT-qPCRTP and to RT-qPCRE1C. 
Subsequently, ubC copies, the E6*I/E1^E4 ratio and E1C copies were calculated.  
A median of 1,219 and 328 ubC copies were quantified in 4,000 µL and 1,000 µL extracts, 
respectively (p<0.0001, Wilcoxon matched-pairs signed rank test). This was also observed 
with the mean RNA concentration measured in 16 samples: 18.4 ng/µL in 4,000 µL and 6.6 
ng/µL in the 1,000 µL extracts. Likewise, the E6*I (p<0.0001, Wilcoxon matched-pairs 
signed rank test) and E1^E4 (p=0.031, Wilcoxon matched-pairs signed rank test) copy 
numbers were significantly higher in 4,000 µL than in the 1,000 µL extracts. The slopes (m) 
of the ubC, E6*I and E1^E4 regression lines were between 1.06 and 2.63 confirming higher 
amount of copy numbers detected in 4,000 µL extracts (Figure 4.9, a-c). Statistical analyses 
for E1C were not performed due to small number of positive samples (n=9).  
The qualitative comparison of E6*I detected in 1,000 µL and in the 4,000 µL extracts 
showed concordantly 23 E6*I-positive, 35 negative and 13 discordant samples (4 positive in 
1,000 µL and 9 in 4,000 µL extracts only) (κ=0.6, CI.95=0.44-0.81) (Figure 4.9, b). The 
qualitative comparison of E1^E4 detected in 1,000 µL and in the 4,000 µL extracts showed 
17 concordant positive samples, 47 concordant negative and 7 discordant samples resulting 
in a κ=0.8 (CI.95=0.59-0.93) (Figure 4.9, c). One of the three E1^E4-positive NIL/M 
samples positive in 1,000 µL extracts only was also E6*I-positive only. Equally, the one 
CxCa and one of the three NIL/M positive in 4,000 µL extracts only, were the same samples 
also E6*I-positive only.  
To exclude, that the additional positive samples detected in the 4,000 µL extraction volume 
only were attributed to a worse reproducibility of RNA extraction or RT-qPCR, this will be 
focused in the following chapter (4.1.5). 
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Figure 4.9. Influence of extraction volume on HPV16 RNA patterns analyses. UbC (a), E6*I (b), E1^E4 
(c), E6*I/E1^E4 ratio (d) and E1C (e) detected in 1,000 µL extraction volume (x-axis) are plotted against 
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4,000 µL extraction volume (y-axis). The diagonal is indicated in (a-c). Slope (m) of the regression line is 
depicted, a value of 1 should indicate the same copy number per PCR detected with both extraction volumes. 
CxCa samples are displayed as filled triangles and NIL/M samples as empty circles. All templates were 
applied in duplicates and mean Cp value was used for the calculation of copies per PCR. Negative results, i.e. 
no detectable RT-qPCR signal within 42 cycles, are indicated below 1 copy per PCR under the dotted cutoff 
line. An E6*I/E1^E4 ratio was set to 0.00001 below the dotted cutoff line if both transcripts showed negative 
RT-qPCR results.  
The concordance of E6*I/E1^E4 classification as negative and positive between 4,000 µL 
and 1,000 µL extracts was κ=0.8 (CI.95=0.64-0.94) with 22 concordantly positive, 42 
concordantly negative and 7 discordant samples (Figure 4.9, d). Three CxCa and one NIL/M 
E6*I/E1^E4 ratio-positive in 4,000 µL extracts only were same samples E6*I-positive only 
in 4,000 µL extracts and were borderline ubC-positive in 1,000 µL extracts with less than 
100 copies. The one CxCa, E6*I/E1^E4 ratio-positive in 1,000 µL extracts only was the 
same sample, E1^E4-positive in 4,000 µL extracts only and thus above E6*I/E1^E4 ratio 
cutoff. The two discordant NIL/M samples were either below 100 ubC copies in 1,000 µL 
or in the 4,000 µL extracts. 
For E1C, three cervical samples were concordantly positive, 63 concordantly negative and 
six discordant (κ=0.45, CI.95=0.04-0.87) (Figure 4.9, e). However, three CxCa samples 
analysed by RT-qPCRE1C were positive only in 4,000 µL while only one was discordantly 
positive in 1,000 µL extracts.  
Since the number of CxCa samples above cutoff increased using 4,000 µL extraction 
volumes while at the same time the number of NIL/M samples above cutoff did not 
increase, the larger volume was used further for validating HPV16 RNA patterns. 
 
4.1.5 Reproducibility of RT-qPCR and RNA extraction 
4.1.5.1 Reproducibility of RT-qPCRTP and RT-qPCRE1C 
Intra- and inter-plate variations of the final RT-qPCRTP and RT-qPCRE1C were determined 
with ten-fold dilution series of the in vitro transcripts E6*I, E1^E4, E1C and ubC in 
duplicates on the same plate and on two different plates.  
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For E6*I in vitro transcripts the mean intra-plate coefficient of variation (CV) was 1.07% 
(range 0.17 to 2.38%) (Table 4.5, a) and the mean inter-plate CV was 1.73 % (range 0.57 to 
3.05%) (Table 4.5, b). The mean intra-plate CV of the other HPV16 transcripts and of ubC 
ranged between 0.57 to 0.87% and the inter-plate CV between 0.73 to 1.62% (Table 4.5). As 
expected, inter-plate was higher than intra-plate CV for all viral transcripts and ubC. 
Variation increased with decreasing RNA dilutions, i.e. the closer the template 
concentrations to DL the higher the CV.  
Table 4.5. Intra (a) - and inter (b) -plate reproducibility of RT-qPCRTP and RT-qPCRE1C.  
(a) Intra-plate reproducibility
mean Cp CV (%)a mean Cp CV (%) mean Cp CV (%) mean Cp CV (%)
10 37 2.37 > 42 > 42 35 2.02
100 33 2.27 36 0.88 34 0.12 34 0.13
1,000 30 0.16 34 0.54 31 1.41 31 0.30
10,000 27 0.18 31 0.18 28 0.52 28 0.10
100,000 24 0.48 28 0.38 24 1.56 25 0.68
1,000,000 21 0.96 24 0.84 21 0.72 21 0.30
Meanb: 29 1.07 31 0.57 28 0.87 29 0.59
(b) Inter-plate reproducibility 
mean Cp CV (%) mean Cp CV (%) mean Cp CV (%) mean Cp CV (%)
10 36 2.46 > 42 > 42 36 3.09
100 33 1.40 36 0.78 34 0.24 34 2.91
1,000 30 0.57 34 1.08 31 1.22 31 0.82
10,000 27 1.25 31 0.48 28 0.63 28 0.78
100,000 23 1.64 28 0.26 24 1.14 25 1.46
1,000,000 20 3.05 24 1.03 21 0.51 21 0.65
Mean: 28 1.73 31 0.73 28 0.75 29 1.62
ubC E1C
RNA 
dilutions 
E6*I E1^E4 ubC E1C
E6*IRNA 
dilutions 
E1^E4
 
a coefficient of variation (CV) calculated as standard deviation/mean*100 with 0% indicating no difference 
between Cp values, b Cp >42 was not included in calculation of the mean 
A reduced DL as observed for E1^E4 and ubC in this experiment might be explained by 
RNA degradation of the in vitro transcript dilution series over time (Table 4.5). Therefore 
dilution series were periodically renewed.  
Overall, high inter- and intra-plate reproducibility of the RT-qPCRTP and RT-qPCRE1C was 
observed with mean CV from 0.59 to 2.27% and 0.75 to 1.94%, respectively. 
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4.1.5.2 Reproducibility of RNA extraction 
The reproducibility of RNA extraction was determined by extracting twice the RNA from 
48 HPV16 DNA-positive exfoliated cervical cell samples from Bad Münder (CIN0 (n=5), 
CIN1 (n=8), CIN2 (n=18), and CIN3 (n=17)). All RNA extracts were applied in duplicates 
to the RT-qPCRTP. 
Only 1 out of 48 exfoliated cervical cell samples was discordantly ubC-positive, however, 
quantified with 102 copies numbers only in extraction 2 (Figure 4.10, a). In total, 42 
exfoliated cervical cell samples were concordantly positive or negative for all viral 
transcripts and six were discordant, being negative once either for E6*I or E1^E4. The three 
discordant E6*I cases were once borderline positive (below 12 copies per PCR) (Figure 
4.10, b). The three discordant E1^E4 cases were quantified with copies between 102 and 103 
per PCR (Figure 4.10, c), however, showed in either both or one of the extracts low ubC 
copies per PCR (<100 copies per PCR).  
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Figure 4.10. Reproducibility of the RNA extraction. UbC (a), E6*I (b) and E1^E4 copies per PCR (c) are 
shown in extraction 1 (y-axis) compared to extraction 2 (x-axis). The diagonal is indicated. Slope (m) of the 
regression line is depicted, a value of 1 indicates the absence of systematic differences between the extractions. 
Coefficient of determination (R2) describes the correlation between copies per PCR of extraction 1 and 2, with 
value of 1 being perfect. All templates were applied in duplicates and mean Cp value was used for the 
calculation of copies per PCR. Negative results, i.e. no detectable RT-qPCR signal within 42 cycles, are 
indicated below the dotted cutoff line.  
Across E6*I, E1^E4 and ubC, the coefficient of determination (R2) ranged between 0.81 to 
0.98, p<0.0001, indicating a highly significant linear correlation. The slopes (m) of the 
regression lines were between 0.93 and 0.99 confirming a robust reproducibility of the RNA 
extraction (Figure 4.10). The Cp values <42 measured in exfoliated cervical cell samples 
from extraction 1 and extraction 2 varied with a mean CV of 1.96% (0-16%) for E6*I, 
2.24% (0-18.3%) for E1^E4 and 1.41% (0-18.3%) for ubC. The reproducibility of the 
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repeated extraction was slightly weaker compared to the intra-/inter-plate CV of RT-qPCRTP 
(Table 4.5).  
Overall, a high reproducibility of RNA extraction was observed. 
 
4.1.6 Comparison of RT-qPCR and singleplex NASBA 
The performance of RT-qPCRTP and RT-qPCRE1C for the detection of E6*I, E1^E4, E1C 
and ubC was compared to the established NASBA method detecting E6*II, E1^E4, E1C, L1 
and ubC. The comparison was performed using cervical cancer cell lines (chapter 4.1.6.1) 
and followed by oropharyngeal squamous cell carcinomas (OPSCC) (chapter 4.1.6.2). RNA 
from the cervical cancer cell lines originated from different passages, but the RNA extracts 
from OPSCC were the same samples applied to both methods. 
 
4.1.6.1 Transcript quantification in cervical cancer cell lines  
A comparison of RT-qPCRTP and RT-qPCRE1C and the established NASBA method was 
done using RNA from cervical cancer cell lines MRI-H186, SiHa, CaSki and MRI-H196.  
The NASBA data was based on two experiments run on two different days using the same 
cell line RNA without intra-assay duplicates showing very high variations. MRI-H186 was 
known to contain between 7.5 and 7,500 E6*I, between 0.75 and 750 E1^E4, between 0.08 
and 0.75 E1C, between 0.08 and 7.5 L1 and between 0.75 and 750 ubC copies per cell148 
(Figure 4.11, a). Variations observed in SiHa, CaSki and MRI-H196 were shown in figure 
4.11, b-d.  
Total RNA (33 ng, corresponding to approximately 2,200 cells) extracted from cell lines 
MRI-H186, SiHa, CaSki and MRI-H196 was applied 2 to 12 (in case of MRI-H186)-times 
to RT-qPCRTP and RT-qPCRE1C. 
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Figure 4.11. Comparison of RT-qPCR and singleplex NASBA. Copies per cell of E6*I, E1^E4, ubC and 
E1C in RNA from HPV16-tranformed cervical cancer cell lines MRI-H186 (a), SiHa (b), CaSki (c) and MRI-
H196 (d) quantified in NASBA148 (grey bars) and RT-qPCR (red bars). Calculation of copies per cell based on 
the assumption that 5 ng of RNA correspond to 330 cells. A value below 1 indicates that the transcript is not 
present in every cell. All templates were analysed in duplicates and in RT-qPCR in dodecuplicate in case of 
MRI-H186 and presented as boxplots with whiskers from minimum to maximum. If duplicates are nearly 
identical, whiskers cannot be recognised. If transcript was not detected in any duplicate, value was set to 
0.0001.  
The mean copies per cell of all high-abundance transcripts quantified by RT-qPCRTP were 
either identical (ubC in SiHa), between 3- (E6*I in MRI-H196) and 50-times (E6*I and 
E1^E4 in MRI-H186) lower or between 4- (E6*I in SiHa) and 5-times (E1^E4 in MRI-
H196) higher than by NASBA (Figure 4.11). In all cell lines, the mean E1C copies per cell 
were lower by RT-qPCRE1C (refer to 5.2.5 for discussion).  
However, CV of NASBA duplicates were high: between 139 and 141%. Therefore, the 
difference of mean copies per cell was not significant. In contrast, the quantified number of 
transcripts per cell by RT-qPCRTP and RT-qPCRE1C was highly reproducible with CV 
between 0% (E1C) and 72% (E6*I). 
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To exclude mistakes of the RT-qPCRTP and RT-qPCRE1C quantification, the in vitro 
transcription of all transcripts as well as the titration curve of the transcript dilutions was 
repeated (data not shown). The DL as well as RT-qPCRTP and RT-qPCRE1C efficiency was 
confirmed, excluding the possibility that mistakes in RT-qPCRTP and RT-qPCRE1C standard 
curves caused the discrepancy to NASBA (refer to 5.2.5 for discussion).  
 
4.1.6.2 Transcript quantification in oropharyngeal squamous cell carcinomas  
RNA samples had been extracted from 32 fresh-frozen OPSCC biopsies and the copies of 
E6*II, E1^E4, E1C and ubC had been determined by singleplex NASBA performed by Dr. 
Dana Holzinger152. The same RNA samples were now analysed by RT-qPCRTP and RT-
qPCRE1C. A comparison of E6*I with E6*II could be performed as their transcript 
expression highly correlates in HPV infected cells, though the E6*I expression is around 
ten-fold higher than for E6*II (see introduction 1.7)136,146,167.  
The qualitative comparison of E6*I and E6*II (E6*I/*II) detected by RT-qPCRTP and 
NASBA, respectively, showed 24 concordantly E6*I/*II positive samples, 1 concordantly 
negative and 7 discordant samples resulting in an overall agreement of 78.1% (Figure 4.12, 
a). The discordant samples that were only positive with RT-qPCRTP were attributed to the 
higher level of E6*I than E6*II in HPV16-positive cells. A very good quantitative 
correlation of E6*I/*II detected by both methods was indicated by Pearson correlation (rp) 
of 0.94 (p<0.0001) (Figure 4.12, a).  
The qualitative comparison of E1^E4 detected by RT-qPCRTP and NASBA, respectively, 
showed 21 concordant positive samples, 5 concordant negative and 6 discordant samples 
resulting in an overall agreement of 81.3% (Figure 4.12, b). Three were borderline positive 
with RT-qPCRTP only and three with NASBA. A good quantitative correlation of both 
methods for E1^E4 was observed with an rp of 0.69 (p<0.0001) (Figure 4.12, b).  
A 100% concordance of OPSCC samples defined as positive or negative by the E6*I/E1^E4 
ratio in RT-qPCRTP and by the E6*II/E1^E4 ratio in NASBA, respectively, was observed 
(Figure 4.12, d).  
E1C detection was concordantly positive in 16, concordantly negative in 14 and discordant 
in 2 OPSCC cases that were detected by RT-qPCRE1C only resulting in an overall agreement 
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of 93.8%. Thus, E1C detection by RT-qPCRE1C was slightly more sensitive than with 
NASBA. A quantitative correlation of E1C was not observed (rp=0.15, p=0.41) (Figure 
4.12, c) which can be explained by the fact that NASBA was at best semi-quantitative for 
E1C while RT-qPCRE1C enabled a quantification over 5 logs (see Introduction 1.7).  
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Figure 4.12. Comparison of transcript quantification by RT-qPCR (copies per PCR on x-axis) and by 
NASBA (ratio of wildtype (wt)/calibrator (q) signal on y-axis) as well as comparison of E6*I/E1^E4 
ratio by RT-qPCRTP and E6*II/E1^E4 ratio by NASBA (d). Dotted lines indicate the cutoffs. In RT-qPCR, 
all templates were applied in duplicates and mean Cp value was used for the calculation of copies per PCR. 
Negative values are set below 1 copy per RT-qPCR, set to 0.00001 for the NASBA ratio wt/q (a-c), set to 
0.001 for the NASBA ratio E6*II/E1^E4 and to 0.00001 for the RT-qPCR ratio E6*I/E1^E4 (d).  
The overall concordance of the HPV16 RNA patterns (E6*I(I)/E1^E4 ratio and E1C) was 
100%: In total, 21 OPSCC cases were concordantly classified as CxCa-like RNA patterns-
positive (CxCaRNA+) and 11 concordantly as CxCa-like RNA patterns-negative 
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(CxCaRNA-). The 11 tumours not displaying viral RNA patterns exhibited very low signals 
for all viral transcripts in NASBA and RT-qPCRTP and RT-qPCRE1C.  
 
4.1.7 Clinical validation of the HPV16 RNA patterns 
The RT-qPCR-based HPV16 RNA patterns test to detect advanced (≥CIN2) cervical lesions 
was clinically validated with exfoliated cervical cells fixed in PreservCyt buffer. The 
samples were obtained from women cytologically and/or histologically diagnosed as 
NIL/M, CIN0, CIN1, CIN2, CIN3 and CxCa in studies from Bad Münder and Mongolia. 
The presence of HPV DNA was determined by BSGP5+/6+-PCR/MPG. Subsequently, in 
the singly infected HPV16 DNA-positive cervical cell samples the spliced HPV16 
transcripts E6*I, E1^E4 and E1C and the cellular transcript ubC were quantified by RT-
qPCRTP and RT-qPCRE1C.  
The HPV16 RNA patterns were compared with the cytological or histological diagnoses 
near the time of sampling and at follow-up if available. Slides for liquid-based cytology 
were prepared using a Thin Prep 2000 processor and diagnosed as described elsewhere149. 
Histological diagnoses of colposcopy-directed biopsies were based on independent blinded 
readings of two pathologists with knowledge of cytological, HPV DNA and p16INK4a 
staining results in the Bad Münder study. Discordant readings were discussed to reach a 
final consensus diagnosis. In the Mongolia study, CxCa histology diagnoses were based on 
agreement of three study pathologists12.  
 
4.1.7.1 Ascertainment of histological case diagnoses 
The accuracy of histological diagnoses in cervical biopsies is critical for adequate patient 
management and also for evaluation of new screening technologies for cervical cancer 
precursors such as the HPV16 RNA patterns test. 
This chapter summarises the agreement of two pathologists on the diagnosis of 104 cervical 
biopsies with HPV16 single-infected RNA-positive exfoliated cervical cells from the Bad 
Münder study. 
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Overall agreement of initial readings was 58% (60 out of 104). CIN3 had the highest class-
specific agreement, with 78% concordance of all initially diagnosed CIN3 cases. 
Concordant CIN1 diagnosis was present in only 15% of all initially diagnosed CIN1 cases 
(Table 4.6).  
Table 4.6. Overall agreement of initial histological diagnoses by two pathologists in the Bad Münder 
study a. 
CIN0 CIN1 CIN2 CIN3 Total
CIN0
N 7 5 3 0 15
% 7 5 3 0 14
Row % 47 33 20 0
Column % 70 56 8 0
CIN1
N 0 2 8 3 13
% 0 2 8 3 13
Row % 0 15 62 23
Column % 0 22 21 6
CIN2
N 1 2 20 13 36
% 1 2 19 13 35
Row % 3 6 56 36
Column % 10 22 53 28
CIN3
N 2 0 7 31 40
% 2 0 7 30 38
Row % 5 0 18 78
Column % 20 0 18 66
Total
N 10 9 38 47 104
% 10 9 37 45 100
Pathologist 2
Pathologist 1
 
a Shaded diagonals represent concordant interpretations. In the shaded diagonals, values in boldface indicate 
the frequencies (N) of concordance.  
Pathologist 2 tended to give more severe diagnoses than pathologist 1. After rediscussion of 
discordant cases, the diagnosis of pathologist 2 was taken as final diagnosis in 21% of cases, 
that of pathologist 1 in 17% and in 4% a new diagnosis was given. 
The moderate intraobserver reproducibility in initial diagnosis in part may reflect the 
subjectivity of histological diagnoses. This should be kept in mind when histology, 
especially derived from a single pathological viewing, is used as gold standard in validation 
of novel diagnostic assays.  
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4.1.7.2 Type-specific HPV DNA prevalence in validation samples 
DNA was extracted from 691 exfoliated cervical cell samples from Bad Münder and 
subsequently analysed by BSGP5+/6+-PCR/MPG (Table 4.7). The data from 98 cervical 
samples from Mongolia have been described before149.  
Table 4.7. HPV16 DNA prevalence in HPV DNA-positive exfoliated cervical cell samples from Bad 
Münder and Mongolia. 
 HPV DNA-
positive
N N % N % N %
CIN0 Bad Münder 116 27 23 17 15 10 9
CIN1 Bad Münder 129 34 26 19 15 15 12
CIN2 Bad Münder 190 92 48 51 27 41 22
CIN3 Bad Münder 170 109 64 65 38 44 26
NIL/M Mongoliab 71 71 100 34 48 37 52
CxCa Mongoliab 27c 27 100 9 33 18 67
Total 703 360 51 195 54 165 46
Histological or 
cytological stage
Origin
Single HPV16 
DNA-positive 
HPV16 DNA-
positive 
Multiple HPV16 
DNA-positivea
 
a HPV16 plus any mucosal HPV type, b pre-selected for HPV16 DNA-positivity, c selected for HPV16 E6*I 
mRNA positivity by the analysis of corresponding FFPE biopsies using ultra-short HPV E6*I mRNA assays12 
Of 789 exfoliated cervical cell samples, 703 (89%) were HPV DNA-positive with 360 
(51%) containing HPV16 DNA, of these 165 (46%) as single mucosal HPV type. Viral 
RNA patterns were analysed in HPV16 single-infected samples (chapter 4.1.7.8), in HPV16 
multiple-infected samples (chapter 4.1.7.10), and in all HPV DNA negative samples. No 
false-positive detection of viral transcripts in the HPV negative samples (n=86) was 
observed (data not shown).  
 
4.1.7.3 RNA quality assessment of validation samples 
RNA quality might affect the sensitivity of the HPV16 RNA patterns analyses. In particular 
storage time and storage conditions of cervical cell samples might be critical for RNA 
quality.  
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RNA quality was assessed in RNA samples extracted from the cell line MRI-H196 as well 
as from a subset of 12 archived exfoliated cervical cell samples stored at 4°C in PreservCyt 
for 9 to 84 months. The RNA integrity number (RIN) as well as the ubC copies per cell 
were determined. The RIN is calculated by using the entire RNA profile that is separated 
according to the molecular weight giving a continuous value from 10 down to 1 defining the 
extend of RNA degradation (10=intact, 1=totally degraded). 
A RIN value of 8.7 measured in MRI-H196 indicated a good RNA quality (Table 4.8). 
However, the RIN values in the archived cervical cell samples of only 1.0 to 5.2 (median 
2.3) indicated partial up to severe degradation of the RNA. 
Table 4.8. RNA quality in extracts from fresh frozen cell line and archived validation samples. 
Source Material Storage
Archived at 
4°C (months)
Number of 
samples
Median RNA 
concentration [ng/µL] 
Median RIN 
(range)a
Mean ubC RNA 
copies/PCRb (range)
Median ubC RNA 
copies/cellc (range)
Heidelberg MRI-H196 Fresh-frozen 0 1 19 8.7 22,485 (19,055-28,489) 16 (11-23)
Bad Münder Cervical smear PreservCyt 9-12 5 16 2.1 (1-2.4) 6,955 (53-69,614) 2 (1-3)
Bad Münder Cervical smear PreservCyt 13-24 5 45 3.44 (2-5.2) 1,687 (81-15,757) 2.8 (1-6)
Mongolia Cervical smear PreservCyt 84 2 24 1.95 (1.6-2.2) 3,661 (1,521-5,800) 3 (1-5)  
a median RNA integrity number (RIN) where 1 indicates totally degraded and 10 completely intact RNA,  
b mean ubC RNA copies per PCR in MRI-H186 was calculated from same RNA extract applied 5-times to RT-
qPCRTP and in cervical smear from 5 and 2 different samples, respectively, applied in duplicates to RT-
qPCRTP, c ubC RNA copies per cell were calculated using the measured RNA concentration per µL, the 
quantified ubC RNA copies per PCR and the assumption that 5 ng of RNA correspond to 330 cells  
The calculated ubC copies per cell were up to 8-times higher in the fresh-frozen cell line 
than in the archived cervical cell samples (Table 4.8). However, no correlation of ubC copy 
number with RIN was observed (rp=0.25, p=0.4, Figure A8.2). 
RNA quality was reduced in archived cervical cell samples compared to the fresh-frozen 
cell line sample. 
 
4.1.7.4 Qualitative prevalence of single transcripts in validation samples 
The previous NASBA pilot study had shown that the qualitative transcript analyses cannot 
discriminate mild from severe lesions87. The aim of this chapter was to reproduce these 
findings by using the RT-qPCRTP and RT-qPCRE1C. 
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RNA was extracted from 4 mL of the single HPV16 DNA-positive cervical cell samples 
from Bad Münder (n=110) and Mongolia (n=55). Subsequently, RNA samples were 
analysed in duplicates by RT-qPCRTP and RT-qPCRE1C. 
Of the 165 RNA samples, 158 (96%) were valid (>80 ubC or >200 E6*I copies per PCR, 
chapter 3.12). Overall prevalence of any viral transcript increased from NIL/M (8%) to 
CIN0 (50%) and reached 95-100% in the cervical lesions (Table 4.9). 
Table 4.9. Prevalence of individual transcripts in 158 HPV16 single-infected cervical cell samples with 
valid RNA by cytological or histological lesion stage. 
n % n % n % n % n % n % n %
RNA invalid 7 4 1 3 0 0 4 30 0 0 2 5 0 0
RNA valid
   E6*I-positive 113 72 3 8 4 40 9 82 39 95 40 95 18 100
   E1^E4-positive 96 61 2 6 3 30 10 91 39 95 36 86 6 33
   E1C-positive 34 22 1 3 0 0 0 0 7 17 22 52 4 22
   Any viral transcript-positive 117 74 3 8 5 50 11 100 40 98 40 95 18 100
   ubC-positive 158 100 36 100 10 100 11 100 41 100 42 100 18 100
Transcript NIL/M CIN0 CIN1 CIN2 CIN3All CxCa
Cytological or histological stage
 
In agreement with the previous NASBA pilot study, E6*I prevalence increased from NIL/M 
(8%) and CIN0 (40%) to CIN1 (82%) and remained between 95% and 100% for CIN2, 
CIN3 and CxCa. Likewise, E1^E4 prevalence increased as well, reaching a plateau around 
90% in CIN1, CIN2 and CIN3, but decreased substantially in CxCa (33%). In contrast, the 
prevalence of E1C was below 11% until CIN2, peaked in CIN3 (52%) and decreased again 
in CxCa (22%). The decrease of the E1C prevalence in CxCa was not in agreement with the 
pilot study, where 57% of CxCa samples were E1C-positive (refer to 5.3.3 for discussion).  
While viral transcripts were more frequent in cervical abnormalities compared to healthy 
cytology, the qualitative expression of E6*I and E1^E4 cannot discriminate ≤CIN1 from 
≥CIN2 lesions. In contrast, a qualitative detection of E1C appears to be a specific marker for 
≥CIN2 lesions.  
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4.1.7.5 Quantitative expression levels of single transcripts in 158 validation samples 
The previous NASBA pilot study showed that E6*I and E1C encoding transcripts were 
strongly upregulated in severe lesions, whereas spliced E1^E4 encoding transcript was 
markedly downregulated146. The aim of this chapter was to reproduce these findings by 
using the RT-qPCRTP and RT-qPCRE1C. 
The median ubC copy number in the single HPV16 DNA-positive cervical cell samples 
(Table 4.7) was 901 (range 54 to 69,614). The copy number distribution showed no 
significant difference neither between the different cytological and histological stages 
(Figure 4.13, d) nor between samples from Bad Münder and Mongolia (p=0.7, Mann-
Whitney-Test) (Figure A8.3).  
Among the E6*I-positives, the median copies per PCR increased from CIN0 (30 copies per 
PCR), CIN1 (75), CIN2 (381), CIN3 (894) to CxCa (1,180). E6*I showed a significant 
upregulation in ≥CIN3 compared to ≤CIN1 (p=0.0039, Mann-Whitney-Test) (Figure 4.13, 
a).  
Among the E1^E4-positives, the median copies per PCR were equivalent in NIL/M (4,114 
copies per PCR), CIN0 (2,972) and CIN1 (2,243), increased from CIN2 (6,679) to CIN3 
(13,082) and declined in the CxCa samples (5,973), however, without significant differences 
between the different stages (p=0.91, 1-way-Anova) (Figure 4.13, b).  
A wide range of copies (between 2 and 841,438) of the high-abundance transcripts E6*I and 
E1^E4 was observed.  
The mean E1C copies per PCR were nearly equivalent in CIN2 (40 copies per PCR) and 
CIN3 (16) and significantly reduced in CxCa (9) in comparison to CIN2 (p=0.0424, Mann-
Whitney-Test) (refer to 5.3.3 for discussion) (Figure 4.13, c).  
Compared to ≤CIN1, in ≥CIN2 transcript levels of E6*I (p=0.0088), E1^E4 (p=0.0267) and 
E1C (significance not possible to calculate due to low number of positives among ≤CIN1) 
were significantly augmented. However, in further analyses CIN2 was categorised as 
intermediate and not grouped within the severe lesions since CIN2 classification has been 
reported to have the highest intraobserver variation among pathologists107.  
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Figure 4.13. Copy number per PCR (y-axis) of E6*I (a), E1^E4 (b), E1C (c) and ubC (d) transcripts in 
158 cervical cell samples of different cytological or histological lesion stages (x-axis, categories). NIL/M 
(n=36), CIN0 (n=10) and CIN1 (n=11) are combined in the ≤CIN1 (n=57) category and CIN3 (n=42) and 
CxCa (n=18) in the ≥CIN3 (n=60) category. Negative values are indicated below 1 copy per PCR. Cutoff is 
shown as dotted line, red lines represent the arithmetic median with interquartile range. All templates were 
applied in duplicates and mean Cp value was used for the calculation of copy number.  
The spliced E6*I and E1^E4 changed the most in different grades of lesion. However, the 
E6*I and E1^E4 copy numbers alone cannot discriminate ≤CIN1 from ≥CIN2 lesions. Only 
very low E1C copy numbers were detected in E1C-positive samples, which may hint at a 
regulatory function of the E1C protein (refer to 5.3.3 for further discussion).  
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4.1.7.6 Influence of cell number on viral transcript quantification 
Supposing that all cells in the cervical smear are HPV-infected, a positive correlation 
between the quantified ubC and the viral transcript copies per PCR is expected. 
Furthermore, a negative correlation is expected if a high copy number of ubC inhibits the 
quantification of viral transcripts. 
The viral transcript copy numbers (described in chapter 4.1.7.5) were directly compared to 
ubC copy numbers (Figure 4.14).  
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Figure 4.14. Correlation of viral transcript copies per PCR (y-axis) and ubC transcript copies (x-axis) in 
158 cervical cell samples of different cytological or histological lesion stages. NIL/M (n=36), CIN0 (n=10) 
and CIN1 (n=11) are combined as ≤CIN1 (n=57) and CIN3 (n=42) and CxCa (n=18) as ≥CIN3 (n=60). 
Lesions ≥CIN3 are depicted as black triangles, CIN2 as grey triangles and ≤CIN1 as open rhombi. All 
templates were applied in duplicates and mean Cp value was used for the calculation of copies per PCR. 
Negative values are indicated below 1 copy per PCR. Dotted lines indicate cutoffs.  
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No correlation of ubC and E6*I copy numbers was observed neither in all samples, nor in 
≥CIN3 or in ≤CIN1 as indicated by the low Pearson correlation of rp=0.02 (p=0.8), rp=0.06 
(p=0.7) and rp=-0.1 (p=0.9), respectively. Only 5 out of 16 samples with ubC <200 copies 
per PCR were E6*I-negative. Thus, a low number of ubC copies did not correlate with a 
low number of E6*I copies. As already shown above (Figure 4.13), high E6*I copy numbers 
are mainly present in lesions diagnosed as ≥CIN2.  
Likewise, no correlation of ubC and E1^E4 copy numbers was observed neither in all 
samples (rp=0.2, p=0.1), nor in ≥CIN3 (rp=0.06, p=0.7) nor in ≤CIN1 (rp=0.04, p=0.8). Low 
ubC copy numbers did not correlate with the quantification of E1^E4 since only 5 of 16 
(31%) samples with ubC <200 copies and 57 out of 142 (40%) with ubC >200 copies were 
E1^E4-negative. 
Similarly, no correlation of ubC and E1C copy numbers was observed neither in ≥CIN3 
(rp=0.2, p=0.3), nor in ≤CIN1 (cannot be calculated due to small number of data points) nor 
in all samples (rp=0.02, p=0.8) (Figure 4.14, c). E1C was mostly detected in high-grade 
lesions with copies ranging between 4 and 156. Eight cervical cell samples diagnosed as 
≥CIN3 had ubC copies per PCR <200, however two of those were E1C-positive with 35 and 
100 copies per PCR, respectively. As not all ≥CIN3 lesions were expected to be E1C-
positive, low ubC copies did not correlate necessarily with low E1C copies. 
Consequently, the assumption that all cells are HPV-infected and that ubC influences viral 
transcript quantification can be rejected. Cervical smear samples contain variable amounts 
of HPV-positive cells. 
 
4.1.7.7 Cutoff definition of HPV16 RNA patterns in HPV16 single-infected validation 
samples  
As mentioned in the previous chapter, the relative and total number of HPV-positive cells 
per cervical smear can vary. Thus, a copy number ratio of E6*I and E1^E4 was computed 
allowing the normalisation for variable quantities of HPV-infected cells in cervical smears 
assuming that the transcript ratio is similar in the majority of HPV-positive cells in a given 
sample. This chapter summarises the cutoff definition of the E6*I/E1^E4 ratio.  
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To obtain a clinically useful cutoff for the E6*I/E1^E4 ratio in detecting ≥CIN3, a panel of 
117 HPV16 single-infected samples was analysed by RT-qPCRTP and RT-qPCRE1C. The 41 
CIN2 samples were excluded due to the low diagnostic accuracy of this histological 
category107. Cutoff for E6*I/E1^E4 (cutoffE6*I/E1^E4) was determined by Receiver Operating 
Characteristic (ROC) curves comparing E1C-negative samples ≤CIN1 with E1C-negative 
≥CIN3. 
The area under the curve (AUC) of 0.9 indicated that all calculated cutoffs were better than 
random (Figure 4.15, a). Sum of sensitivity and specificity was highest with a cutoffE6*I/E1^E4 
of 0.095 with 80.56% and 84.21%, respectively. When E1C RNA positivity was added to 
the definition of advanced lesions the sensitivity for ≥CIN3 increased to 88%, without 
loosing specificity. 
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Figure 4.15. Determination of E6*I/E1^E4 cutoff. (a) Receiver operating characteristic (ROC) curve 
calculates sensitivity and specificity for discriminating ≤CIN1 and ≥CIN3 lesions. Combination of highest 
sensitivity and specificity is marked in blue. The diagonal divides the ROC space, points above indicate good 
(better than random) and points below poor (worse than random) classification. (b) E6*I/E1^E4 ratio (y-axis) 
in NIL/M, CIN0, CIN1 are combined in the ≤CIN1 category and CIN3 and CxCa in the ≥CIN3 category with 
no E1C detection (left) and E1C detection (right). The cutoff line (0.095) is shown as dotted line. All templates 
were applied in duplicates and mean Cp value was used for the calculation of copy numbers.  
The cutoffE6*I/E1^E4 of 0.095 divided the cervical samples in three groups: E1C-positive only, 
E1C and E6*I/E1^E4 double positive and E6*I/E1^E4 ratio-positive only (Figure 4.15, b) 
(refer to chapter 4.1.7.8 and 5.3.5 for discussion). 
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In conclusion, a cutoffE6*I/E1^E4 of 0.095 was used in all further analyses.  
 
4.1.7.8 HPV16 RNA patterns in HPV16 single-infected validation samples 
Next, I analysed the presence of transformation-specific HPV16 RNA patterns (copy 
number ratio of E6*I/E1^E4 >0.095 and/or presence of E1C) in the same HPV16 single-
infected cervical lesions used for cutoff definition before (Figure 4.16).  
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Figure 4.16. HPV16 RNA patterns in 158 cervical lesions of different cytological and histological stages 
(x-axis, categories). (a) Transcript copy number ratio of E6*I/E1^E4 (y-axis) and presence of E1C (marked in 
blue) in NIL/M (n=36), CIN0 (n=10) and CIN1 (n=11) are combined in the ≤CIN1 (n=57) category and CIN3 
(n=42) and CxCa (n=18) in the ≥CIN3 (n=60) category. Cutoff (0.095 for E6*I/E1^E4 ratio) is shown as 
dotted line, red lines represent the median with interquartile range. E6*I and E1^E4-negative samples are 
indicated arbitrarily by a ratio of 0.00001. E1C-positive samples were detected with Cp <42. (b) Black bars in 
the bar diagram summarise the only E6*I/E1^E4 ratio-positives, blue bars the only E1C-positives and grey 
bars the E6*I/E1^E4 ratio and E1C double positives. 
The frequency of E6*I/E1^E4 ratio-positive samples increased from NIL/M (8%) to CIN1 
(18%), CIN3 (67%) and increased in CxCa (100%) (Figure 4.16). The frequency in CIN0 
with 40% was elevated but this is based on 4 of 10 data points only (Figure 4.16, a). 
Compared to mild lesions (≤CIN1), the increase was significantly higher in CxCa 
(p<0.0001, Wilcoxon-signed-rank test), in CIN3 (p=0.0005) and in CIN2 (p=0.0135) as well 
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as in the group of severe lesions (≥CIN3) (p<0.0001). All samples with an E6*I/E1^E4 ratio 
above 2, were E1^E4 negative. The frequency of E1C-positives rose from NIL/M (3%) to 
CIN3 (52%) and dropped again in CxCa (22%) (Figure 4.16). In CIN2 lesions reported to 
have low diagnostic accuracy107, 37% were E6*I/E1^E4 ratio- and 17% E1C-positive, as 
expected for the intermediated group between CIN1 and CIN3 diagnosed lesions. Overall, 
the frequency of samples positive for at least one of the HPV16 RNA patterns increased 
from NIL/M (8%), CIN0 (40%), CIN1 (19%) to CIN3 (83%) and to CxCa (100%). Thus, 48 
out of 57 (84%) HPV16 single-infected cervical cell samples with NIL/M, CIN0, CIN1 
were correctly classified as mild and 53 out of 60 (88%) CIN3 and CxCa were correctly 
classified as severe lesion. 
 
4.1.7.9 HPV16 load in HPV16 single-infected validation samples 
High HPV16 load is a more precise marker for predicting the presence of cervical lesions 
than HPV DNA positivity alone. Viral loads can reliably discriminate between no lesion and 
any lesion134. For a comparison between the two markers (HPV16 RNA patterns and high 
HPV16 load (defined as >0.0007 %HPV MFI/ß-globin MFI)), the prevalence of high 
HPV16 loads in 158 single-infected HPV16 DNA-positive cervical cell samples was 
examined. 
The HPV16 loads in cervical cells of single infected CIN0 (p=0.0002, Mann-Whitney-Test), 
CIN1 (p=0.0004), CIN2 (p<0.0001), CIN3 (p<0.0001) and CxCa (p=0.0018) lesions were 
significantly increased compared to NIL/M (Figure 4.17). However, insignificant viral load 
difference was observed between CIN0 and CIN1 (p=0.5, Mann-Whitney-Test), CIN2 
(p=0.9), or CIN3 (p=0.6). The frequency of high HPV16 load increased from NIL/M (8%) 
to CIN0 (100%), CIN1 (100%), CIN2 (97%), CIN3 (98%) and CxCa (100%). 
Results 
 
89 
NIL/M CIN0 CIN1 CIN2 CIN3 CxCa
10- 5
10- 4
10- 3
10- 2
10- 1
100
Group
size (n):      36           10   11   41        42          18
Cytological or histological stages
H
PV
16
 lo
ad
 (%
H
PV
16
 M
FI
/ -
gl
ob
in
 M
FI
)
HPV16 RNA
patterns-positive
 
Figure 4.17. Distribution of viral load among cervical lesions of different grades in single-infected 
HPV16 DNA-positive cervical cell samples. HPV16 loads (y-axis) are plotted for groups of cervical lesions 
defined by cytology or histology (x-axis, categories) including NIL/M (n=36), CIN0 (n=10), CIN1 (n=11), 
CIN2 (n=41), CIN3 (n=42) and CxCa (n=18). Cutoff (0.0007 for high viral load) is shown as dotted line, red 
lines represent the median with interquartile range in black. Samples with transformation-specific HPV16 
RNA patterns are marked in blue. 
Of interest, two NIL/M samples had high HPV16 loads and showed transformation-specific 
HPV16 RNA patterns (Figure 4.17). One additional NIL/M sample showed high HPV16 
load only. Moreover, all CIN0 and CIN1 had a high HPV16 load, while only 4 of 10 CIN0 
and 3 of 11 CIN1 were HPV16 RNA patterns-positive. In contrast to the HPV16 RNA 
patterns, 41 of 42 CIN3 showed high HPV16 load. All CxCa showed high HPV16 load and 
were HPV16 RNA patterns-positive.  
In concordance to the literature133,134, high viral load cannot discriminate between CIN0, 
CIN1, CIN2 and CIN3 while HPV16 RNA patterns can specifically identify 84% of the 
HPV16 single-infected ≤CIN1 as negative for transformation-specific HPV16 RNA 
patterns.  
Results 
 
90 
4.1.7.10 HPV16 RNA patterns and HPV16 load in multiple-infected cervical cell 
samples 
Next, I compared the presence of transformation-specific HPV16 RNA patterns with the 
cytological or histological classification of cervical cell samples that in addition to HPV16 
contained also at least one additional mucosal HPV type (Table 4.7). Identifying the 
“driving” HPV type for cervical neoplasia is difficult because multiple HPV types are 
frequently detected within the epithelium of the uterine cervix134,158. In addition, multiple 
cervical lesions within an individual patient may be caused by different types and a 
precursor lesion, caused by a specific carcinogenic type, can be surrounded by transient 
HPV infections168. In this chapter, HPV16 E6*I-negative samples with HPV16 not being the 
driving force to carcinogenesis were excluded. HPV16 E6*I-positive samples were 
additionally analysed for viral load. 
RNA was extracted from 195 HPV16 DNA-positive cervical cell samples with multiple 
HPV infections identified (see chapter 4.1.7.2) in the series from Bad Münder (n=152) and 
Mongolia (n=43) using an extraction volume of 4 mL exfoliated cervical cell sample. RNA 
was applied in duplicates to RT-qPCRTP and RT-qPCRE1C. Viral loads of all mucosal types 
were determined by the quantitative BSGP5+/6+-PCR/MPG assay. 
Out of the 195 RNA samples, 181 (93%) were RNA-valid (ubC >80 or E6*I >200 copies 
per PCR, chapter 3.12) and composed of NIL/M (n=34), CIN0 (n=11), CIN1 (n=19), CIN2 
(n=48), CIN3 (n=60) and CxCa (n=9). The median ubC copies was 958 ranging from 53 to 
70,887 with insignificant difference in the cervical cell samples from Bad Münder und 
Mongolia (p=0.06, Mann-Whitney-Test) (data not shown).  
Of the 64 ≤CIN1, 24 were E6*I-positive including NIL/M (5 out of 34, 15%), CIN0 (7 out 
of 11, 64%) and CIN1 (12 out of 19, 36%). The frequency of HPV16 RNA patterns-positive 
samples increased from NIL/M (2 out of 5, 6%), CIN0 (4 out of 7, 36%) to CIN1 (8 out of 
12, 42%) (Figure 4.18, a). However, these false-positive cervical cell samples 
(transformation-specific HPV16 RNA patterns but ≤CIN1 by histology) will be focused in 
the next chapter (4.1.7.11).  
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Figure 4.18. HPV16 RNA patterns in multiple HPV16 DNA-positive cervical lesions of different stages 
selected for HPV16 E6*I-positivity. (a) Transcript copy number ratio of E6*I/E1^E4 (y-axis) and presence of 
E1C (marked in blue) in cervical lesions defined by cytology or histology (x-axis, categories). NIL/M (n=5), 
CIN0 (n=7) and CIN1 (n=12) are combined in the ≤CIN1 (n=24) category and CIN3 (n=57) and CxCa (n=8) 
in the ≥CIN3 (n=65) category. Cutoff (0.095 for E6*I/E1^E4 ratio) is shown as dotted line, red lines represent 
the median with interquartile range in black. E1C-positive samples were detected with Cp <42. (b) Subgroup 
of E6*I/E1^E4 ratio-positive (y-axis) and/or E1C-positive CIN2 (n=21) and CIN3 (n=41) (x-axis, categories) 
with low HPV16 load (filled stars), high HPV16 load (open triangles) and highest HPV16 load (filled circles). 
(c) Subgroup of E6*I/E1^E4 ratio-negative (y-axis) and E1C-negative CIN2 (n=20) and CIN3 (n=16) (x-axis, 
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categories) with low HPV16 load (filled stars), high HPV16 load (open triangles) and highest HPV16 load 
(filled circles).  
Of the 117 ≥CIN2, 106 were E6*I-positive including CIN2 (n=41), CIN3 (n=57) and CxCa 
(n=8). The frequency of HPV16 RNA patterns-positive samples increased from CIN2 
(n=21, 51%), CIN3 (n=41, 72%) to CxCa (n=7, 88%) (Figure 4.18, a). In addition, 20 of the 
21 (95%) HPV16 RNA patterns-positive CIN2 had high HPV16 load and 8 (38%) highest 
HPV16 load (Figure 4.18, b). Of the 20 HPV16 RNA patterns-negative CIN2, all (100%) 
had high HPV16 load and 9 (45%) highest HPV16 load (Figure 4.18, c). However, high 
HPV16 load could also be caused by temporarily productive HPV16 infection without any 
significance and another HPV type could be responsible for lesion. Confirmatively, 12 
CIN2 (60%) had high load with at least one additional hrHPV type. Of the 41 HPV16 RNA 
patterns-positive CIN3, all (100%) had high HPV16 load and 30 (73%) highest HPV16 load 
(Figure 4.18, b). However, of the 16 HPV16 RNA patterns-negative CIN3, 13 (82%) had 
high load with at least one additional hrHPV type (Figure 4.18, c). 
As mentioned before, all CxCa samples had been pre-selected for HPV16 E6*I mRNA 
positivity12, thus for CxCa samples another HPV type being the driving force to 
carcinogenesis was excluded. However, FFPE biopsies corresponding to CxCa cervical 
smear were also analysed by HPV16 RNA patterns (Chapter 4.1.8.1) and the one cervical 
smear falsely patterns-negative was also patterns-negative in the corresponding FFPE 
biopsy (refer to 5.3.2 for further discussion). 
In summary, the HPV16 RNA patterns positivity was reduced in multiple-infected cervical 
cell samples selected for E6*I-positivity: Among the CIN2 samples, the number of pattern-
positives decreased from 56% (23 out of 41) in HPV16-single to 51% (21 out of 41) in 
HPV16-positive but multiple-infected samples and among the CIN3 from 83% (35 out of 
42) to 72% (41 out of 57) demonstrating the need to extend the HPV16 RNA patterns by 
other hrHPV types (see chapter 4.2). 
 
4.1.7.11 The predictive value of HPV16 RNA patterns  
Samples diagnosed as false-positives by the HPV16 RNA patterns (transformation-specific 
HPV16 RNA patterns but ≤CIN1 by histology) could indicate transformed cells not yet 
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identified by histology and thus could represent a diagnostic improvement with an earlier 
detection of progressing lesions and thus indicate higher sensitivity.  
Thirteen HPV16 RNA patterns false-positive samples with histological follow-up data were 
available, eight multiple infected HPV16 DNA-positive CIN0 and CIN1, and five single 
infected HPV16 DNA-positive CIN1. 
Of the eight patients with multiple HPV infections, two CIN0 lesions remained CIN0 and 
three CIN0 lesions and three CIN2 lesions, respectively, progressed to CIN2 and CIN3 
(Figure 4.19). Four patients with single HPV16 infections progressed from CIN0 and CIN1, 
respectively, to CIN2 and CIN3, while one CIN1 lesions remained CIN1.  
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Figure 4.19. Histological follow-up in HPV16 RNA patterns false-positive patients. Histological diagnosis 
at base line (blue) and histological diagnosis at 5-24 months follow-up (grey) of two multiple- and two single-
infected HPV16 DNA-positive patients with HPV16 RNA patterns indicating presence of severe lesions.  
Thus in eleven of the thirteen patients with base line false-positive classification by RNA 
patterns, the mild histological lesion persisted in one case (follow-up after 5 month) and 
progressed in ten cases (follow up after 9-24 month). Longitudinal studies with higher 
sample numbers are required to further verify the increased predictive value of HPV16 RNA 
patterns in cervical cancer precursor screening. 
 
Results 
 
94 
4.1.8 HPV16 RNA patterns in FFPE biopsies 
The aim of this chapter was to examine whether HPV16 RNA patterns analyses is also 
applicable to RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue blocks, 
which would allow use of these tissue samples collected and processed in clinical and 
pathological standard procedures and also would give access to large sample banks for 
retrospective studies.  
 
4.1.8.1 HPV16 RNA patterns in paired FFPE tumour biopsies and exfoliated cervical 
cells 
For 27 Mongolian CxCa patients (18 singly HPV16-infected and 9 multiple HPV infected), 
RNA extracted from exfoliated cervical cells and FFPE biopsies as described in 3.1.2 were 
analysed by RT-qPCRTP and RT-qPCRE1C for transformation-specific HPV16 RNA 
patterns. Formalin fixation and size of biopsies followed a strict protocol as described 
elsewhere169. 
RNA analysis was valid (>80 ubC or >200 E6*I copies per PCR, chapter 3.12) in both 
exfoliated cervical cell and FFPE samples of 23/27 (85%) patients. UbC numbers were 
significantly lower (p<0.0001, Mann-Whitney-Test) in the FFPE biopsies than in the 
exfoliated cell samples with a median ubC copies per PCR of 54 (8 to 885 copies per PCR) 
and 863 (53 to 7,976 copies per PCR), respectively. 
For E6*I and E1^E4 detection a moderate quantitative correlation was observed between 
paired exfoliated cervical cells and FFPE biopsies (rp=0.35 and 0.29, respectively, Figure 
4.20, a and b). The correlation was good for E1C (rp= 0.73, Figure 4.20, d). In contrast to 
the quantification of single transcripts, the quantitative correlation of the E6*I/E1^E4 ratio 
was good (rp=0.61, p=0.0019), indicating a high robustness of this normalisation for 
variable HPV16-positive cell numbers obtained from different specimens from the same 
patient.  
Results 
 
95 
100 101 102 103 104 105
100
101
102
103
104
105
15
23
24
46
48
53
57
58
60
61
66
76
79
82 91
94
96
100
103
104
105 106
107
(a) E6*I copies per PCR
rp= 0.35
in exfoliated cervical cells
in
 F
FP
E 
bi
op
si
es
100 101 102 103 104 105
100
101
102
103
104
105
15
53
57
58
66
76
82
91
94
103
104
(b) E1^E4 copies per PCR
rp= 0.29
in exfoliated cervical cells
in
 F
FP
E 
bi
op
si
es
10- 2 10- 1 100 101 102 103 104 105
10- 2
10- 1
100
101
102
103
104
105
15
23
24
46
48
53
57
58
60
61
66
76
79
82
91
94
96
100
103104
105
106
107
(c) E6*I/E1^E4 ratio
in exfoliated cervical cell samples
in
 F
FP
E 
bi
op
si
es
100 101 102 103
100
101
102
103
53
57
58
66
76
82
103
104
(d) E1C copies per PCR
in exfoliated cervical cell samples
in
 F
FP
E 
bi
op
si
es
 
                (Continued on the following page) 
 
 
 
 
 
 
 
Results 
 
96 
100 101 102 103 104
100
101
102
103
104
15
23
24
46
48
53
57
58
60
61
66
76
79
82
9194
96
100103
104
105
106
107
in exfoliated cervical cells
in
 F
FP
E 
bi
op
si
es
(e) ubC copies per PCR
rp= 0.4
 
Figure 4.20. E6*I (a), E1^E4 (b), E6*I/E1^E4 ratio (c), E1C (d) and ubC (e) copies per PCR in exfoliated 
cervical cells (x-axis) and in FFPE biopsies (y-axis) from the same CxCa patients. All templates were 
applied in duplicates and mean Cp value was used for the calculation of copies per PCR. Negative values are 
indicated below 1 copy per PCR. E6*I and E1^E4-negative samples are indicated arbitrarily by a ratio of 
0.00001. Dotted lines indicate cutoffs (0.095 for E6*I/E1^E4 ratio and Cp <42 for E6*I, E1^E4, E1C and 
ubC).  
For the E6*I/E1^E4 ratio 22 RNA samples (96%) were concordantly positive (n=21) or 
negative (n=1) and one discordantly positive in FFPE biopsy only (κ=0.65; CI.95=0-1) 
(Figure 4.20, c) which might be due to a higher number of HPV-transformed cells in this 
sample compared to the smear. E1C was concordantly positive in 5 pairs and concordantly 
negative in 15 pairs. One sample was E1C-positive only in the cervical smear, which may 
be explained by degraded RNA in the corresponding FFPE sample containing 8 ubC copies 
only. Another two samples were E1C-positive only in the FFPE. One of those was 
irreproducible E1C-positive in smear (Figure 4.20, d-ID53) indicating lower number of 
HPV-transformed cells. This resulted in an E1C agreement of κ=0.68; CI.95=0.34-1 (Figure 
4.20, d).  
In total, 21 of 23 CxCa patients were concordantly grouped as having transformation-
specific HPV16 RNA patterns, while one (ID61) was concordantly diagnosed as negative, 
despite high ubC RNA copy numbers in both samples (refer to 5.3.2 for further discussion). 
The remaining patient (ID53) was HPV16 RNA patterns-positive (E6*I/E1^E4 ratio plus 
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E1C) only in the FFPE sample resulting in a total concordance of 96% between exfoliated 
cervical cells and FFPE biopsies. 
A good correlation of E6*I/E1^E4 ratio and E1C detected in FFPE biopsies and PreservCyt 
stored exfoliated cervical cells was observed. However, one CxCa samples was HPV16 
RNA patterns-positive only with FFPE, suggesting that the corresponding cervical cell 
sample contained to little HPV-transformed cells. Consequently, FFPE biopsies obtained 
under same conditions regarding fixation and tissue size used in this Mongolian study can 
be applied to the HPV16 RNA patterns analyses. 
 
4.1.8.2 HPV16 RNA patterns in FFPE biopsies of different storage histories 
The RNA quality in FFPE biopsies depends among other things strongly on storage times of 
FFPE blocks. In this chapter, in addition to the Mongolian, FFPE biopsies from the archived 
Barcelona study including routine biopsies from 38 countries all over the world (Chapter 
2.11) collected between 1929 and 2006170 (Halec et al., submitted to JNCI151) were analysed 
for HPV16 RNA patterns. Criteria for including Barcelona biopsies in this thesis were 
positivity with the HPV16 E6*I mRNA assay and single HPV16-positivity by the 
BSGP5+/6+-PCR/MPG assay -consequently good DNA quality due to the long amplicon 
size of HPV. Besides the varying storage time, Barcelona biopsies differ in size and fixation 
time. 
RNA extracted from 51 FFPE tissues from CxCa patients from Mongolia (n=27) and 
Barcelona (n=24) were applied in duplicates to RT-qPCRTP and RT-qPCRE1C. While the 
FFPE tissues from the Barcelona study were collected between years 1929 and 2006, FFPE 
tissues from Mongolia were collected in 2005. 
Only 13% of the Barcelona study (all stored since 1997-2006) and 78% from Mongolia 
were ubC-positive with a median of 1 and 117 copies per PCR, respectively (Table 4.10). In 
general, the prevalence of all transcripts was lower in samples from Barcelona (58%) 
compared to Mongolia (89%). Only 50% of FFPE tissues from the Barcelona study and 
89% from Mongolia were E6*I-positive. Among these E6*I-positive FFPE tissues from 
Barcelona, 33% were stored since 1929 to 1993 and 66% since 1997 to 2006.  
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Table 4.10. Frequency of single transcripts and HPV16 RNA patterns in CxCa FFPE biopsies from 
Barcelona and Mongolia. 
Barcelona Mongolia Total
ubC
N 3/24 21/27 24/51
% 13% 78% 47%
Any viral transcript
N 14/24 24/27 38/51
% 58% 89% 75%
E6*I
N 12/24 24/27 36/51
% 50% 89% 71%
E1^E4
N 7/24 11/27 18/51
% 29% 41% 35%
E1C
N 0/24 7/27 7/51
% 0% 26% 14%
HPV16 RNA patterns
N 2/3a 22/23a 23/26a
% 67% 97% 89%
FFPE samplesPositivity of
 
a samples with valid RNA only (ubC >80 or E6*I >200 copies per PCR) 
Among the RNA valid FFPE tissues, the percentage of HPV16 RNA patterns-positives was 
97% in Mongolian samples and 67% in Barcelona samples.  
This data indicates that the HPV16 RNA patterns analyses cannot be applied to routine 
FFPE biopsies as long as no consistent protocol is used similar to that used in the 
Mongolian study. 
 
4.2 Other hrHPV types 
After HPV16, the hrHPV types 18, 31, 33, 35, 45, 52 and 58 most prevalent in CxCa 
account for about 28% of cervical cancer cases71.  
In preparation for RNA patterns analyses for these HPV types, in this chapter, the 
identification of splice junctions analogous to the HPV16 E1^E4, E1C and L1 splice 
junctions was performed, followed by first singleplex HPV18 RT-qPCR experiments.  
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4.2.1 Identification of splice junctions 
While some splice junction had already been described in the literature (Table 4.11) E1^E4, 
E1C and L1 splice donor and acceptor site for four hrHPV types 35, 45, 52 and 58 as well as 
the E1C and L1 splice donor and acceptor site for two hrHPV types 33 and 18 were 
unknown.  
Seventy-two exfoliated cell samples were selected from the Mongolian population-based 
study harbouring types of interest as single or multiple infections. The criterion for selection 
was HPV DNA MFI values for the type of interest in BSGP5+/6+-PCR/MPG assay above 
120.  
For all the seven hrHPV types (HPV18, 31, 33, 45, 35, 52, 58) the locations of the detected 
or confirmed E1C, E1^E4 and L1 splice sites were homologous to those of HPV16 (Table 
4.11).  
Table 4.11. Position of splice junctions of selected hrHPV types. 
E1C E1^E4 L1
splice junction splice junction splice junction
16 880^2582 880^3358 3632^5639 
18 929^2779a 929^3434b 3696^5613a
31 877^2646b 877^3295b 3590^5552c
33 894^2702a 894^3351b 3589^5597a
45 929^2737a 929^3392a 3360^5608a
35 883^2649a 883^3298a 3575^5574a
52 879^2696a 879^3345a 3625^5643a
58 898^2706a 898^3355a 3608^5647a
HPV type
 
a newly identified, b confirmed as described in the literature161,162,171, c described in the literature without 
confirmation in this thesis162,161 
Sequencing results demonstrated that all seven hrHPV types of interest undergo splicing of 
their E1, E4 and L1 gene. 
 
4.2.2 Singleplex HPV18 RT-qPCR  
In the following experiments, designed primers and TaqMan probes detecting the HPV18 
transcripts E6*I, E1C, E1^E4 and L1 were applied in singleplex RT-qPCR to test specificity 
and DL.  
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Serial dilutions of the HPV18 in vitro transcripts E6*I, E1C, E1^E4 and L1 with copies per 
µL ranging from 1 to 106 as well as 106 for genomic HPV18 DNA were applied in 
duplicates to singleplex RT-qPCR using different combinations of primers and TaqMan 
probes.  
For all transcripts, primers had to be relocated relative to the HPV16 targets to reach a 
sensitive, efficient and specific detection (Table 4.12). For E6*I, one of seven combinations 
tested, detected 10 copies per PCR with a median Cp value of 41. The R² induced by this 
E6*I was 0.99 indicating a perfect linear correlation. In addition, E was 1.91. The detection 
of 105 E6*I copies per PCR was observed from cycle 26 onwards. The same parameters are 
depicted for the other HPV18 transcripts (Table 4.12). 
Table 4.12. Detection limit and specificity of spliced HPV18 transcripts. 
Transcript
fw 
primer
bw 
primer
TaqMan 
probe
Nr of 
combinations 
tested
DLa           
(copies per 
PCR)
Median Cp 
at DL R
2 b Ec
Median Cp at 105 
copies per PCR
Sensitive& 
efficientd
Specifice
E6*I 1/3f 1/3 1/1 7 10 40.96 0.99 1.91 26.7 yes yes
E1C 1/2 1/2 1/1 5 10 41.73 1.00 2.02 29.35 yes yes
E1^E4 1/3 1/2 1/1 6 100 34.89 1.00 2.11 25.69 no yes
L1 1/1 1/2 1/1 2 100 36.67 0.98 2.07 28.46 no yes  
a detection limit (DL) defined as lowest copy number tested with signals above background in duplicates,  
b coefficient of determination (R2) describes the correlation between crossing point (Cp) and the log of 
transcript copy number per PCR, c PCR efficiency (E); under optimal conditions PCR run with an efficiency of 
2, meaning that the number of target molecules doubles with every PCR cycle, d defined as sensitive and 
efficient if DL at most 10 copies per PCR, e defined as specific if no cross-reaction with fl HPV18 was 
observed, f tested primer/efficient primer and probe, e.g. three different forward primer and three different 
backward had to be designed and tested for the amplification of E6*I und only one forward and one backward 
primer worked sensitively, efficiently and specifically 
After relocation of primers, two out of four transcripts were sensitively, efficiently and 
specifically detected with DL of 10 copies per PCR. For E1^E4 and L1 more experiments 
are required in order to improve DL.  
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5 Discussion 
5.1 Rationale 
A major limitation of current HPV-based cervical cancer precursor screening programs is that 
they detect infection rather than disease. This leads to poor clinical specificity and low 
positive predictive value for precancerous lesion resulting for many women in unnecessary 
anxiety, unnecessary referral to costly follow-up and/or overtreatment138-140.  
This thesis aimed at transferring a recently described HPV16 RNA patterns assay87 on a new 
technological platform (RT-qPCR) and validating its potential for substantially improving the 
clinical specificity of HPV-based tests by discriminating between the presence of mild 
(cytological NIL/M and LSIL and histological CIN0 and CIN1) and severe cervical neoplastic 
lesions (cytological HSIL and histological CIN3 and CxCa). CIN2 samples representing 
rather an intermediate between mild and severe frequently were excluded from test 
qualification analyses. Furthermore, the various RNA patterns observed in severe lesions in 
the context of HPV-DNA status and transformation mechanism is discussed. The thesis also 
included preparatory work to extend the HPV RNA patterns analysis to hrHPV types 18, 31, 
33, 35, 45, 52 and 58.  
The HPV16 RNA patterns analysis comprises the quantification by RT-qPCR (Chapter 
4.1.2.1) of the spliced viral transcripts E6*I, E1^E4, E1C and initially comprised also L1 
(modification will be discussed in 5.2.3) that display different expression levels in mild versus 
severe lesion grades. An important event in cervical carcinogenesis is the deregulation of the 
oncogene E6 and E7 expression81,82,172. However, the underlying mechanisms for the 
deregulation are diverse and genome integration, viral DNA methylation as well as the 
involvement of HPV16 E1C protein are discussed: Integration of HPV DNA often leads to a 
loss of E2 expression and the subsequent deregulation of oncogene E6 and E7 
expression21,173,174. Thus, expression of E6 and E7 from the p97 promoter increases in the 
absence of high amounts of E2, which can act as a transcriptional repressor. The integration 
status of HPV16 might be assessed by the ratio of the amount of E6*I copy numbers and the 
amount of E1^E4 copy numbers87,146. For these cases with intact E2, accounting for ~60% of 
CxCa83, other mechanisms for the deregulation of the E6 and E7 oncogenes must exist. 
Methylation of the viral URR might be such an alternative mechanism that is intensively 
studied at the moment82,175,176-178. Chaiwongkot and colleagues described that the methylation 
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level of the E2 binding sites (E2BS) in the HPV16 URR was higher in all lesions with only 
episomal HPV16 genomes compared with lesions displaying single integrated copies178. In 
addition, samples with multiple integrated HPV16 copies displayed high methylation levels 
for all E2BS suggesting that the majority of the copies were silenced by extensive 
methylation. However, recent data from our laboratory indicates that also a substantial 
fraction of CxCa samples with multiple HPV copies per cell did not show any methylation of 
the E2BS (Holzinger et al., manuscript in preparation). Thus, at least a third mechanism 
should exist to deregulate E6 and E7 oncogenes. The third mechanism might be seen in an 
upregulation of the viral transcript E1C that is hardly detectable in mild lesions but frequently 
detected in severe lesions87,146,179. E1 with a truncated N-terminus (E1C) is translated from 
880^2582 spliced mRNA and has been described to be a potential trans-activator of the viral 
URR, promoting the upregulation of E6 and E717. Data from our laboratory indicated that the 
fraction of CxCa samples with multiple HPV copies per cell which did not show methylation 
of the E2BS were E1C-positive (Holzinger et al., manuscript in preparation). Consequently, in 
addition to methylation, E1C might be responsible for an E2 deletion-independent mechanism 
of HPV16-mediated transformation of cervical cells. 
 
5.2 HPV16 assay development 
5.2.1 RT-qPCR versus NASBA 
RT-qPCR greatly enables simple amplicon recognition by using fluorescent reporter 
molecules to monitor the level of amplicons after each PCR cycle. Consequently, no post-
PCR processing is required and the analysis is performed in a closed system which can then 
be disposed of without a contamination risk for the laboratory environment. In addition, the 
wide dynamic range allows the analysis of samples differing in target abundance by several 
orders of magnitude. Furthermore, there is little inter-assay variation, which helps generating 
reliable and reproducible results180 (see chapter 4.5). 
RT-qPCR also allows an although limited degree of multiplexing, an important step towards 
high-throughput analyses in large studies and diagnostic applications. Ergo, large numbers of 
samples can be screened within a short period of time and at rather low costs, therefore, 
leading to better patient management. 
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In contrast, the NABSA assay comprised two separate reactions, amplification plus 
hybridisation and multiplexing could not be implemented despite extensive efforts (personal 
communication Dr. Markus Schmitt). Additional disadvantages of NASBA were the high 
reagents cost per sample (~20€ per NASBA reaction) and the enormous amount of time and 
labour required for conducting the assay (for 90 samples 7-8 hours per single NASBA with 
subsequent hybridisation).  
In this thesis, multiplex RT-qPCR were developed using the Cobas z480 platform as 
promising robust, sensitive, specific and cost-efficient technology for detecting the HPV16 
RNA patterns.  
 
5.2.2 Design of RT-qPCR primers and TaqMan probes 
For a specific and sensitive amplification of the spliced HPV16 transcripts via RT-qPCR, 
primers and probes were newly designed (see 4.1.1) and sequences were altered to optimise 
DL and specificity. Primer and probe sequences were designed according to strict rules181, 
however, for E6*II a DL better than 103 copies could not be reached, although 12 different 
primer/probe combinations were tested. With NASBA detection the E6*I and E6*II transcript 
numbers had been strongly correlated and a replacement of E6*II by E6*I in the E6*II/E1^E4 
ratio led to almost identical results. In addition, the E6*I expression is around ten-fold higher 
than for E6*II, which may be beneficial when analysing poor quality samples146,136,167. 
Finally, with regard to extending RNA patterns analysis to other hrHPV types that express 
only E6*I but no E6*II, the E6*II RT-qPCR was replaced by E6*I RT-qPCR. 
To improve DL of splice site-specific detection of E1C, two strategies were tested: either the 
forward primer or the probe covered the splice junction. Primers covering the splice junction 
led to unspecific amplification and detection of genomic HPV16 DNA. This could be reduced 
but not eliminated by shortening the primer 3´ end. The shortening reduced the number of 
matches between HPV16 DNA and primer from 12 to 5 nucleotides. Still, 105 genomic 
HPV16 DNA copies were detectable (see chapter 4.1.2.2). In the final assay, probes were 
included covering the splice junction. The sensitivity could be increased by a semi-nested 
detection of E1C which included two primer pairs in one reaction, one outer and one inner 
primer pair, both flanking the splice junction. 
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As mentioned above, E2 deletion and, thus, HPV integration was monitored using the E1^E4 
transcript as surrogate marker. The E1^E4 splice donor is located at nt 880 within the E1 
ORF, while the splice acceptor is located at nt 3358 within the E2 and E4 ORF. Breakpoints 
of integrated HPV16 DNA are located within the E1 ORF (59%), the E2 ORF (31%), the E1-
E2 overlap region (3%), the E5 ORF (7%) and the L1 ORF (1%)85,182. Consequently, 92% of 
viral integrates show E2 ORF deletions. The remaining 8% of CxCa with intact E2 ORF 
despite integration must depend on different mechanisms of E6 and E7 upregulation (see 
discussion 5.1). Using RT-qPCRTP, 94% of the E2 deletions were recognised as having E2 
deletions. This was made possible by placing the backward primer binding within the E2 and 
E4 ORF region as close to the E5 ORF as possible. However, to cover all cases with E2 
deletions, the backward primer would have to be moved downstream for an additional 230 
nucleotides. The present E1^E4 amplicon size of 199 bp exceeded already the ideal amplicon 
length in RT-qPCR, which is around 150 bp. Longer amplicons are less efficiently amplified 
and are prone to false-negative results in case of RNA template degradation. Consequently, 
the current E1^E4 RT-qPCR represents a compromise between detecting as many HPV 
integrates with E2 deletions as possible and the technical limitations of the RT-qPCR.  
To make the assay as sensitive as possible, potential mismatches of known HPV16 variants 
with primer and probe sequences were minimized in order to reduce number of false-negative 
results. Placing the primers in conserved regions, identical between HPV16 variants, 
minimized the possibility of false-negative results. To this end, alignments of target regions 
were performed with all variants of HPV16, available in public data bases. Degenerate 
primers or probes, i.e. a pool of oligonucleotides which differ slightly in sequences were 
ordered if more than 1% of HPV16 isolates had sequence diversity at a specific position. 
Thus, two E1C primers and the E1C and E1^E4 TaqMan probes were designed with one 
degenerate position each. E6*I primers and probes were not designed with degenerate 
positions since sequence variations were present in only 0.3% of HPV16 isolates. 
To test the analytical specificity of the assay, undesired amplification of genomic HPV16 
DNA, human placenta DNA and human RNA as well as cross-reactivity among the 
transcripts were examined. Unspecific detection was successfully eliminated by redesigning 
primers and probes as it was described for E1C (Chapter 4.1.2.2). Cross-reactivity with other 
HPV types was excluded by in silico analysis using BLAST at the NCBI homepage (data not 
shown). As expected183, the identity within the E1^E4, E1C and E6*I transcript regions 
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between HPV35 and HPV16 was 95%, and 80% between HPV31 and HPV16. Primers and 
probes had 2 to 10 mismatches within the primer and between 4 and 6 mismatches within the 
probe regions. However, the degree of cross-reactivity between these highly related HPV 
types still needs to be tested experimentally in the future.  
 
5.2.3 Fiveplex RT-qPCR 
Development of a fiveplex RT-qPCR enabling the simultaneous quantitative detection of the 
four HPV16 transcripts E6*I, E1^E4, E1C and L1 and of the cellular ubC transcript was the 
initial goal of this thesis. A fiveplex RT-qPCR would have allowed stratifying clinical HPV16 
DNA-positive specimens into mild or severe lesions by a single reaction.  
By changing concentrations of PCR reagents, the final DL for each of the in vitro transcripts 
analysed individually in fiveplex RT-qPCR ranged between 10 and 102 which was 
comparable to singleplex RT-qPCR. Nevertheless, the presence of multiple amplifiable 
transcripts in one sample, led to reduced detection of low-abundance transcripts E1C and L1 
(see 4.1.3.2). An explanation might be found in the fact that co-amplification of highly 
expressed transcripts, such as E6*I and E1^E4 reduced the amount of available PCR reagents, 
to the detriment of these low-abundance transcripts. As a consequence the fiveplex was split 
into two separate RT-qPCR, the RT-qPCRTP for E6*I, E1^E4 and ubC and the RT-qPCRDP 
for E1C and L1. However, a reciprocal interference of the low-abundance transcripts was still 
observed once one transcript was present in higher copy number than the other (see 4.1.3.5).  
In the NASBA pilot study87 as described in chapter 4.1.3.7, L1 had contributed only little to 
the cervical precursor diagnosis: Applying the E1C only algorithm instead of the E1C/L1 
ratio, one out of seven CxCa and three out of twenty-four HSIL samples (13%) would have 
been classified falsely as mild lesion (Figure 4.8). Consequently, these four samples were 
classified as severe lesions only by the presence of very low amounts of L1 and the absence of 
E1C. L1 is the major protein forming the viral capsid and is not actively involved in cancer 
progression. Thus, it was questionable whether the absence of L1 alone should be used for 
diagnosing severe lesions. However, it is tempting to speculate that the approximately 12-fold 
higher sensitivity of the RT-qPCRE1C might have identified these 4 samples as EIC-positive. 
Consequently, L1 was omitted in the RT-qPCRDP resulting in final RT-qPCRE1C. A 
normalisation with another transcript was not necessary since E1C was nearly exclusively 
Discussion 
 
106 
detected in CIN2, CIN3 and CxCa (Chapter 4.1.7.4), meaning once E1C is detected a severe 
lesion can be diagnosed independent of the number of copies.  
As a consequence, in the final setting E6*I, E1^E4 and ubC were quantified in RT-qPCRTP 
and E1C in RT-qPCRE1C. 
 
5.2.4 RNA extraction 
Sensitivity of the RT-qPCR is also dependent on the RNA quality in the tested samples and 
by the presence of inhibitors. Primers and probes detecting ubC were integrated in the RT-
qPCR for controlling the functionality of the assay and the quality of the RNA template. In 
clinical samples, a cutoff of 80 ubC copies per PCR was applied.  
Different extraction methods of RNA including MagNA Pure96 DNA and Viral NA Large 
Volume Kit and MagNA Pure96 Cellular RNA Large Volume Kit as well as different 
extraction volumes (1 mL and 4 mL) were compared to achieve an optimal extraction of 
RNA. Best data was obtained with RNA extracted from 4 mL sample volume using the 
MagNA Pure96 Cellular RNA Large Volume Kit. The ubC quantification was 1.7- and 4-
times higher under these conditions compared to 1 mL and MagNA Pure96 DNA and Viral 
NA Large Volume Kit, respectively (Chapter 4.1.4). 
 
5.2.5 Comparison of RT-qPCR and singleplex NASBA in cell lines and OPSCC samples 
To compare the previously established singleplex NASBA assays with the newly developed 
RT-qPCR assays, RNA from cervical cancer cell lines MRI-H186, MRI-H196, SiHa and 
CaSki and from 32 OPSCC analysed previously by NASBA was here additionally analysed 
by RT-qPCR. NASBA data previously published for these samples were kindly provided by 
Dr. Markus Schmitt (DKFZ)31,148 and by Dr. Dana Holzinger (DKFZ)152. 
When interpreting differences in quantification by NASBA and by RT-qPCR, it has to be kept 
in mind that the RT-qPCR was excellently reproducible even with RNA extracts obtained at 
different dates (Chapter 4.1.5) while NASBA showed large copy number variation (Chapter 
4.1.6.1). 
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In cell lines, the mean transcript copy number per cell for E6*I, E1^E4 and ubC by NASBA 
appeared to be up to fifty-fold and for E1C up to 105-fold higher than by RT-qPCR. 
However, the E6*I, E1^E4 and ubC copies per cell quantified by RT-qPCR were within the 
copy range of the NASBA data. In addition, the quantification of transcripts by NASBA used 
ten-fold dilution steps over four to five orders of magnitude complicating the direct 
comparison to RT-qPCR (Chapter 1.7). The dose-response curve of NASBA standards that 
were almost linear for E1^E4 and E6*I but polynomal for E1C complicating the accurate 
quantification and might be an explanation for the huge difference especially for E1C 
quantification in NASBA and RT-qPCR. 
Consequently, the RT-qPCR appears to be more reliable than the previous NASBA data. 
 
MRI-H186 cells have been described to contain around 26 integrated full-length as well as 
truncated HPV16 genome copies184. Consistently, RT-qPCR quantified a low amount of 
E1^E4 (mean 8 copies per cell) and high E6*I (mean 76 copies per cell) and the calculated 
E6*I/E1^E4 ratio was above cutoff (ratio-positive). E1C was also detected with 0.002 copies 
per cell.  
SiHa cells contain one integrated HPV16 genome with disruption of the E2 region and 
deletion of bases nt 3132 to nt 338422. Consistently, we found no transcripts containing the 
splice acceptor at nt 3358 but we found the E1C transcript having the splice acceptor at nt 
2582.  
In contrast, CaSki cells contain around 600 truncated but also full-length HPV16 genomes at 
multiple integration sites22,185. Here, all three viral transcripts were detected, with a mean of 
546 E1^E4 copies and 29 E6*I copies per cell, thus E6*I/E1^E4 ratio-positive. E1C was 
detected with 0.0004 copies per cell.  
Taken together, the quantitative HPV16 expression data correlated well with the known 
integration status of the HPV16 genome.  
The conspicuously low ubC copy number per cell (RT-qPCR: median 90 copies per cell, 
range 30-400; NASBA: median 375, range between 0.75-750) was found by both methods. 
Unfortunately, no reference information was found in the literature. 
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For defining OPSCC as CxCa-like RNA patterns-positive (CxCaRNA+) and as CxCa-like 
RNA patterns-negative (CxCaRNA-), a 100% concordance was achieved between NASBA 
and RT-qPCR.  
However, the concordance for single transcripts was lower: E6*I positivity detected by RT-
qPCR and E6*II positivity by NASBA, respectively, were concordantly classified in 25 
OPSCC samples (78%), seven further samples were E6*I positive by RT-qPCRTP only 
(κ=0.2, CI.95=0-0.7). This could be attributed to the higher level of E6*I than E6*II in 
HPV16-positive cells136,167. For E1^E4, 26 OPSCC samples were concordantly classified and 
6 were discordantly, although only borderline positive by RT-qPCR or NASBA (κ=0.4, 
CI.95=0.1-0.8). Nevertheless, the quantitative correlation of these two transcripts detected by 
both methods with an rp=0.94 for E6*I was excellent and moderate with an rp=0.69 for 
E1^E4. 
The quantitative correlation of E1C was low (rp=0.15) and as mentioned above can be 
explained by the fact that NASBA is at best semi-quantitative for E1C while RT-qPCRE1C 
enables a precise quantification over 5 logs (Figure 4.12). By NASBA and by RT-qPCR E1C 
copy numbers were much lower than those of E6*I or E1^E4. However, the transcript copies 
per reaction for E1C by NASBA ranged between 2,500 and 250,000 (median 25,000) and by 
RT-qPCR between 5 and 21,000 (median 33). Since the initial E1C copy numbers detected by 
RT-qPCR were so low, a new batch of reference in vitro transcripts as well as the reference 
titration curve of the transcript dilutions were repeated and the validity and accuracy of the 
E1C transcript quantification by RT-qPCR was confirmed. Besides the semi-quantitative 
detection of E1C, the low reproducibility of NASBA could be an explanation for the 
quantitative discrepancy between the two methods: E1C quantification of the same samples in 
two independent experiments by NASBA showed a thousand-fold difference ranging between 
0.08-0.75 and 75-750. Similarly, applying the E1C standard curve to NASBA reaction twice 
had coefficients of variation (CV) for the six dilution steps between 2 to 140%. Nonetheless, 
between both methods the concordance of classifying OPSCC samples as E1C-positive or 
E1C-negative was very high (κ=0.9, CI.95=0.71-1). 
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5.3 HPV16 RNA patterns in clinical specimens 
5.3.1 Cell concentration and RNA quality in validation samples 
Of all three viral transcripts E1C shows the lowest abundance frequently close to the detection 
limit and thus is most sensitive to low concentration of reverse-transcribable and amplifiable 
RNA due to low number of HPV-infected cells or RNA degradation.  
In conventional cytological diagnoses the number of abnormal cells in the sample is also 
critical for true-positive diagnosis186,187. Cell numbers in exfoliated cervical cell samples 
determined by qPCR of human β-globin show huge variation.  
Twenty mL of PreservCyt-stored cervical cell samples from Bad Münder (n=40) contained 
only a median of 76,969 (mean of 155,562 with a minimum of 314 and a maximum of 
1,056,806) cells while samples from Mongolia (n=20) contained a median 5,602,338 (mean of 
10,213,686 with a minimum of 275,246 and a maximum of 50,659,658) cells (personal 
communication Dr. Markus Schmitt, DKFZ). No reference information for absolute cell 
content of exfoliated cervical cell samples was found in the literature. With this data, the 
median number of cells applied to a RT-qPCR assay was 385 cells in the Bad Münder and 
28,012 in the Mongolian samples. 
Quantification of ubC was integrated into the RT-qPCR to monitor RNA quantity and thus to 
control the sum of cell content, RNA extraction, RT-qPCR performance, and RNA quality 
since ubC is the longest amplicon in the assay (238 bp). 
The ubC transcripts observed in the 158 single-infected HPV16 RNA-positive cervical cell 
samples ranged between 54 and 69,615 copies per PCR. Surprisingly, despite the different 
cell concentrations in the samples, differences in the ubC quantification between PreservCyt-
stored exfoliated cervical cells from Bad Münder and from Mongolia were insignificant 
(p=0.7, Mann-Whitney-Test). This indicated strongly increased RNA degradation of the 
Mongolian samples archived for about 84 months compared to the Bad Münder samples 
archived for 9-24 months. Low RNA quality of all archived PreservCyt-stored exfoliated 
cervical cell samples was also confirmed by a median RIN factor of only 2.3 (see 4.1.7.3). It 
has been described that a reduction of RIN from 9 to 2 resulted in a reduced quantification by 
a factor of approximately 20188,189. However, the relative to the Bad Münder samples further 
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increased RNA degradation in the Mongolian samples did not result in even further reduction 
of the RIN factor.  
The median number of ubC transcripts per cell (ubC copies per PCR/number of cells per 
PCR) was 4 in the Bad Münder and 0.31 in the Mongolian exfoliated cervical cell samples. 
However, since the median RIN of the Bad Münder samples was 2.6, the ubC quantification, 
as mentioned above, was presumably 20-times reduced, thus, theoretically, 80 ubC transcript 
copies per cell could be present and would be similar to the number of ubC copies detected in 
cell lines (Chapter 5.2.5). However, these calculations can only give a rough idea about the 
RNA quality of cervical samples.  
Still, the same cutoff of 80 ubC copies per PCR as marker of minimal absolute-number of 
amplifiable RNA can be used for Bad Münder as well as for Mongolian samples. In this study 
comprising highly degraded RNA samples, the number of E6*I copies (>200) was 
additionally included for defining a sample as valid. With it, the number of analysable 
samples was increased by two HPV16 RNA patterns-positive CIN3 and CxCa but also by one 
HPV16 RNA patterns-negative CIN2. The definition for validity could also have been the 
following: >80 ubC copies or E6*I/E1^E4 ratio positivity with E6*I >200 copies or E1C 
positivity. Retrospectively, this definition would include another HPV16 RNA pattern-
positive CIN3. However, using non-archived material probably needs another definition for 
validity and probably does not need the inclusion of E6*I.  
In summary, poor sampling and a too long storage period of cells even in PreservCyt buffer 
can both lead to false-negative results and this has to be kept in mind when interpreting data 
resulting from archival exfoliated cervical cells. Furthermore, in future studies RNA quality in 
samples stored for shorter time periods has to be assessed to define the maximum storage 
period suitable for HPV RNA patterns analyses. 
 
5.3.2 HPV16 RNA patterns in FFPE biopsies 
Expanding the application of the HPV16 RNA patterns to formalin-fixed paraffin-embedded 
FFPE would allow use of the tissue samples collected and processed in clinical and 
pathological standard procedures and also would give access to large sample banks for 
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retrospective studies. The major limitation of the use of FFPE samples is potential RNA 
degradation and cross-linking. 
While 85% of the Mongolian FFPE samples collected 7 years ago under strict study 
conditions were RNA valid, FFPE biopsies collected between 1929 and 2006 from nine 
different countries under clinical and pathological standard procedures (not using the same 
protocol for fixation-time and size of biopsy) were RNA valid in only 13%. 
Nevertheless, HPV16 RNA patterns classification of RNA extracted from FFPE biopsies and 
from exfoliated cervical cells of the same single and multiple HPV16 DNA-positive 
Mongolian CxCa patients was compared. A total of 21 of 23 CxCa patients were concordantly 
diagnosed as having severe lesions, while one (ID61) was concordantly diagnosed as mild 
lesion and one sample (ID53) was positive in the FFPE biopsy only. In ID61 HPV 
involvement is questionable in the absence of p16INK4a upregulation and p53 and pRb 
downregulation (immunohistochemical data of Dr. Gordana Halec, DKFZ12). The discordant 
sample (ID53) was diagnosed as severe lesion by the E1C presence in the FFPE biopsy. In the 
cervical smear RNA EIC was detected in only one of the duplicates and with only 12 copies, 
indicating a probably insufficient number of cancerous cells in the smear.  
Adequately fixed PreservCyt samples remain the targets of HPV16 RNA patterns in primary 
screening. However, to expand the application to FFPE samples and thus, to enable the 
amplification of partially degraded and cross-linked RNA, a complete re-design of the RT-
qPCR with shortened amplicon sizes would be necessary. Nevertheless, as discussed above, 
shortening the E1^E4 amplicon, i.e. moving the backward primer upstream led to a reduced 
detection of HPV integrates and consequently, to a reduced analytical and thus also clinical 
sensitivity of the HPV16 RNA patterns test.  
 
5.3.3 Prevalence and amount of HPV16 transcripts in validation samples 
The prevalence and expression of the three transcripts E6*I, E1^E4 and E1C quantified by the 
novel RT-qPCR in 158 single-infected HPV16 RNA-positive cervical cell samples were 
compared to previously described prevalence and expression quantified by singleplex 
NABSA assays in a study of 77 HPV16 RNA-positive cervical cell samples146. Discrepancies 
are summarized and discussed.  
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As a quick reminder: E6*I and E1^E4 prevalence was between 82 and 95% in CIN1-3, 
increased in CxCa to 100% for E6*I but decreased to 33% for E1^E4 (Table 4.9). This is in 
concordance to Sherman et al., 199220 and Schmitt et al., 2011146, where the prevalence of 
E6*I and E1^E4 was also not specifically associated with lesion stage (CIN1, CIN2 or CIN3), 
indicating the need for E6*I and E1^E4 quantification.  
In contrast, E1C was observed almost exclusively in CIN2 (17%), CIN3 (52%) and CxCa 
(22%) patients in this thesis (Table 4.9). As a consequence, the qualitative detection of E1C 
appeared to be a specific albeit alone not a sensitive marker for severe lesions. The reduced 
E1C prevalence in CxCa patients compared to CIN3 is contradicting the NASBA data where 
57% of CxCa were E1C-positive87,146. One explanation might be that NASBA data included 
CxCa samples from France with a short storage time, while CxCa samples in this study were 
collected from Mongolian women 7 years before RNA extraction. Thus, RNA degradation 
could have caused the lower sensitivity of E1C detection in the 7-years old CxCa samples. 
Another explanation could be a low number of cancer cells in the Mongolian cervical smear 
compared to France and Bad Münder due to sampling device or expertise and consequently a 
lack of E1C-positive cells. Supporting the assumption that less E1C-positive cells were 
present in Mongolian samples, in Mongolian CxCa a reduced mean of E1C copies per PCR 
was observed compared to CIN2 and CIN3 from Bad Münder. Nevertheless, only 4 out of 18 
Mongolian CxCa samples were E1C-positive with copy numbers similar to the lower quartile 
of E1C-positive CIN2 and CIN3.  
 
E6*I, E1^E4 and E1C were quantified by RT-qPCR. As a quick reminder: E6*I and E1C 
encoding transcripts were strongly upregulated in severe lesions, whereas the level of E1^E4 
was similar in mild and severe lesions (Figure 4.13) which is in concordance with the 
NASBA data146. In contrast to the E6*I and E1^E4 transcripts, the E1C copy number was 
always low and ranged between 4 and 156 (median=16). Thus, less than one copy per cell was 
present under the incorrect assumption that all analysed cells were HPV-infected. However, 
from the literature it is known that in a cervical smear diagnosed as HSIL lesion only up to 
2% of cells are HPV-infected147. Under the assumption that 4 ubC transcript copies are 
present per cell (Chapter 5.3.1), a median of 425 cells were analysed in all E1C-positive 
CIN2, CIN3 and CxCa samples (calculated as median 1,701 ubC copies per PCR/4 ubC 
copies per cell). With 2% of cells HPV-infected (8 out of 425 cells) the number of E1C per 
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HPV-infected cell would range between 1 and 20 (median=2). That underlines the importance 
of a high quality cervical smear in order to make a correct classification that cannot be 
compensated by RT-PCR.  
 
5.3.4 Sensitivity and specificity of HPV16 RNA patterns  
In order to validate the HPV16 RNA patterns as diagnostic marker for severe cervical 
neoplastic lesions, RNA was analysed from the 158 single-infected HPV16 RNA-positive, 
histologically and/or cytologically defined exfoliated cervical cell samples already presented 
above.  
In total, RT-qPCR-based HPV16 RNA patterns analysis correctly classified 88% of ≥CIN3 as 
severe lesions (sensitivity) and 84% of ≤CIN1 as mild lesions (specificity). CIN2 was 
categorised as intermediate stage with 49% HPV16 RNA patterns-positive and not classified 
within the severe lesions.  
The complexities of HPV16 RNA patterns in severe lesions are discussed in 5.3.5 and 
discordant samples with either false-negative or false-positive lesion classification in 5.3.6.  
In conclusion, RT-qPCR-based HPV16 RNA patterns analysis was confirmed as diagnostic 
tool to distinguish mild from severe neoplastic cervical lesions. 
In multiple-infected exfoliated cervical cell samples (n=185), i.e. samples containing HPV16 
and at least one other hrHPV type, the fraction of correctly classified severe lesions decreased 
from 88 to 70% and the fraction of correctly classified mild lesions from 84 to 79%. The 
reduced sensitivity probably is due to cases transformed by the other hrHPV type rather than 
by HPV16. 
 
5.3.5 Complexity of HPV16 RNA patterns in single-infected samples concordantly 
classified as severe lesions  
HPV16 RNA patterns analysis may indicate the viral genome integration status by the ratio of 
E6*I versus E1^E4 and the presence of HPV16 E1C. Loss of E1^E4 was used as surrogate 
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marker for integration and consequently, loss of E2 repressor, at least in 94% of cases covered 
by the RT-qPCR (see discussion 5.2.2).  
Exfoliated cervical cell samples defined by HPV16 RNA patterns as severe lesion fall in 3 
groups: group 1 is only E1C-positive (Cp<42), in group 2 the E6*I/E1^E4 ratio is positive 
(above cutoffE6*I/E1^E4=0.095) and in group 3 both, E1C and the E6*I/E1^E4 ratio are positive. 
This chapter focuses on these three groups with regard to the HPV-DNA status and proposes a 
possible explanation of how lesions developed.  
HPV-DNA status can only be assumed from transcriptional active DNA, the additional 
presence of transcriptionally inactive episomal and integrated full-length HPV16 genomes 
cannot be excluded. 
Of the 158 single-infected HPV16 RNA-positive ≥CIN3 12% were group 1, 45% were group 
2 and 32% were group 3 (Chapter 4.1.7.8). 
In group 1 E1C is present as well as E1^E4, the latter leading to a low E6*I/E1^E4 ratio. This 
indicates that at least the region upstream of splice acceptor nt 3358 must be intact (Figure 
5.1). So, E1C is expressed from full-length integrated or episomal HPV or, if truncation 
occurred, it must be downstream of nt 3358. With this DNA-status, also E2 could be 
expressed. Expressed E2 could counteract E1C. I have observed higher E1C copies in group 1 
with a mean of 51 as in group 3 with a mean of 21 (p=0.0183, Mann-Whitney-Test). This 
could indicate that higher E1C copy numbers in group 1 are needed to counteract E2 and thus 
further supports a function of E1C in maintenance of transformation. 
E6 E7 E2/4 E5E1 L2 L1ORF
E1C E1^E4Transcripts
nt 880 nt 2582 nt 3358
Position of deletion 
Consequence No E1^E4No E1C
No E1^E4
But E1C
E1^E4
E1C
E6*I/E1^E4 ratio-positive, E1C-positive
yes, no 
yes, yes
no, yes
Group
2
3
1
 
Figure 5.1. Position of viral sequence deletion due to integration and the consequences for presence of E1C 
and E1^E4 and for E6*I/E1^E4 and/or E1C positivity. 
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Group 2 contains only E6*I/E1^E4 ratio-positives indicating the absence of splice acceptor nt 
3358. The absence of E1C in group 2 could be due to either loss of E1C splice acceptor or 
absence of the transcription mechanism that is active in E1C-positive severe lesions. In the 
case of loss of E1C splice acceptor, truncation would be upstream of nt 2582. Group 2 was 
observed in 45% of all ≥CIN3 in this thesis being in consistence with the frequency of HPV16 
breakpoints identified upstream of nt 2582 in the literature85. The loss of E1C expression in 
group 2 could still be compatible with transformation because concomitantly the E2 repressor 
is absent due to the truncation.  
Group 3 contains samples double positive for E6*I/E1^E4 ratio and E1C, indicating either 
transcriptionally active episomes as well as truncated integrates or truncated integrated forms 
only with integration upstream of nt 3358 but downstream of nt 2582. In the literature, 
breakpoints within this region have been described in 35% of CxCa samples analysed85. E2 
repressor expression is reduced or absent and the reduced E1C copy numbers are sufficient 
for maintenance of transformation.  
So in summary, in all three groups E2 repressor is either undetectable or if present could be 
out-titrated by E1C. However, in view of E1C absence in mild lesions, the activation of E1C 
in severe lesions still remains to be explained. 
 
5.3.6 False-negative and false-positive lesion classification by HPV16 RNA patterns 
analysis in single-infected HPV16 DNA-positive exfoliated cervical cells 
Overall, 35 out of 42 CIN3 (83%) were correctly classified as severe lesions. The 7 false-
negative CIN3 (17%) may be explained by (i) non-optimal storage conditions, (ii) wrong 
histological diagnosis or (iii) poor sampling (as described in 5.3.1) and ergo lack of abnormal 
cells. In addition, when a cell sample contains a mixture of non-transformed but HPV16-
infected cells and others exhibiting severe lesion, the HPV16 RNA patterns analysis may give 
equivocal results if EIC is not expressed in the severe lesion and E1^E4 from the non-
transformed, HPV16-infected cells leads to a low E6*I/E1^E4 ratio. RNA degradation in the 
up to two years old samples may have contributed to E1C negativity. Future studies should 
include freshly collected, non-archived cervical cell samples which also better represent the 
potential application of the HPV16 RNA patterns assay as clinical diagnostic test. 
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In this study, the sensitivity of HPV16 RNA patterns analysis increased by including samples 
in the E6*I/E1^E4 ratio computation (described in detail in chapter 3.12) with E6*I copy 
numbers lower than 10 and simultaneously negative for E1^E4. Thereby, two CxCa and one 
CIN3 were classified as severe lesion with E6*I/E1^E4 ratio above cutoff while at the same 
time only a single CIN0 became false-positive. The ubC copies per PCR of all four samples 
ranged between 377 and 2,831. However, when using the HPV16 RNA patterns analysis as 
routine diagnostic test, samples with low E6*I together with absence of E1^E4 should be 
classified as invalid and a repeat sample should be analysed.  
Furthermore, 48 out of 57 (84%) single-infected HPV16 DNA-positive exfoliated cervical 
cell samples were correctly classified as mild lesion demonstrating a high specificity of the 
HPV16 RNA patterns analysis for detection of severe lesions. The 16% false-positive samples 
(8% of NIL/M, 40% of CIN0 and 18% of CIN1) may be explained by incorrect biopsy or 
histological misclassification. Of the false-positive CIN1, none was E1C-positive but 
E6*I/E1^E4 ratio-positive. An upcoming progression as an explanation for false-positive 
samples might be rejected, since -as mentioned above- a mixed form of non-transformed but 
HPV16-infected cells and others exhibiting severe lesion could give equivocal results by the 
HPV16 RNA patterns analysis when E1C is negative. However, follow-up data were 
available for seven HPV16 RNA pattern-positive CIN1 samples: Within 9-24 months six 
progressed to CIN2 and CIN3, respectively. Furthermore, one HPV16 RNA patterns-negative 
CIN2 was diagnosed as CIN0 at follow-up 12 months later. This may indicate a potential 
predictive value of the HPV16 RNA patterns in mild lesions. Larger longitudinal studies are 
required to further investigate the predictive value of HPV16 RNA patterns in cervical cancer 
precursor screening. 
 
5.4 Intraobserver reproducibility of histological CIN diagnosis 
In most studies histological diagnosis of CIN lesions has been used as gold standard. 
However, only a moderate reproducibility of histological CIN diagnosis has been reported 
between different pathologists108,191. Dalla Palma et al., 2009109 described that 30% of cases 
with a negative diagnosis, 63% of CIN1, 62% of CIN3 and 48% of CIN2 were agreed on by 2 
reviewers. Similarly, Stolar et al., 2001108 described concordant histological diagnosis in 43% 
of CIN1 and in 77% of ≥CIN2. 
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Similar variation was also observed in this study with 44 out of 104 CIN0 to CIN3 samples 
(42%) discordantly diagnosed. 50% of CIN0 and CIN1 samples diagnosed by pathologist 1 
were diagnosed as CIN2 or worse by pathologist 2 and 7% of CIN2 and CIN3 as CIN0 or 
CIN1. This is surprising since for histological diagnosis also immunohistochemistry for 
p16INK4A in a parallel tissue section was available.  
HPV16 RNA patterns analysis correctly classified 48 out of 57 (84%) single-infected HPV16 
DNA-positive ≤CIN1 samples as mild lesion and 53 out of 60 (88%) ≥CIN3 samples as 
severe lesion when the consensus histological diagnoses were used as reference. However, 
using the diagnoses of pathologist 1 the number of correctly classified mild lesions by HPV16 
RNA patterns was reduced to 49 out of 64 (77%) and that of correctly classified severe 
lesions decreased to 50 out of 58 (86%). Similarly, with pathologist 2 diagnoses the 
corresponding numbers for mild lesions were reduced to 45 out of 55 (82%) and to 52 out of 
65 (80%) for severe lesions. 
These observations underline that the validation of novel diagnostic tools for cervical lesions, 
such as the novel HPV16 RNA patterns test, is complicated by variability of the histological 
diagnoses used as gold standard.  
 
5.5 Alternative molecular markers for cervical lesion staging 
HPV DNA tests recognise HPV-induced cervical lesions but also clinically not relevant 
infections. The determination of high viral load is a clinically more useful marker as it can 
reliably discriminate between no lesion and any lesion134. In this thesis 98% of ≥CIN3 were 
classified as severe lesion by high viral load analysis, but also 100% of CIN0 and CIN1. It has 
to be kept in mind that patients diagnosed as histologically normal CIN0 in the colposcopy 
clinic in Bad Münder had preceding suspicious cytology findings as reason for referral. 
However, only 30% of NIL/M from another study149 were classified as high viral load-
positive.  
As alternative modalities, novel biomarkers for stages of cervical carcinogenesis are emerging 
based on methylation of viral but also of human sequences175,192. With human genes such as 
AM3, EPB41L3 and TERTC13ORF18, CADM1 and MAL as marker, sensitivities for hrHPV 
positive ≥CIN3 patients193,194 between 54% and 84%193,194 and specificities for ≤CIN1 of 
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69%193 and 53%194 were reported. However, the methylation frequencies even for the same 
human gene varied widely between studies192. Methylation of HPV sequences seems to be a 
more promising biomarker. Alterations of the HPV-methylome in high-grade precancer and 
invasive cancer were observed particularly in the URR and L2 and L1 genes82. In general, 
methylation of viral DNA distinguishes women with ≥CIN2 from those without lesion or a 
lesion <CIN2175. A sensitivity for ≥CIN2 of 60% and a specificity of 91% have been reported 
when methylation of a combination of three CG sites (in L1, L2 and E2-E4) was used195. 
Whether HPV methylation is suited as biomarker for triage of screening HPV-positive women 
requires further evaluation175. 
 
5.6 Potential consequences of HPV RNA patterns analysis for cervical 
cancer screening 
Hitherto, discrimination of mild and severe lesions in exfoliated cervical cells by cytology as 
primary screening tool is of limited sensitivity and specificity. As mentioned above, HPV-
DNA tests and even high viral load determine mild lesions (≤LSIL and ≤CIN1) as test-
positive. It is therefore necessary to develop new modalities that are sensitive and allow 
differentiation of mild (clinically less relevant) and severe lesions (clinically more relevant).  
The HPV16 RNA patterns test could be used as triage test for secondary cervical cancer 
prevention in HPV16 DNA (high viral load)-positive cases for the sensitive discrimination of 
mild (wait and follow-up) versus severe (intervention) lesions which could allow extension of 
follow-up intervals. At a follow-up visit, the HPV16 RNA patterns test exclusively could be 
sufficient as diagnostic tool and if (i) negative for HPV16 E6*I RNA, the patient could return 
to normal routine screening, (ii) positive for HPV16 E6*I RNA, but HPV16 RNA patterns-
negative follow-up would be necessary and (iii) HPV16 RNA patterns-positive intervention 
would be necessary. Such sequential combinations of HPV DNA and HPV16 RNA patterns 
tests could be more reliable and particularly useful for limiting extensive examinations to 
patients identified at high risk only. 
At present, the limitation of the HPV RNA patterns test is the restriction to HPV16 only 
which covers only about future 55% of cervical cancer cases. If successfully extended to 
further hrHPV types, RNA patterns test could also be used in primary screening. 
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6 Outlook 
In this thesis, HPV16 RNA patterns analysis has been transferred from cumbersome 
NASBA technology to robust and much simpler RT-qPCR. HPV16 RNA patterns analysis 
of large numbers of clinical samples by the new RT-qPCR confirmed the suitability of this 
biomarker to sensitively and specifically discriminate severe from mild cervical lesions. 
Furthermore, 6 out of 7 HPV16 RNA patterns-positive CIN1 progressed to ≥CIN2 in the 
follow-up histology after 9-24 months. This observation requires larger follow-up studies in 
order to confirm the predictive value of the HPV16 RNA patterns.  
In future experiments care should also be taken to extract RNA within days after sampling 
since I observed loss of amplifiable RNA after extended storage of exfoliated cell samples 
despite use of PreservCyt buffer. Establishing the logistics of fast sample processing would 
also bring the analysis closer to clinical routine.  
From the literature it is known that HPV-DNA detection works excellent in self-collected 
lavage samples196-198. Such samples, provided that they can be stored in a RNA-protecting 
buffer and after careful test validation, could also represent a suitable sample source for 
HPV RNA patterns analysis. 
Extension of the HPV16 RNA patterns to other hrHPV types appears doable with 
reasonable effort and well justified. Together with HPV16, the 7 hrHPV types 18, 31, 33, 
35, 45, 52 and 58 most prevalent in CxCa account for about 83% of cervical cancer cases71. 
All splice sites of these seven hrHPV types necessary for RNA patterns analyses have been 
identified and/or confirmed in this thesis. With the experience gained with HPV16 the 
technical development of HPV RNA patterns analysis to these 7 types is expected to take 
approximately another 2 years. The extension to the second most prevalent hrHPV type 18 
has already been started. For the validation of non-HPV16 RNA patterns tests a substantial 
number of clinical samples has already been collected and characterised in the course of this 
thesis. In total, 718 cervical cell samples positive for at least one of the seven other hrHPV 
types are available ranging from a minimum of 5 HPV58-positive CxCa samples to a 
maximum of 108 HPV31-positive CIN samples. RNA of all the samples has been already 
extracted. 
For other cancer entities with HPV involvement, extension of RNA patterns testing beyond 
HPV16 is of lower importance. HPV16 causes more than 90% of all HPV-driven 
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OPSCC152,199. The HPV16 RNA patterns may be used in order to select the primary 
treatment modalities for patients with oropharyngeal squamous cell carcinomas as 
demonstrated before152: It could be shown that tumours being HPV16 RNA patterns-
positive have a better overall survival and progression free survival. In situations like in 
Germany, with heterogeneity among the HPV DNA-positive tumour patients, precise 
definition of HPV activity by the usage of the HPV16 RNA patterns test could help in 
selection of the primary treatment modality152. 
Of all HPV DNA-positive anal cancer cases, HPV16 DNA is found in 86%200. Squamous 
cell carcinoma of the anus, like CxCa, is thought to be preceded by a spectrum of 
intraepithelial changes, anal intraepithelial neoplasia (AIN) of varying severity. High-grade 
AIN can be identified using high-resolution anascopy (HRA) or colposcopy of the anus and 
perianus after application of acetic acid followed by biopsy and histology. However, in 
comparison to the number of cervical colposcopists, there are currently far fewer trained 
experts in HRA. Since there are no recommendations for screening, many patients are either 
diagnosed serendipitously during surgery for benign anal conditions or occasionally during 
colonoscopy or if they present with anal symptoms201. A potential use of HPV16 RNA 
patterns for the identification of high-grade AIN and anal SCC needs to be examined in 
future studies. 
HPV related vulvar intraepithelial lesions (VIN) and invasive vulvar cancer is mainly (73%) 
associated to HPV16202. Examination of the vulva is part of the gynecologic evaluation and 
a suspicious lesion needs to undergo a biopsy for further diagnosis. A potential use of 
HPV16 RNA patterns for the identification of high-grade VIN and vulvar carcinoms needs 
to be examined in future studies. 
HPV16 RNA patterns can also potentially be used for the identification of vaginal 
intraepithelial neoplasia (VAIN) and vaginal cancer where HPV16 was most prevalent 
subtype203,204. 
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7 Abbreviations  
ADC   Adenocarcinoma 
ADSCC  Adenosquamous cell carcinoma 
AIN   Anal intraepithelial lesion 
AMV-RT  Avian myeloblastosis virus reverse transcriptase 
ASC-US  Atypical squamous cells of undetermined significance 
AUC   area under the curve 
Bg   betaglobin 
bp   base pair 
BS   broad-spectrum 
bw   backward 
°C   degree Celsius 
Cell RNA  MagNA Pure96 Cellular RNA Large Volume Kit 
CI   confidence interval 
CIN   cervical intraepithelial neoplasia 
Cp   crossing point 
CV   coefficient of variation 
CxCa   cervical cancer 
DGGG  Deutsche Gesellschaft für Gynäkologie und Geburtshilfe 
DKFZ   Deutsches Krebsforschungszentrum 
DL   detection limit 
DNA   Desoxyribonucleic acid 
DP   duplex 
E   efficiency 
e.g.   example gratia 
E1C   N-terminal truncated E1 
E6AP   E6-associated protein 
EGF   epidermal growth factor 
ELISA   enzyme-linked immunosorbent assay 
ER   endoplasmatic reticulum 
FCS   fetal calf serum 
FELASA  Federation of European Laboratory Animal Science Association 
FFPE   formalin-fixed paraffin embedded 
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fl   full-length  
fw   forward 
HC2   Hybrid Capture 2 
HCT   Hybrid Capture Tube 
HE   hematoxylin and eosin 
HPV   Human papillomavirus(es) 
hr   high-risk 
HRA   high-resolution anascopy 
HSIL   high-grade squamous intraepithelial lesion 
i.e.   id est 
ICO   Catalan Institute of oncology 
IP   intellectual property 
κ   kappa 
LA   Linear Array HPV Genotyping 
LBC   Liquid-based cytology 
LC480 RNA  Light Cycler 480 RNA Master Hydrolysis Probes Kit 
LCR   long control region 
lr   low-risk 
LSIL   low-grade squamous intraepithelial lesion 
m   slope 
mM   millimolar 
MFI   median fluorescence intensity 
MPG   multiplex HPV genotyping 
mRNA  messenger-RNA 
µL   micro liter  
N   number 
NASBA  nucleic acid sequence-based amplification 
NIL/M   negative for intraepithelial lesion or malignancy 
NPV   negative predictive value 
nt   nucleotide 
OPSCC  oropharynx squamous cell carcinomas 
ORF   Open reading frame 
Pap   Papanicolaou 
PBS    Phosphate buffered saline  
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PCR   Polymerase chain reaction 
PPV   positive predictive value 
pRb    retionoblastoma tumor suppressor protein 
PV   Papillomavirus(es) 
q   quantitative 
R2   coefficient of determination 
rBFF   rodent bacteria and fungus finder 
rDVF   rodent DNA virus finder 
RIN   RNA integrity number 
RNA   Ribonucleic acid 
ROC   Receiver operating characteristic 
rp   Pearson correlation 
RPA   replication protein A 
rRVF   rodent RNA virus finder 
RT   reverse transcriptase 
RT-qPCR  reverse transcriptase quantitative PCR 
SCC   squamous cell carcinomas 
sj   splice junction 
SP   singleplex 
TP   triplex 
ubC   ubiquitin C 
URR   upstream regulatory region 
VAIN    vaginal intraepithelial neoplasia 
VIN   vulvar intraepithelial neoplasia 
Viral NA  MagNA Pure96 DNA and Viral NA Large Volume Kit 
VLP   virus-like particle 
WHO   World Health Organization 
wt   wildtype 
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8 Appendix 
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Figure A8.1. Dose-response curves of in vitro transcript copies and NASBA wt/q signal. NASBA signals 
(ratio of wildtype (wt)/calibrator (q) signal on y-axis) for dilution series of in vitro transcribed E6*I (a), E6*II 
(b), E1^E4 (c), E1C (d), L1 (e) and ubC (f) RNA (data were kindly provided by Dr. Schmitt (DKFZ)). All 
templates were applied in duplicates, error bars show standard error. 
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Figure A8.2. Correlation of ubC copies per PCR and RIN factor in cervical cell samples of different 
storage times. UbC copies per PCR (x-axis) and RIN factor of cervical cell samples archived between 9-12 
months (rhombi), 13-24 months (triangles), 84 months (open circles) and MRI-H186 cell line (filled circle) are 
blotted. All templates were applied in duplicates and the mean Cp value was used for calculation of copies per 
PCR. 
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Figure A8.3. RNA quality of HPV16 single-infected cervical cell samples from Bad Münder (n=104) and 
Mongolia (n=54). UbC copies per PCR (whiskers min to max) (y-axis) in exfoliated cervical cells from 
Mongolia and Bad Münder (x-axis). The lower edge of the box plot is the first 25th quartile, the upper edge the 
75th percentile. 
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One side project that had been started during my diploma thesis was the further 
development of three multiplex assays detecting DNA-viruses (rDVF), RNA-viruses 
(rRVF), bacteria and one fungus (rBFF) in laboratory rodents.  
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Briefly, conventional methods used to date for the detection of pathogens as enzyme-linked 
immunosorbent assay (ELISA), immunofluorescence and singleplex PCR assays are 
expensive, time-consuming, not standardised or lack high-throughput abilities. We 
developed multiplex assays based on multiplex PCR and multiplex detection of amplimers 
by Luminex for the simultaneous identification of pathogens in mice and rats, transplantable 
tumours, embryos, cell lines and other biological materials.  
The rDVF and rRVF are already integral part of laboratory animal quality assurance 
program of the DKFZ, supplementing traditional serology, virology and pathology 
techniques as it is time- and cost-efficient, and reduces the number of animals needed.  
Following publications of this project are in preparation: 
Höfler D, Nicklas W, Mauter P, Klaessen E, Pawlita M., Schmitt M. A bead-based 
multiplex assay for the detection of DNA viruses in laboratory rodents and biological 
material. Submitted to Journal of Virological Methods. 
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for the detection of bacteria and fungus in laboratory rodents and biological material. In 
preparation. 
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material. In preparation. 
